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Summary 
Methicillin-resistant Staphylococcus aureus (MRSA) is an endemic pathogen of 
public health concern in Ireland, as in many other health systems. For the nasal 
clearance of MRSA, the site that is often colonised in humans, the antibiotic 
mupirocin remains one of the most successful topical antibiotics to date. 
However, increasing bacterial resistance to mupirocin and limited effective 
alternate antibiotic options necessitate the need for unconventional approaches 
to eradicate nasal MRSA. Colonisation is a precursor for infection, and 
infections due to MRSA are associated with a greater risk of treatment failure, 
increased patient mortality and higher costs. 
 
Natural honey has been used by many traditional systems of medicine as a 
healing agent. In modern medicine, it is used as a wound healing agent. A 
recent Cochrane review reports that honey appears to heal partial thickness 
burns more quickly than conventional treatment, and infected post-operative 
wounds more quickly than antiseptics and gauze.  
 
Interest in an alternative agent for nasal decolonisation of MRSA led the 
researcher to the pilot study that employed medical grade honey (MGH). The 
results of the pilot study were encouraging which lead to the conduct of a 
clinical study ‘Natural Honey to Eradicate Nasal MRSA (NHNMRSA) a 
Randomised Control Trial (RCT)’. Patients were recruited from Beaumont 
Hospital to the single centre open label RCT, which investigated the 
comparative efficacy of nasal decolonisation of MRSA using MGH and 
mupirocin 2% nasal application.  
 
Patient characteristics, including age, gender, comorbidity, dependency of care, 
presence of invasive and indwelling devices, skin integrity, colonisation with 
multi-resistant drug resistant organisms, MRSA status on study enrolment, past 
decolonisation attempts and mupirocin use, as well as infection prevention and 
control practices during the study period were assessed, to determine the 
impact if any, on the outcome of intervention on nasal MRSA. The data were 
then analysed to establish the correlation, if any, between the outcomes of the 
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intervention, and between the intervention and control groups. The relationship 
between nasal as well as non-nasal MRSA colonisation was assessed, in 
addition to other factors that are previously reported as factors associated with 
failed decolonisation. 
 
Five specific objectives formed the foundation of the RCT, the key findings of 
which are summarised. The first objective a literature review on mupirocin 
resistance (MR), presented a comprehensive picture on the prevalence of MR, 
which ranges from 1% - 81%, associated chlorhexidine resistance, which 
ranges from 0.6% - 91%, as well as multi drug resistance among MRSA 
isolates. The emergence of high-level MR amongst coagulase negative 
Staphylococci (CoNS) isolates indicates an expanding reservoir of plasmids 
encoding MR, which can be transferred to other CoNS strains as well as to S. 
aureus including MRSA. HLMR and resistance to other antibiotics amongst 
CoNS curtails the oral antibiotic options for prolonged treatment of prosthetic 
infections with CoNS. Resistance to mupirocin and chlorhexidine limits the 
options for patients who may benefit from MRSA suppression or decolonisation 
therapy. Alternative agents such as octenidine dihydrochloride, polyhexanide, 
ethanol (70%), sodium hypochlorite, lysostaphin, omiganon pentahydrochloride, 
natural honey, tea tree oil, silver and bacteriophages have been investigated 
with varying success for MRSA decolonisation. However, therapeutic trials of 
alternative agents that show some promise must be further evaluated in clinical 
trials before they can be recommended for use in clinical practice. 
 
In the RCT, robust comparability of the study participants in the intervention and 
control groups was confirmed on univariate analysis. The univariate analysis 
also confirmed that none of the patient variables analysed was of statistical 
significance on the patient outcome, i.e. eradication of nasal MRSA. On an 
intention to treat (ITT) analysis, 18 (36%) in the intervention group and 25 (50%) 
in the control group were decolonised of nasal MRSA. A χ2 test was performed 
to assess the difference in the rate of decolonisation of MRSA between the 
intervention and control group. There was no statistically significant difference 
between the two groups (χ2=1.999, p=0.157). On a per-protocol (PP) analysis, 
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in the intervention group 18 (43%) participants and in the control group 25 
(57%) participants were decolonised of  nasal MRSA, however, a χ2- test 
showed no significant difference (χ2=1.675, p=0.196). Based on the ITT and PP 
analysis, as there was no statistical significance difference in the outcome of 
nasal MRSA decolonisation between the intervention and control groups, the 
null hypothesis was not rejected. On multivariate logistic regression, 
concomitant non-nasal MRSA colonisation was significantly associated, 
(χ2=7.241, p=0.008) with persistent nasal MRSA. In addition, altered skin 
integrity and the application of more than two courses of mupirocin 2% nasal 
ointment prior to RCT enrolment were also associated with persistent nasal 
carriage of MRSA. However the less than anticipated number of patients 
enrolled in the study impacted on the power to detect significant differences 
between the intervention and control groups. 
 
The third objective was to determine and compare bacterial susceptibility to 
mupirocin and changes over time from first identification to completion of the 
RCT. Of the historic, baseline and final isolates, mupirocin susceptibility (MS) 
was 91%, 88% and 77% respectively. The prevalence of MR progressively 
increased from the time initially identified to the end of the study, 8% on first 
time identification, 12% at study enrolment, and 23% at the end of study. New 
acquisition of MR amongst RCT participants was 10% and of all the cases who 
newly acquired MR, 75% were HLMR. The acquisition of MR necessitates the 
monitoring of MS amongst MRSA isolates, risk assessment, the judicious use of 
mupirocin as well as the use of alternative agents for MRSA decolonisation. 
 
Laboratory investigations of MRSA isolates and assays to determine 
antimicrobial efficacy of MGH together formed the fourth study objective. The 
MRSA isolates were characterised using spa typing and compared where 
available, at three time points; historic, baseline and on study completion. Of the 
baseline and persistent MRSA isolates (143), 26 different spa types were 
identified. The common spa types were; t032, 59 (41%), t515, 19 (13%), t127, 
17 (11.8%) and t4599, 10 (7%). Based on the spa types, a sequence-type (ST) 
could be inferred for 110 (77%) isolates. The common STs were ST22, 91 
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(63.6%), followed by ST1, 17 (11.8%), and one isolate each of the ST5 and ST8 
type. In summary, the spa type of the carriage isolates did not appear to 
influence the outcome of the nasal decolonisation. Persistent colonisation with 
the same spa type was evident even over relatively long time-spans.  However, 
replacement of the colonising spa type was also identified.  
 
The minimum inhibition concentration (MIC) and minimum bactericidal 
concentration (MBC) of MGH (test honey) was determined using laboratory 
assays. The MIC determined using the agar well diffusion method demonstrated 
antibacterial activity of test honey at 5% and higher concentrations for the 
clinical and reference MRSA isolates. Using the broth micro-dilution method to 
differentiate bactericidal or bacteriostatic action, it was established that the MIC 
and MBC of the test honey were both 12.5% to the MRSA isolates tested. The 
findings are in concordance with reports by other investigators who have 
reported MIC at concentrations of 4% and higher to antibacterial honey. 
 
The participant’s perception on MRSA carriage and their experience following 
the use of MGH and mupirocin 2% was evaluated which formed the basis of the 
fifth objective. An adapted brief illness perception questionnaire (BIPQ) that 
composed of nine elements was utilised to collate patient perceptions of MRSA. 
In summary the participants perceived MRSA colonisation as a chronic 
condition and that it did not have serious consequences on their daily lives. 
They were in general emotionally detached from the condition and few had 
MRSA related symptoms. Although most participants felt they had limited or no 
control over carriage, decolonisation was considered beneficial, indicating the 
importance attached to treatment/control of MRSA. The survey result shows a 
sub-optimal understanding of MRSA among 40% of patients that necessitates 
measures to target improving knowledge about MRSA. Such an intervention 
should enable patients to understand MRSA acquisition and transmission as 
well as adherence to treatment/decolonisation, potentially leading to better 
outcomes. 
 
A Likert scale type rating was used in the product experience questionnaire 
(PEQ) to collate participants' experiences of MGH cream and mupirocin nasal 
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application. In the investigative group, most patients (95%) concurred that 
Medihoney™ Derma Cream was easy to apply, not sticky (90%), did not lead to 
a runny nose (85%) and they did not experience an unpleasant sensation 
(95%). Based on the participants’ response it could be inferred that 
Medihoney™ Derma Cream may be applied to the human nasal passages with 
minimal undesirable effects. In the control group, most respondents (87%) 
concurred that mupirocin 2% nasal ointment was easy to apply, but it was sticky 
(20%), and a runny nose was experienced by 33% of respondents. Almost all 
(95%) respondents agreed that they did not experience any unpleasant 
sensation following its application. Overall the patients’ preferred choice was a 
natural alternative to an antibiotic, if available, for MRSA decolonisation. 
 
The NHNMRSA RCT, I believe, is the first study that has used MGH for nasal 
MRSA decolonisation. The RCT results offer potential but larger and multisite 
studies must be conducted to confirm the results to facilitate the development of 
MGH as an alternate agent for nasal decolonisation of MRSA. 
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Chapter 1 Introduction and background 
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Natural Honey to Eradicate Nasal MRSA A Randomised Controlled Trial 
1.1 Introduction 
Methicillin resistant Staphylococcus aureus (MRSA) was first identified in 
England in 1961 and has since emerged as an important nosocomial pathogen. 
MRSA is an endemic pathogen of public health concern in Ireland, as in many 
other European countries and elsewhere. The antibiotic mupirocin is one of the 
most successful topical antibiotics for the clearance of nasal MRSA. However, 
increasing bacterial resistance to mupirocin and a dearth of effective antibiotic 
options necessitates the need for alternative approaches to eradicate human 
nasal MRSA.  
 
1.2 Staphylococcus aureus  
Staphylococcus aureus (S. aureus) was discovered in 1880 by the Scottish 
surgeon Sir Alexander Ogston, who coined the name Staphylococcus aureus, 
‘Staphylococcus’  from the Greek expression staphylé, which means ‘bunch of 
grapes’ and ‘aureus’ from the Latin golden, due to the yellow-orange 
appearance of the colonies. (1) S. aureus is a member of the Staphylococcus 
genus, which are Gram-positive cocci. Staphylococci typically appear in 
clusters, but can be seen in pairs, tetrads or short chains. Staphylococci are 
non-motile, non-spore forming, facultative anaerobes. There are at least 40 
different species in the Staphylococcus genus of which more than half are found 
in humans. S. aureus is the most virulent member of the genus Staphylococci 
and can be differentiated from other Staphylococci by coagulase production, 
which converts fibrinogen to fibrin. S. aureus is both a coloniser and a pathogen 
of humans. It is a ubiquitous organism which colonises a variety of different 
body sites in humans such as the anterior nares, throat, groin and axilla.  
 
The most frequent carriage site is the anterior nares with 20-30% of the human 
population being persistent carriers of S. aureus and a further 60% carrying S. 
aureus intermittently. (2-4) Nasal carriage is probably due to a combination of 
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host and organism mediated factors. The ability of particular strains of S. aureus 
to adhere to the desquamated cells of the nasal epithelial surface may be due 
to the presence of certain proteins on the organism. S. aureus behaves as a 
commensal in the majority of the people, i.e. colonisation. However, 
colonisation with S. aureus significantly increases the risk of infection in the host 
if their defences become compromised. (2)  
 
S. aureus is a virulent organism capable of causing pathologic effects in the 
host (human and animals) resulting in a range of infections from superficial to 
fatal. Virulence is defined by Dorland’s Medical Dictionary for Health 
Consumers as the degree of pathogenicity of a microorganism, as indicated by 
the severity of disease produced and the ability to invade the tissues of the 
host, or as the ability of any infectious agent to produce pathogenic effects.  
Clinical diseases caused by S. aureus can range from more superficial skin and 
soft tissue infections to more invasive diseases such as bone and joint 
infections, bloodstream infections (BSI), pneumonia, infective endocarditis and 
the toxin mediated toxic shock syndrome. In most cases S. aureus infection is 
endogenous in origin, with the anterior nares being the most important reservoir 
of S. aureus in humans.  
 
The incidence of S. aureus infection has increased over the last 25 years. (5) S. 
aureus was the most common cause of BSI, skin and soft tissue infection and 
pneumonia in the United States, Canada, Europe, Latin America and Western 
Pacific in the 1990’s. (6) S. aureus is also a cause of medical-device related 
infection, and can infect a variety of prosthetic devices such as central vascular 
catheters (CVCs), prosthetic joints and implantable cardiac devices. (7)  
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1.3 Methicillin-resistant Staphylococcus aureus  
A number of factors have contributed to the success of S. aureus as a 
pathogen. One of the factors that has enhanced the virulence potential of this 
pathogen has been the evolution of antibiotic resistance.  The first strains of 
MRSA were identified in England in 1961, two years after the introduction of 
methicillin, the first anti-staphylococcal penicillin. (8) This organism was also 
found to be resistant to most other β-lactam antibiotics, such as flucloxacillin, 
cefuroxime and co-amoxiclav. Other methicillin resistant strains were soon 
identified in various parts of the world. (8) MRSA emerged as a nosocomial 
pathogen in the 1980’s and its prevalence increased dramatically worldwide. 
MRSA has been endemic in Ireland since the 1970’s and is a major public 
health concern, resulting in increased morbidity and mortality, and is 
responsible for increased healthcare costs. (9) 
 
Infections due to MRSA, in comparison with methicillin-susceptible S. aureus 
(MSSA), are associated with greater risk of treatment failure, increased patient 
mortality and higher costs. (10-11) In Scotland, the overall prevalence of MRSA 
colonisation in patients being admitted to hospital was 7.5% during 2008. (12) 
This translates to around one in 13 patients presenting to hospital were 
colonised with MRSA, and in some specialties this was as high as one in five 
patient admissions.  
 
The methicillin resistance gene (mecA) is carried on a mobile genetic element, 
the staphylococcal cassette chromosome mec (SCCmec). SCCmec consists of 
the mecA gene and cassette chromosome recombinase (ccr) gene complexes, 
which integrates into the S. aureus chromosome. Eleven different SCCmec 
types (SCCmec1-XI) have been identified in MRSA to date, with different 
combinations of mec and ccr gene complexes. The mecA gene codes for an 
alternative penicillin binding protein (PBP) 2a, which has reduced affinity for β-
lactam antibiotics and in turn facilitates cell wall synthesis when native PBPs 
have been inactivated by β-lactam antibiotics. (13) The majority of healthcare-
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associated MRSA (HA-MRSA) strains belong to one of the five genetic lineages 
or clonal complexes (CCs), CC5, CC8, CC22, CC30 and CC45. (8) ST22-
MRSA-IV (MRSA sequence type 22, mec type IV), the predominant HA-MRSA 
strain circulating in Ireland and the UK, at present belongs to CC22. (14)  
 
Community-acquired MRSA (CA-MRSA), which is increasing in prevalence 
worldwide, is often associated with more severe infections than HA-MRSA. (15) 
CA-MRSA is not the result of HA-MRSA strains spreading into the community 
but the more recent acquisition of SCCmec elements with distinct MSSA 
lineages e.g. ST1-MRSA-IV (CC1), ST80-MRSA-IV) (CC80) and ST5-MRSA-IV 
(CC5). (16)  
  
The epidemiology of MRSA is continuously evolving as exemplified by the 
emergence of CA-MRSA and its spread within healthcare settings. The 
emergence of livestock-associated MRSA among farmers in Europe underpins 
the changing epidemiology of MRSA. (17) With increasing resistance, not only 
to glycopeptides but to older antimicrobials such as fusidic acid and rifampicin, 
the management of MRSA is also challenging. (18-20)  
 
S. aureus bloodstream infection surveillance 
In Ireland, the Health Protection Surveillance Centre (HPSC) collects data on 
invasive isolates of S. aureus as part of the European Antimicrobial Resistance 
Surveillance Network (EARS-Net).   Data are collected on the first isolate from 
blood per patient per quarter (i.e. no duplicates or second strains are included) 
in accordance with the EARS-Net case definition.  In Ireland between 1,100 and 
1,400 S. aureus BSIs are reported annually (EARS-Net) data Q4, 2015, Figure 
1.1) with the majority of BSIs caused by MSSA. The proportions of S. aureus 
that are MRSA have decreased from 42% in 2006 to 18.5% in Q4 2015. In 
2014, the overall number of S. aureus BSIs increased compared to 2013, 
however, it coincided with a 0.9% reduction in MRSA BSI.  The numbers 
6 
 
reported to EARS-Net represent only a proportion of the total number of people 
infected and/or colonised with MRSA in Ireland.  
 
Figure 1.1 Trends in S. aureus bloodstream infections showing %MRSA in 
Ireland  
 
*2015 data provisional to the end of Q4; and missing data from 3 laboratories for 2 quarters each 
 
The EARS-Net surveillance provides data on the burden of MSSA and MRSA 
BSIs which enables the ongoing monitoring of BSIs as well as the impact of 
various infection prevention and control (IPC) efforts. However, in the absence 
of a national surveillance program monitoring the incidence of MRSA from non 
BSI sources, BSIs represents the ‘tip of the iceberg’ i.e. the burden of both 
susceptible and resistant S. aureus, infection and colonisation.  
 
Prevention and control of MRSA 
Colonisation with MRSA increases the risk of adverse health outcomes and it is 
estimated that 10% to 30% of carriers subsequently developing infection. (21) 
The nose as well as extra-nasal sites such as the throat and perineum, skin 
ulcers and skin lesions e.g. wounds and eczema, are commonly colonised. (22-
24) Eradication of MRSA carriage reduces the risk of infections due to MRSA. 
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Nasal and non-nasal MRSA eradication is attempted with varying success. A 
multipronged strategy is advocated for the control and prevention of 
transmission of MRSA. This includes screening of high risk patients, early 
detection, isolation, decolonisation, education of health care workers, cleaning 
and disinfection of the environment and most importantly, practices such as 
hand hygiene among all healthcare workers, which is one of the components of 
standard precautions in infection prevention and control. (25)  
 
Standard precautions  
Standard precautions (SP) are a set of infection control practices used to 
prevent transmission of diseases that can be acquired by contact with blood, 
body fluids, non-intact skin (including rashes), and mucous membranes. 
Standard precautions are designed to reduce the risk of transmission of 
microorganisms from both recognized and unrecognized sources of infection in 
hospitals. (26) The elements of SP are; hand hygiene, use of personal 
protective equipment such as; gloves, apron and facial protection, prevention of 
needle stick injuries, safe injection practices, safe practices for lumbar puncture 
procedure, respiratory hygiene and cough etiquette, environmental hygiene, 
safe management of linen, safe disposal of waste and decontamination of 
patent equipment. While the practice of SP are essential in the care of all 
patients regardless of their infective status, additional precautions are required 
to prevent and control transmission of pathogens from patients colonised or 
infected with infectious organisms. 
 
Transmission-based precautions  
Transmission-based precautions are additional infection control precautions in 
health care, and the latest routine infection prevention and control practices are 
applied for patients who are known or suspected to be infected or colonised 
with infectious agents, including certain epidemiologically important pathogens. 
These include contact, droplet and airborne precautions. (26)  
8 
 
Contact precautions (CP) are intended to prevent transmission of infectious 
agents, including epidemiologically important microorganisms, which are spread 
by direct or indirect contact with the patient or the patient's environment. A 
single-patient room is preferred or, when not available, cohorting of patients 
with similar pathogens, who require CP. Healthcare personnel caring for 
patients on CP’s must wear a gown and gloves for all interactions that may 
involve contact with the patient or potentially contaminated areas in the patient's 
environment. 
Droplet precautions are intended to prevent transmission of pathogens spread 
through close respiratory or mucous membrane contact with respiratory 
secretions. In addition to contact precautions, isolation or cohorting is essential 
and a spatial separation of more than three feet is especially important for 
patients in multi-bed rooms, with infections transmitted by the droplet route. In 
addition to gloves and apron healthcare personnel must wear a mask for close 
contact with patients who are infectious. 
Airborne precautions prevent transmission of infectious agents that remain 
infectious over long distances when suspended in the air, and the preferred 
placement for patients who require airborne precautions is in an airborne 
infection isolation room (AIIR). Healthcare workers must use the personal 
protective equipment used for CP in addition to a high filtration mask such as 
N95 or higher level respirators while caring for patients on airborne precautions. 
 
Patient decolonisation of MRSA 
Eradication of MRSA carriage from the nose and from other sites forms an 
integral part of the strategies to prevent and control of MRSA in many countries. 
(27-29) This includes nasal decolonisation, decolonisation from intact and non-
intact skin, as well as from other MRSA colonising sites. 
The warm moist environment in the human nasal passages provides a 
conducive environment for the survival and growth of S. aureus including 
MRSA. Mupirocin calcium ointment was clinically introduced in the late 1980s 
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and has proved to be one of the most successful topical antibiotics for the 
clearance of nasal S. aureus, including MRSA. (30,24,31-33)   
 
Mupirocin nasal ointment 
The antibiotic mupirocin (pseudomonic acid A) is produced by the bacteria 
Pseudomonas fluorescens. Mupirocin is a competitive inhibitor of bacterial 
isoleucyl transfer-RNA synthetase, and is active against most Gram positive 
and some Gram negative bacilli. Mupirocin-mediated inhibition of isoleucyl-
tRNA synthetase impedes protein and RNA synthesis, ultimately leading to 
bacterial death. There is very little systemic absorption following the topical 
application of mupirocin. After systemic administration, mupirocin has a short 
half-life (15 mins) and is rapidly converted into inactive monic acid, which is 
excreted principally through the kidney.  The therapeutic indication for mupirocin 
is the elimination of the nasal carriage of staphylococci, including MRSA. The 
method of application is nasal ointment, usually 2%, applied to the anterior 
nares two to three times a day. Nasal carriage is then normally cleared within 
five to seven days of commencing treatment. (30,33) 
Mupirocin 2% ointment is used for nasal decolonisation alone or as part of a 
comprehensive MRSA decolonisation strategy along with skin antiseptics such 
as chlorhexidine. The impact of the application of mupirocin to the nose has 
been investigated by various researchers with varying success, in terms of 
immediate as well as medium to long term sustained nasal MRSA 
decolonisation. (24,34-36) 
Neomycin sulphate (Naseptin Nasal 0.5% v/v Cream) is an alternate option for 
eradicating staphylococcal carriage in the nose. For nasal decolonisation, it is 
applied four times a day for ten days. In clinical practice, a single course of 
neomycin is generally used for nasal decolonisation of mupirocin resistant S. 
aureus carriage. 
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Non-nasal MRSA decolonisation 
MRSA colonises nasal as well as non-nasal body sites such as the throat, 
groin/perineum, axilla and non-intact skin, namely ulcers and wounds. 
Antiseptics such as 4% chlorhexidine, 7.5% povidone iodine or 2% triclosan are 
reported to be equally efficacious for decolonisation of non-nasal sites. (25)  
In most MRSA IPC programs, chlorhexidine is a major component and is often 
used in various forms as part of oral care, skin antisepsis prior to intravascular 
device placement, before surgical procedures, during patient bathing, and as a 
component of some antimicrobial-impregnated catheters and dressings. 
Chlorhexidine is a biguanide cationic bactericidal agent which is rapidly taken 
up by S. aureus. (37-38) At low concentrations, it disrupts the integrity of the cell 
wall and membranes, resulting in leakage of the intracellular contents, and at 
high concentrations chlorhexidine causes coagulation of the intracellular 
contents. 
Attempts at non-nasal MRSA decolonisation involves the use of antiseptic 
preparations such as chlorhexidine soap / triclosan and includes daily body 
washes and shampoo for at least two days during a consecutive five day period. 
More than one course of antiseptic body washes are reported to be beneficial 
for some patients.  However, decolonisation is challenging where multi-site 
colonisation is present.  
 
1.4 Mupirocin resistance 
In modern medicine the discovery and use of antibiotics to treat bacterial 
infections has been largely successful since their introduction. However, the use 
of antibiotics has also lead to the development of bacterial resistance which 
limits the effective use of several antibiotics.  
For nasal MRSA eradication a significant limitation to the use of mupirocin is 
resistance, which ranges from 1% to 81%. (39-46) Mupirocin resistance (MR) is 
clinically important for IPC personnel who are engaged in MRSA control efforts 
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and also in the management of individual patients such as before major surgery 
to minimise post-operative MRSA infection.  
 
Laboratory detection of mupirocin resistance 
Phenotypically, resistance to mupirocin is determined according to minimum 
inhibition concentration (MIC) breakpoints with susceptible being ≤4 mg/L, an 
MIC of 8-256 mg/L indicating low level resistance and MIC >512 mg/L indicating 
high level resistance. (46-47) Mupirocin MICs of 8-64 mg/L are usually due to 
non-synonymous changes in the native isoleucyl-tRNA synthetase gene.  
 
Categories of mupirocin resistance 
There are two types of MR reported; low level (LLMR) and high level mupirocin 
resistance (HLMR).  A MIC of 8-256 mg/L reflects LLMR and MIC of ≥512 mg/L 
reflect HLMR. HLMR is mediated by the acquisition of a conjugative plasmid 
containing mupA (ileS2), which encodes an alternate isoleucyl tRNA 
synthetase. (47-48) 
In addition to the mupA gene, another mechanism of HLMR, mediated by a 
novel locus, mupB, has been reported. (49) The mupB gene (3,102 base pairs) 
shares 65.5% sequence identity with mupA but only 45.5% with ileS. The 
resultant MupB protein shares 72.3% similarity and 41.8% similarity with MupA 
and ileS, respectively. These findings support the presence of non-mupA-
mediated HLMR as reported by others. (49,46,50) Molecular studies of MR in S. 
aureus populations indicate that nearly all S. aureus isolates with HLMR have 
the mupA gene. (51) However, low or non-expression of the ileS2 gene has 
been described amongst LLMR isolates. (52)  
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1.5 Alternative agents to mupirocin 
While mupirocin remains the most successful topical antibiotic for the clearance 
of nasal S. aureus, including MRSA, increasing resistance to mupirocin along 
with concurrent resistance to antiseptics used for non-nasal eradication in 
addition to multidrug resistance, necessitates the need for alternatives. There 
are very few antibacterial agents with new mechanisms of action under 
development to meet the challenge of multidrug resistance. The EU identifies a 
widening gap between the burden of infections due to multi-drug anti-bacterial 
resistance and the development of new systemic agents, as a key priority. (53)  
This also applies to topical agents used in decolonisation.  
Tea tree oil (Melaleuca alternifolia) exhibits antimicrobial and anti-inflammatory 
properties, and has been investigated as a potential agent for MRSA 
decolonisation. In a clinical trial, a tea tree oil (10%) based regimen was 
compared with standard treatment consisting of mupirocin, chlorhexidine or 
silver sulfadiazine. (54) Of the patients who received standard treatment, overall 
56/114 (49%) were cleared of MRSA carriage. Of the patients who received the 
tea tree oil regimen, 46/110 (41%) were cleared. The results show that 
mupirocin was significantly more effective at clearing nasal carriage (n=58/74), 
than tea tree oil cream (n=36/76), (78% vs 47%; P = 0.0001). However, tea tree 
oil treatment was more effective than chlorhexidine or silver sulfadiazine in 
clearing superficial skin sites and skin lesions of MRSA. Variable success on 
the use of tea tree oil for MRSA decolonisation is also reported. (55)  
 
Sodium hypochlorite or bleach is another agent that has been used extensively 
as a topical antimicrobial for the treatment of wounds and burns since it was 
originally described in 1915 by Dakin. The Infectious Diseases Society of 
America guidelines recommend nasal mupirocin and dilute bleach baths for 15 
min twice weekly for three months, as eradication of colonisation for patients 
with refractory MRSA skin and soft tissue infections (SSTI). (56) A randomised 
controlled trial (RCT) comparing various decolonisation regimens using 
mupirocin, chlorhexidine and bleach on patients with community based SSTI 
and multisite S. aureus colonisation revealed that the highest rate of successful 
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S. aureus eradication (71%) in patients occurred with a combination of nasal 
mupirocin and daily bleach baths. (57)  
 
Honey has been used for centuries as a topical treatment for a wide range of 
wounds. Honey is once again of interest to healthcare practitioners involved 
with wound management. Medical grade honey based dressings are used with 
reported wound healing stimulating properties in human burns, wounds and 
ulcers. In burns there is also reported evidence for its antibacterial capacity. The 
antibacterial action of honey leads to a lower incidence of infection and the 
elimination of MRSA. Researchers claim that honey has deodorizing, 
debridement, anti-inflammatory and wound pain reducing properties, although 
the evidence for these properties is rather limited. (58)  
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1.6 Honey and its medical importance  
This section will consider the historic as well as evidence-based scientific 
literature on the use of honey for various medicinal purposes. It will provide the 
rationale for the use of honey in the pilot study, and later in the randomised 
controlled trial.  The composition of honey and its antibacterial properties will be 
presented. The use of honey for healing ulcers and wounds by various 
investigators will be considered along with the Cochrane review conclusion 
(2015) on the use of honey for the management of wounds, ulcers and burns. 
 
What is honey and its composition? 
Honey is a viscous, supersaturated sugar solution derived from nectar gathered 
and modified by the honeybee, Apis mellifera. Honey is an acidic, hygroscopic 
and hyperosmolar solution. (59) It is composed of water, sucrose, glucose, 
fructose, amino acids, wax, pollen, pigments, minerals and enzymes. (60) 
Honey contains low levels of sugars, other than the four main sugars (fructose, 
glucose, sucrose and maltose), organic acids, proteins and minerals in addition 
to water molecules which comprise less than 20% of the weight of honey, which 
renders it a supersaturated sugar solution. (61)  
Honey has a pH of 3.2-5.5, which is mainly due to the presence of gluconic 
acid. (62-63) Various enzymes are present in honey, namely diastase also 
known as α amylase, glucose oxidase and invertase. The enzyme invertase 
converts sucrose in the honey into simpler glucose and fructose, and glucose 
oxidase, oxidizes glucose in honey producing gluconic acid and hydrogen 
peroxide. (60) Various honeys have been studied for their chemical 
composition, almost all of which has demonstrated low pH, hydrogen peroxide 
production, and hyperosmolarity.  However, Manuka honey is distinctive with 
high concentrations of the enzyme methylglyoxal (MGO). (64)  
 
The beneficial role of honey for medicinal purposes is ascribed to its high 
osmolarity, acidity, content of hydrogen peroxide and non-peroxide 
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components, i.e., the presence of phytochemical components like MGO. (64-65)  
Most types of honey generate hydrogen peroxide when diluted, due to the 
activation of the enzyme glucose oxidase that oxidises glucose to gluconic acid, 
which in turn yields hydrogen peroxide. (66) Several components are known to 
contribute to the nonperoxide activity, such as methyl syringate and MGO. (64) 
Honey originating from Leptospermum trees contains a number of aromatic 
acids of which syringic acid and phenyllactic acid are the most abundant. (64)  
 
A study examining the antimicrobial properties of honey in vitro concluded that 
hydrogen peroxide, MGO and an antimicrobial peptide, bee defensin-1, are 
distinct components contributing to the bactericidal activity of honey. (67) Of the 
different types of honeys studied, darker honeys are richer in phenolic 
compounds like flavonoids and tannins, and posses the strongest antioxidant 
and radical scavenging activities. (68) The antimicrobial characteristics of honey 
will be explored in detail later on in the chapter. 
 
Source of honey and recognised characteristics 
The flora origin, bee species, geographical source and post-harvesting 
conditions impacts on the properties of honey. (69) The variations in the 
antimicrobial activity of some natural honeys are attributed to spatial and 
temporal variation in the sources of nectar. Honey derived from Leptospermum 
trees (Manuka) is perhaps the most studied monofloral honey, which has been 
shown to have significant antibacterial properties independent of hydrogen 
peroxide and osmolarity as confirmed during in vitro studies. (70-71) Manuka 
honey contains a number of aromatic acids and high concentrations of the 
enzyme MGO. Honey from the Ulmo tree (Eucryphia cordifolia), is another 
honey that has been investigated for antimicrobial activity. 
Honey use in human history 
The medicinal importance of honey has been documented in the world's oldest 
medical literatures. The healing properties of honey is recorded in the 
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Ayurveda, a system of medicine in ancient Hindustan, the modern day Indian 
sub-continent, Hippocrates, Aristotle, ancient Greece, and the Egyptian medical 
literatures. (72-73) A Sumerian tablet writing, dating back to 2100-2000 BC, is 
one of the first known written references to honey, which mentions honey’s use 
as a drug and an ointment. One of the world’s oldest surgical texts, the Edwin 
Smith papyrus, dates back to 1600–2200 BC, describes treating a head wound 
with an oil-and-honey–soaked linen bandage. (74) Aristotle (384-322 BC) refers 
to pale honey as being good as a salve for sore eyes and wounds. (75) The 
belief that honey is a nutrient, a drug and an ointment thus has been passed on 
to generations. In contemporary times the use of honey for medicinal purposes 
has developed into an alternate branch of medicine called apitherapy. 
 
In the modern era honey’s anti- microbial qualities were first documented in 
1892 by B.A. Van Ketel, a Dutch scientist, and research in the United States 
and Europe has noted its worth in treating infected wounds. (76) The use of 
honey for medicinal purposes fell out of favour in modern medicine, perhaps 
with the advent of antibiotics. However, the emergence of bacteria that are 
resistant to antibiotics such as MRSA and the limited armour on hand in the 
fight against antimicrobial resistance has seen a resurgence of interest in 
natural agents that have demonstrated antibacterial properties such as honey. 
(69)  
 
Honey for skin care 
Honey is considered particularly suitable for skin care, and its regular use is 
thought to keep the skin juvenile and retard wrinkle formation. Honey is 
hygroscopic, antibacterial and fungicidal, nurtures skin and contributes to 
regulating the mildly acid pH of the upper protective skin layer. (77) The 
mechanisms of action of honey on skin cells are deeply conditioned by the 
botanical sources and include antioxidant activity, the induction of cytokines and 
matrix metalloproteinase expression, as well as epithelial-mesenchymal 
transition in wounded epidermis. (77) The hydrating effect of honey is mainly 
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linked to the high content of fructose and glucose, forming hydrogen bridges 
with  water and maintaining the moisture of the skin’s horny layer. (78) The 
hydrating ability of honey also derives from the presence of amino acids and of 
organic acids which can supplement the natural moisturizing factors of the 
horny layer of the skin. 
The dermatological uses of honey are generally based on empirical knowledge. 
However there is a growing interest in demonstrating the scientific evidence 
supporting empirical knowledge for its use of in dermatological applications. 
Due to large variations in the qualities of honeys from different natural sources, 
much interest is paid to the development of medical-grade honey, especially for 
the treatment for skin infections and wound healing. (67)  
In cosmetic formulations, honey is used for its emollient, humectants, soothing, 
and hair conditioning effects, and because it regulates pH and prevents 
infections. Honey-based cosmetic products include lip ointments, cleansing 
milks, hydrating creams, after sun, tonic lotions, shampoos, and conditioners. 
The physical and chemical properties of honey and the fact that it can be 
painlessly removed along with the use of a non-adherent dressing is particularly 
suitable for its use in the care of wounds and burns. Honey is also used in the 
treatment of pityriasis, tinea, seborrhea, dandruff, diaper dermatitis, psoriasis, 
hemorrhoids, and anal fissure. (77)  
 
Honey and wounds 
The healing properties of honey are believed to be a combination of 
antibacterial, antioxidant and immuno-modulatory properties. (79,76,58) 
Honey when applied to wounds maintains a moist wound condition, and its high 
viscosity helps to provide a protective barrier to prevent infection, by inhibiting 
bacterial growth, in addition to preventing adhesion of dressings to wounds. (80-
81) Honey is thought to decrease oedema, allowing better circulation and 
delivery of oxygen and essential nutrients for wound repair. (63) The high sugar 
content of honey draws fluid by osmosis from deep in the wound bed, which 
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enhances debridement and aids in wound healing. This high osmotic pressure 
is also thought to be responsible for extracting water from bacteria thus 
contributing to its anti-bacterial activity. (70) The osmotic pressure from honey 
also aids in removal of necrotic and devitalized tissue by drawing out lymphatic 
fluid from the wound base. (80)  
 
The sugary wet environment may also improve local nutrition and 
epithelialisation of the wound, in addition to an acidic environment that provides 
an optimal medium for fibroblast activity, which aids in wound healing. (59) 
During the inflammatory and proliferative wound healing phase, honey is able to 
either stimulate or inhibit the release of certain factors (cytokines, Matrix 
metalloproteinase 9 (MMP-9), reactive oxygen species (ROS) from immune and 
cutaneous cells, depending on wound condition. (82) When wound inflammation 
is uncontrolled, honey prevents prolonged wound inflammation and reduces the 
elevated levels of pro-inflammatory cytokines, ROS, and MMP-9. It is also 
speculated that honey can act as an immuno-modulator with both pro-
inflammatory and anti-inflammatory properties, inducing or stimulating the 
release of tumour necrosis factor-α (TNF-α), interlukin (IL), IL-1β, and IL-6 from 
monocytic cell line Mono Mac 6 (MM6) cells and peripheral blood monocytes.  
The  production of pro-inflammatory cytokines, decreases biofilm formation, 
inhibits bacterial cell cycle production, decreases pain perception, reduces 
malodour, and decreases exudates, all factors that are relevant to wound repair 
and healing. (82)  
One of the other attributes of honey that aids wound healing is its ability to 
produce hydrogen peroxide which is both antibacterial but at concentrations that 
are nontoxic to granular cells. (59) The low levels of hydrogen peroxide in 
honey are thought to promote growth of new cells, such as fibroblasts that are 
important in early wound healing. However, even in the presence of catalase, 
which has the potential to inactivate hydrogen peroxide, some researchers 
claim honey has antimicrobial properties which are beneficial for the healing of 
wounds. (83)  
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Honey and diabetic foot ulcers  
The management of diabetic ulcers and their healing is challenging. Wound 
care experts have investigated the potential for various types of dressings that 
are used in routine wound care as well as other natural cures, including honey, 
to improve clinical outcomes.  
A RCT investigated the effect of Manuka honey-impregnated dressings 
compared with conventional dressings in the healing of neuropathic diabetic 
foot ulcers (NDFU) and followed up 59 patients on a weekly basis for up to 16 
weeks. The investigators reported that, the proportion of ulcers that healed did 
not differ significantly between Manuka honey 97% (n=31) and for conventional 
dressings 90% (n=28). However, Manuka honey was associated with a 
significant reduction in the time to healing and with rapid decolonisation of 
ulcers (78% vs 35%). (84)  
The efficacy of topically applied Royal jelly (RJ), of honey origin, on the healing 
of 64 diabetic foot ulcers (DFU) was evaluated by Siavash and colleagues in a 
double blinded placebo controlled clinical trial. They found that 5% topical RJ 
was not superior to placebo for the treatment of DFU’s. (85) In another clinical 
study that employed honey dressings for DFU’s for up to three months, it was 
observed that 43.3% (n=13/ 30) of the DFU were completely healed, with a 
decrease in ulcer size and healthy granulation was observed. The bacterial load 
of all ulcers from the 30 patients was significantly reduced after the first week of 
honey dressing. (86)  
Comparing the outcome from the three clinical studies alluded to above in the 
management of DFU’s with honey based products, it appears that honey is non-
inferior to routine care and conventional dressings. In addition to the healing 
properties of honey, antimicrobial properties may offer an advantage by which 
bacterial colonisation and subsequent infection of the DFU’s may be prevented 
or reduced by the use of honey based dressings. However, inconsistencies in 
the outcome of DFU’s are evident from the studies examined, which warrants 
further systematic investigation. 
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Honey and venous leg ulcers 
Similar to that of diabetic ulcers, the management and healing of venous ulcers 
is taxing. A RCT evaluated the outcome of calcium alginate dressings 
impregnated with Manuka honey (n=187), in comparison to a range of 
conventional dressings (n=181) in a community setting. There was no 
difference in complete healing, time to healing, or reduction in ulcer area 
between the two groups. Moreover, patients in the honey treated group reported 
>/= 1 adverse event and ulcer pain than in the usual care group. (87) In another 
similar RCT comparing desloughing efficacy in venous leg ulcers (n=108) 
treated with a Manuka honey product (Woundcare 18+) (n=54) compared with 
standard hydrogel therapy using IntraSite Gel (n=54), the WoundCare 18+ 
group had improved healing at or within 12 weeks more effective desloughing 
within four weeks and a lower incidence of infection than the control group. (88)  
In 2013, the German Society for Wound Healing and Wound Treatment 
published a revised guideline on chronic wound management. The 
recommendations included hydrogel, hyperbaric oxygenation, and integrated 
care, and but advised against the use of medicinal honey and growth factors for 
the treatment of chronic wounds in patients with peripheral vascular disease, 
chronic venous insufficiency, and diabetes. (89)  
 
A recent Cochrane review (2015), evaluated the effect of honey compared with 
alternative wound dressings and topical treatments on the healing of acute and 
chronic wounds, including leg ulcers and burns. (90) Twenty six trials were 
included in the review of which, three trials evaluated the outcome of honey in 
minor acute wounds, 11 trials evaluated honey in burns, 10 trials on different 
chronic wounds, including two patients with venous leg ulcers, two trials in 
people with diabetic foot ulcers and single trials in infected post-operative 
wounds, pressure injuries, cutaneous Leishmaniasis and Fournier's gangrene. 
The remaining two trials recruited a mixed population of people with acute and 
chronic wounds. (90) The review concluded that it was difficult to draw overall 
conclusions on the effects of honey as a topical treatment for wounds. The 
reviewers allude to the heterogeneous nature of the patient populations and 
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comparators studied, and the mostly low quality of the evidence, which makes it 
hard to draw definite conclusions. However, the review identified that honey 
appears to heal partial thickness burns more quickly than conventional 
treatment, which includes polyurethane film, paraffin gauze, soframycin-
impregnated gauze, sterile linen and leaving the burns exposed, and infected 
post-operative wounds more quickly than antiseptics and gauze. The reviewers 
also reported that the effects of honey relative to comparators were unclear for 
venous leg ulcers, minor acute wounds, diabetic foot ulcers, Leishmaniasis and 
mixed chronic wounds. (90)  
 
Scrutinising the results of clinical studies that investigated the use of honey for 
the management of DFU and venous ulcers, chronic wound management as 
well as the Cochrane review findings, the scientific evidence in favour of honey 
is limited to that of healing partial thickness burns and infected post-operative 
wounds. In the management of DFU’s and venous ulcers the evidence for the 
use of honey is contradictory. Robust RCT’s must be done in-order to generate 
conclusive evidence that either supports or refutes the use of honey-based 
products in the care of DFU’s and venous ulcers. 
 
Honey and cellular research 
The antimicrobial claims and wound healing properties of honey have 
encouraged researchers to investigate its activity at cellular level. In histological 
studies, honey exposed cells have been shown to have higher levels of 
antioxidants present and decreased numbers of inflammatory cells. (91) In cell 
cultures, honey has been shown to stimulate B and T lymphocytes and 
phagocytes and the release of modulator cytokines tumour necrosis factor-1 
(TNF-1), IL, IL-1, and IL-6. Honey also provides macrophages with the essential 
glucose needed for energy and hydrogen peroxide production. (91-92) In vitro 
studies have demonstrated that honey may be able to modulate the activity of 
immuno- competent cells, such as monocytes. (79,93)  
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The role of universal stress protein A (UspA) and the inhibition of MRSA in 
Manuka honey treated cells were investigated by Jenkins and colleagues from 
Cardiff, UK. (94) The UspA super-family is found in many microorganisms, 
including bacteria as well as some higher organisms. UspA are normally 
induced in response to stress conditions such as temperature shock, starvation 
and the presence of agents that arrest cell growth. Mutant cells lacking UspA 
have been shown to be less fit by growing more slowly and dying prematurely 
during growth arrest. Down-regulation of UspA protein was confirmed by real-
time polymerase chain reaction (PCR), which showed a 16-fold down-regulation 
in honey-treated cells compared with untreated samples. UspA protein is 
involved in the stress stamina response and its down-regulation according to 
the investigators could help to explain the inhibition of MRSA by Manuka honey. 
In addition, the investigators also observed a decreased expression of UspA in 
honey treated cells indicating that MRSA was unable to accommodate the 
stresses caused by exposure to Manuka honey. (94)  
 
 A review on the use of honey or wound healing indicated that honey seems to 
either reduce or activate the production of ROS from neutrophils, and honey-
induced activation of monocytes and macrophages, leading to debridement of a 
wound and faster healing. Along with these factors, it is also claimed that 
human keratinocytes, fibroblasts, and endothelial cell responses such as cell 
migration and proliferation, collagen matrix production and chemotaxis are 
positively affected in the presence of honey, thus accelerating re-epithelisation 
and wound closure. (82)  
 
Antibacterial properties of honey 
The survival and growth of bacteria are influenced by nutrients in the 
environment such as hydrogen donors and acceptors, carbon source, nitrogen 
source, minerals such as sulphur and phosphorus, amino acids, purines, 
pyrimidines, vitamins and certain trace elements. Most pathogenic bacteria 
grow best in pH 7.2-7.4. The high acidity and sugar content of honey along with 
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its low water content present adverse conditions for the growth and the 
replication of micro-organisms.  
The antibacterial nature of honey is dependent on various factors working either 
singularly or synergistically. (68-69) These include the concentration and the 
nature of the bacteria; the higher the concentration the greater its usefulness as 
an antibacterial agent. (95-96)  
The antimicrobial activity of honey is also attributed to the enzymatic production 
of hydrogen peroxide. Levels of hydrogen peroxide in topically applied honey 
are estimated to be 1000 times lower than in medical rinse solutions. (59) While 
the peroxide action of honey is linked to antibacterial properties, investigators 
have also demonstrated significant antibacterial effects even when the 
hydrogen peroxide activity is blocked, for example in honey derived from 
Leptospermum trees. (75) Mandal asserts that this mechanism may be related 
to the low pH and high sugar content/high osmolarity of honey which is 
sufficient to hinder microbial growth. (75)  
In vitro studies indicate that MGO is an effective antimicrobial agent against 
MRSA, and effectively acts in synergy with oxacillin in the treatment of 
otherwise oxacillin-resistant S. aureus. (64,97) Researchers have demonstrated 
that honey of varying types has broad-spectrum in vitro antibacterial activity 
against nearly 60 species of bacteria, including MRSA, vancomycin-resistant 
enterococcus, and Pseudomonas aeruginosa. (91,98-104) The high osmolarity, 
acidity, generation of hydrogen peroxide on dilution and insect derived 
antimicrobial peptides of honey are components that are attributed to 
antibacterial activity. (105) A number of investigators have demonstrated that 
honey reduces the numbers of MRSA in open wounds. (92,106-108)  
According to Cooper, the high sugar and low water content as well as the 
marked acidity of all honeys provide an adverse environment for bacterial 
survival. This could explain why honey infrequently spoils at room temperature 
despite prolonged storage. (69)  
A research team from Greece investigated the antimicrobial activity of various 
botanical origin honeys (n=60), against 16 pathogens and their respective 
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reference strains. In this study, the microbiological quality of honeys and the 
antibiotic susceptibility of the various isolates were also examined. All honey 
samples, whether coniferous, citrus, thyme or polyfloral had antibacterial activity 
against the pathogenic bacteria and their respective reference bacterial strains. 
The highest activity was showed by coniferous and thyme honeys with an 
average minimum dilution of 17.4% and 19.2% (w/v) followed by citrus and 
polyfloral honeys with 20.8% and 23.8%, respectively. Clinical isolates of S. 
aureus, E. coli, Salmonella enterica subsp. Enterica, Streptococcus pyogenes, 
B. cereus and B. subtilis were proven to be more resistant than their respective 
reference strains. These findings emphasize the variability in the antibacterial 
effects of honey. (109)  
 
A bactericidal rather than bacteriostatic mode of action of honey has been 
demonstrated by various investigators. (98,101) It has also been identified that 
Gram positive bacteria are generally more susceptible than Gram negatives, 
and staphylococci seem to be the species most susceptible to honey. (69)  
 
A research team investigated the mode of inhibition of Manuka honey against S. 
aureus ‘NCTC 10017’ by determining the MIC, minimum bactericidal 
concentration (MBC) and the effect of time on viability. (110) In this study, 
structural changes of cells were observed by scanning electron microscopy 
(SEM) and transmission electron microscopy (TEM) of cells suspended in 0.05 
mM Tris buffer containing 10% (w/v) Manuka honey. The structural changes 
observed were compared to cells in buffer alone or buffer containing 10% (w/v) 
artificial honey. Marked structural changes in honey-treated cells were seen 
only with TEM, where a statistically significant increase in the number of whole 
cells with completed septa compared to untreated cells were observed 
(p<0.05). Structural changes found with TEM suggest that honey-treated cells 
had failed to progress normally through the cell cycle and accumulated with fully 
formed septa at the point of cell division without separating. The elevated 
numbers of cells with entire septa were found to accumulate autolysins (also 
known as murein hydrolases) which according to the investigators are 
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implicated in the bactericidal effect. A bactericidal mode of inhibition for Manuka 
honey on S. aureus was thus demonstrated. (110) According to the 
investigators, the close proximity of the MIC and MBC values observed also 
indicates a bactericidal mode of action for Manuka honey with S. aureus NCTC 
10017. The increased sensitivity of an autolysin (atl) mutant compared to its 
parental strain (p<0.001) suggests that the target site is associated with 
bacterial cell division. (110) The investigators claim that sugars are not 
implicated in the observed bactericidal effect. 
 
In a related study, researchers observed an inability to complete the cell cycle in 
MRSA treated with Manuka honey despite an increased expression of the 
autolysin gene, where murein hydrolase activity was at undetectable levels. 
(111) Along with this, the failure to cleave peptidoglycan was thought to 
contribute to the persistence of the septa and to the failure to divide and 
complete the cell cycle. (111) Consequently, the investigators have concluded 
that the action of Manuka honey involves the cell division machinery. (111)  
 
An in vitro study of four types of honey, three sourced from amateur bee 
keepers from Northern Ireland and one commercial honey from Suisse 
Normande, France, found that honey reduced the bacterial count of CA-MRSA 
isolates.  (112) Similar findings were reported in a clinical study of medical-
grade honey applied to chronic wounds. (113) 
 
In time-kill studies, loss of bacterial viability was observed when bacteria were 
incubated in 10% (w/v) Manuka honey in nutrient broth and compared to 
untreated cells. In the presence of Manuka honey the mean time to achieve a 2 
log reduction was 427 min. The investigators claim that failure to recover viable 
bacteria after 8 h confirmed that the bacterial inhibition was irreversible.  
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Eradication of pathogens from wounds using honey 
In one of the early reports on the use of honey in clinical studies, rapid healing 
of an ulcer colonised with MRSA and its successful eradication from the ulcer 
was documented in 2001. (92) Later in 2007, investigators from Germany 
reported on the effects of medical honey on healing wounds. This report alluded 
to seven consecutive patients whose wounds were either colonised or infected 
with MRSA and which healed. (99) The authors state that despite the use of 
topical antiseptics and topical antibiotics in some patients, as well as the 
systemic use of vancomycin in three patients, MRSA had persisted in some of 
the seven patients for up to five years. Following the daily application of honey, 
MRSA was eradicated from all wounds and, in most cases, without the 
additional use of antimicrobial treatments.  
The clinical observations from these two reports imply the potential benefit of 
using honey for the healing of wounds. However, direct causality was not 
established from observational studies, which necessitates RCTs. 
 
A multi-centre RCT on the management of venous leg ulcers found that Manuka 
honey was found to be effective in eradicating MRSA from 70% (n=7 of 10) of 
chronic venous ulcers in comparison to hydrogel where no change on MRSA 
colonisation were identified (n=6). (113) A triple blind RCT concluded that 
honey was effective in healing Caesarean section incisions. (107) In 2015 a  
Cochrane review concluded that honey healed infected post-operative wounds 
more quickly than antiseptics and gauze. (90)  
 
In 2007, the US Food and Drug Administration (FDA) approved the first honey-
related wound product, a sterile, single-use wound care dressing impregnated 
with 95% honey and 5% sodium alginate. It was approved in the United States 
for use in minor traumatic or surgical cuts and burns, and on select ulcers. (114)  
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Honey and bacterial biofilms 
Living organisms have evolved and developed mechanisms to adapt 
themselves to hostile environments and their survival. One of the mechanisms 
which bacteria have developed is to produce a slimy substrate or biofilm. 
Bacteria that attach to various surfaces often produce biofilm which serves as a 
protective covering render them harder to eradicate. 
Many pathogenic bacteria colonising wounds produce biofilms. Streptococcus 
pyogenes (S. pyogenes,) group A Streptococcus (GAS) are some of the 
pathogens of clinical significance in wounds where it can initiate infection, 
destroy skin grafts and persist as a biofilm. Pseudomonas is another 
opportunistic pathogen that can cause persistent wound infections which is 
linked to its ability to form biofilms. The formation of biofilms on wounds 
depends on the adhesion of bacterial cells. It is thought that the most abundant 
sugar in honey namely fructose, prevents bacteria from binding to host-cell 
membrane receptor sites. (69) Without bacterial adhesion to wounds and other 
vulnerable surfaces, neither bacterial biofilms nor infection can develop.  
The effect of Manuka honey on S. pyogenes (M28) in vitro with planktonic and 
biofilm cultures using MIC, MBC, microscopy and aggregation efficiency was 
studied. Bactericidal effects were found in both planktonic cultures and biofilms, 
although higher concentrations of Manuka honey were needed to inhibit 
biofilms. The prevention of adherence and intercellular aggregation were also 
noted. Manuka honey permeated 24 h established biofilms of S. pyogenes, 
resulting in significant cell death and dissociation of cells from the biofilm. (103)  
 
An investigation on the impact of Manuka honey on wound pathogens in vitro, 
focusing on its anti-adhesive properties, found that Manuka honey effectively 
disrupted and caused extensive cell death in biofilms produced by S. aureus, P. 
aeruginosa and S. pyogenes. Sub-lethal doses of Manuka honey inhibited 
bacterial adhesion to fibronectin, fibrinogen and collagen. Manuka honey 
impaired adhesion of laboratory and clinical isolates of S. aureus, P. aeruginosa 
and S. pyogenes to human keratinocytes in vitro, and inhibited invasion by S. 
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pyogenes and vancomycin intermediate S. aureus. (115) Other investigators 
also have demonstrated that Manuka-type honeys showed significantly higher 
anti-biofilm activity than clover honey and an isotonic sugar solution in all S. 
aureus strains tested, including MRSA strains. In some cases honey was able 
to penetrate through the biofilm matrix and was able to kill the embedded cells. 
Based on these findings the investigators suggest that MGO requires other 
components that are present in Manuka-type honeys for the anti-biofilm activity 
observed. (116)  
 
Honey and bacterial log reduction 
Based on time kill studies, Henriques and colleagues calculated the mean time 
to achieve a 2 log reduction of viable bacterial populations of S. aureus, in the 
presence of 10% (w/v) Manuka honey which was 427 min. Using a similar 
approach the same investigation team assessed the time required to achieve a 
3 log reductions for MRSA, and the mean estimated time was 770 min. (110)  
 
Summary on honey for medicinal purposes 
Honey has been used historically for medicinal purposes and in contemporary 
times a renewed interest on the use of honey for its healing purposes has 
invigorated researchers to investigate and validate such claims. The low pH of 
honey which ranges from 3.2 to 5.5 along with its high osmolarity renders honey 
inhospitable to microbial growth. The enzymatic action of hydrogen peroxide 
and the presence of phytochemical components i.e. MGO, the antimicrobial 
peptide; bee defensin-1 contributes to the antibacterial action of honey. An 
observed decreased expression of UspA protein in honey-treated cells implies 
that MRSA is unable to accommodate the stresses caused by exposure to 
Manuka honey. As a wound healing agent, honey acts both as an 
immunomodulator with both proinflammatory and anti-inflammatory properties, 
inducing or stimulating the release of TNF-α, IL-1β, and IL-6 from MM6 cells 
and peripheral blood monocytes. Emerging evidence suggest that other factors 
may also contribute to the beneficial effects of honey. 
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Evolution of the concept leading to the pilot study 
The researcher, an infection prevention and control practitioner was inquisitive 
with regards to the antibacterial claims of licensed medical grade honey (MGH) 
preparations as well as MGH applications on the management of wounds and 
ulcers. The initial enquiry brought forth a wealth of evidence on the antibacterial 
properties of honey in in vitro studies and clinical studies on wounds and ulcers 
following the application of medical grade honey preparations. Various medical 
grade honey preparations that were used for the management of wounds with 
antibacterial claims were investigated. Consideration was given to an off-the-
shelf Conformité Européene (CE) marked MGH preparation that was feasible to 
apply on the nasal passages, with antibacterial claims and which offered 
potential. In consultation with a Consultant Microbiologist in Beaumont Hospital 
(BH), a pilot study was planned. After Ethics (Medical Research) and Irish 
Medicines Board (currently Health Products Regulatory Authority - HPRA) 
approval, the ‘Natural Honey for Eradication of nasal MRSA a pilot study’ was 
carried out in 2012.  
 
Pilot study 
Medihoney™ Derma Cream, a standardised medical grade natural honey, 
licensed for application on the skin was used in the pilot study. Medihoney™ 
Derma cream contains 30% Leptospermum honey, which the manufacturer 
claims is antibacterial. Over a period of 20 weeks, seven patients were 
consented and were enrolled in the pilot study. All the seven patients were 
persistent MRSA colonisers i.e. had at least two courses of nasal and other 
non-nasal decolonisation using standard decolonisation regimen and had failed 
nasal eradication of MRSA. The standard MRSA decolonisation regimen 
employed in BH consists of three times a day application of mupirocin 2% for 
five consecutive days for nasal MRSA colonisation, and triclosan 1% 
(Skinsan®) daily wash and shampoo for at least two days over the five 
consecutive days for decolonisation of intact body sites. A second course of 
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decolonisation was applied in the event of persistent colonisation using 
mupirocin 2% and Skinsan®.  
In the pilot study the following regimen was used for Medihoney™ Derma 
Cream. Medihoney™ Derma Cream was administered three times a day for five 
consecutive days along with Skinsan® wash daily and shampoo for at least two 
days over a period of five days. This was followed by two treatment free days. 
MRSA screening was performed according to the standard MRSA screening 
protocol, i.e. day seven or later after the commencement of the first course of 
Medihoney™ Derma Cream. Patients with persistent nasal colonisation after a 
course of decolonisation were administered a second course of Medihoney™ 
Derma Cream and Skinsan®, which was informed by the results of the patient 
screening. 
Pilot study results 
Of the seven patients who enrolled for the pilot study, two discontinued the 
study between 0-2 days after commencement. One patient completed one, and 
four patients’ completed two full courses of Medihoney™ Derma Cream nasal 
application. Successful nasal MRSA decolonisation was achieved in three of the 
five cases and two had persistent nasal MRSA colonisation after two courses of 
Medihoney™ Derma Cream application. Of the two patients who discontinued 
Medihoney™ Derma Cream, one was due to clinical deterioration of the 
patients’ chronic medical condition. The second patient experienced an 
unpleasant odour and taste which resulted in discontinuation from the study.  
 
The pilot study also involved collating patient experience on the use of 
Medihoney™ Derma Cream, as well as patients’ perception on the use of the 
natural agent for MRSA eradication. Six of the seven patients enrolled in the 
pilot study completed the structured statement questionnaire that used a Likert 
style response to collate patient experience on the use of the Medihoney™ 
Derma Cream. Most of the respondents were of the opinion that the 
investigative product was not sticky, did not cause any unpleasant sensation in 
the nose and was easy to apply to the nasal passages. Two of the six 
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participants felt that their nose was moist and runny after nasal application of 
the product. Of the six participants, five preferred the use of a natural product to 
an antibiotic, if they were given a choice, to eradicate MRSA from the nose. 
 
Overall the pilot study results were encouraging which warranted further 
investigation. Considering the paucity of effective alternatives that are currently 
available along with increasing resistance to agents that are used for MRSA 
eradication, the investigating team proposed that medical grade honey was 
non-inferior to mupirocin 2%, i.e. the current standard of care.  
A proposition must be tested to support or reject the informed hypothesis in 
order to be valid. The research team with a keen interest on prevention and 
control of MRSA developed the study protocol to conduct a clinical trial (CT). A 
well designed CT was essential in demonstrating the eradication of nasal MRSA 
using Medihoney™ Derma Cream in comparison to mupirocin 2%. Potential 
sources for funding for the CT were investigated.  
 
In conclusion, nasal MRSA eradication with mupirocin 2% nasal ointment is 
suboptimal. Therefore, there arose a compelling need for evaluating alternative 
agents for the eradication of MRSA. The pilot study results using medical grade 
honey for nasal MRSA decolonisation offered potential. (Appendix Ⅰ Natural 
Honey for Nasal MRSA Pilot study report). 
 
Justification on the use of honey in the NHNMRSA RCT 
The research team, given past experience with the use of Manuka honey in pilot 
clinical studies, further investigated the potential for honey to eradicate MRSA 
from the nose. The research team were of the opinion that the antibacterial 
properties of honey along with its bactericidal mode of action identified by MIC, 
MBC and time kill studies merited a case for further studies in a clinical 
environment.  
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The idea conceived was further explored by the researcher for medical-grade 
honey preparations that were already available on market. The intended aim 
was to identify a possible ‘off the shelf’ CE marked honey product with a 
manufacturer’s claim of antibacterial properties, that could be clinically 
evaluated.  The search for a potential honey preparation narrowed the 
possibility to two products with varying concentrations of medical grade honey. 
Feedback was received from healthy volunteers who applied the selected 
honey products of varying concentrations on their nostrils. Based on 
antibacterial claims, volunteer feedback, ease of nasal application and 
resemblance to mupirocin 2% nasal ointment, the control product, a cream with 
30% Leptospermum honey, Medihoney™ Derma Cream, was identified as the 
honey that could be used for a comparative investigation.  The manufacturer’s 
claim that Medihoney™ antibacterial honey is effective against S. aureus and 
MRSA at a dilution of 4%, supported by in vitro studies, and that Medihoney™ 
Derma Cream contains 30% Medihoney™ antibacterial honey. 
The dose calculation of the investigative product used in the RCT, Medihoney™ 
Derma Cream was decided based on time kill studies, details of which will be 
discussed in detail in the Materials and Methods chapter. 
 
1.7 Hypothesis 
Medical grade honey is non-inferior to mupirocin 2% for nasal MRSA 
eradication.  
 
1.8 Study Objectives 
The overall aim of this project was to compare the efficacy of medical grade 
honey to eradicate nasal MRSA with that of mupirocin 2%.  
In order to achieve the overall aim, five specific objectives were formulated, 
which are listed in order. 
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1. To conduct a systematic review of the literature on mupirocin resistance and 
alternatives for the decolonisation of MRSA in the nose.  
2. To conduct a RCT comparing medical grade honey with mupirocin for nasal 
decolonisation of MRSA. 
3. To identify rates of mupircoin resistance among MRSA isolates using routine 
laboratory methods i.e. MIC E test.  
4. To investigate the phenotypic and genotypic characteristics of bacterial 
isolates; first time (historic, where available), baseline (at recruitment) and 
subsequent isolates using standard laboratory methods, and to investigate the 
MIC and minimum bactericidal concentration MBC of MGH product used. 
5. To determine the perceptions and attitudes of patients on MRSA and the use 
of nasal decolonisation agents, mupirocin and Medihoney™ Derma Cream. 
 
The methods used to achieve the objectives, results and discussion of the 
results are addressed as follows; chapter Ⅱ describes the methodology applied 
to conduct the study to achieve each of the five stated objectives. Study results 
are collated in chapter Ⅲ in the same order as the study methodology, which is 
followed by discussion, conclusion and recommendations in chapter Ⅳ. All 
appendices are listed in order which follows the bibliography.  
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Chapter Ⅱ Materials and Methods 
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2.1 Literature review methodology  
 
2.1.1   Introduction  
This section summarises the methodology that was used in the search of 
existing literature on mupirocin resistance and alternatives for MRSA 
decolonisation.  
 
2.1.2   Aim of the literature review 
The aim of the review was to determine the prevalence of MR as well as 
measures employed to control MR. In addition, the review also ascertained the 
evidence supporting the use of new agents as potential therapeutic alternatives 
for MRSA decolonisation. The literature review was modified from what was 
initially conceived in the study, based on the initial literature search which we 
consider in the next section. 
 
2.1.3 Literature search   
The initial literature search sought to retrieve articles related to clinical use of 
honey for nasal MRSA decolonisation. No articles were retrieved in the initial 
search that addressed honey and nasal MRSA. Therefore the search was 
subsequently modified to MR and alternatives for MRSA decolonisation.  
2.1.3.1 Information source and search strategy 
The search was conducted using on-line data bases; PubMed, Cumulative 
Index of Nursing and Allied Health Literature (CINAHL), Scopus and Web of 
Science. The search strategy was initially developed for use in PubMed (using 
Medical Subject headings (MeSH) terms to identify alternative phrases for the 
key words) and was then modified for each data base, for example for Medline, 
Medline terminology (MH). Combinations of the following MeSH terms and 
combinations were used in the initial search. MRSA, methicillin-resistant 
Staphylococcus aureus, meticillin -resistant Staphylococcus aureus,  MH 
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methicillin-resistant Staphylococcus aureus, MH methicillin-resistance, MH 
Staphylococcus aureus, Staphylococcus aureus, S. aureus, methicillin-
resistant*, Meticillin-resistan*, nasal colonisation, nasal colonization, nasal, 
nose, MH nose, colonisation, colonization, decolonisation, decolonization, MH 
Honey OR honey, MH infection control OR prevention and control.  
The modified search was done based on the revised literature review and 
included the following additional search terms: wounds and injuries OR wound 
infection OR wound healing OR surgical wound infection,  ulcer, topical, 
administration topical, treatment or application, mupirocin, mupirocin, resistan*, 
Drug resistance OR drug resistance. 
The search parameters were saved on the on-line data bases where the 
function was available and email updates of new publications were requested 
on new publications in the area. Records were kept of what data bases were 
searched and with what terms.  
2.1.3.2 Study selection 
Randomised controlled trials, case control studies, non controlled studies, 
observational studies, diagnostic / laboratory studies, surveillance reports, 
reviews, guidelines, expert opinions, consensus reports, qualitative reports, 
investigation and in vitro studies that focused on MRSA surveillance, 
decolonisation, mupirocin, mupirocin resistance and studies reporting 
alternative and novel agents for MRSA decolonisation were included. Studies 
from 1981 to May 2015 were included and the search was limited to English 
language and human studies. The searches were last updated in 31st January 
2016. 
 2.1.3.3 Data extraction and analysis 
The results of the searches were downloaded to Endnote file and reviewed for 
relevancy based on the article title and abstract. From the title and abstract 
review, those articles that were not relevant to the topic of interest or duplicates 
were deleted. Additional publications were identified by a manual search of the 
reference list of relevant articles. The full texts of the relevant articles were 
sourced either from the library, the web or from the author. Further articles were 
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eliminated following review of the full article. The studies selected were 
analysed qualitatively, findings collated under relevant sub-headings and the 
results summarised. From a total of 4636 titles that were initially found, 499 
articles were shortlisted based on title and abstract review. After exclusion for 
reasons of not relevant or duplicates, 89 articles remained for inclusion 
including those identified from reference lists. The search process is illustrated 
in Figure Ⅰ, appendix - Ⅱ. 
 
2.1.4 Conclusion 
Undertaking a comprehensive literature review offers a unique learning 
experience. The researcher learned skills in carrying out searches in databases, 
the use of the scientific vocabulary, different expressions or terms to express 
similar meaning to broaden the search. The literature review enabled the 
researcher to submit a review to a scientific journal that was subsequently 
published with the title: Mupirocin resistance:  Clinical Implications and potential 
alternatives for the eradication of MRSA, in the Journal of Antimicrobial 
Chemotherapy, October 2015 (appendix - Ⅲ copy of the article). 
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2.2 RCT Methodology  
 
2.2.1 Introduction  
The natural honey to eradicate nasal MRSA, a randomised controlled trial 
investigated the potential for eradication of MRSA from the nasal passages in 
humans with medical grade honey (MGH). The investigator hypothesised that 
MGH is non-inferior to mupirocin 2% for nasal MRSA eradication. This chapter 
outlines the methodology that were applied in the RCT, including the trial 
design, generation of sample size, randomisation and allocation, participants, 
patient data collection after consent, institutional/ethical submission and 
approval. The chapter concludes with a summary on the learning experience 
gained by the investigator. 
 
 2.2.2 Institutional / ethical submission and approval 
The Beaumont Hospital Ethics (Medical Research) Committee reviews 
applications to undertake research in Beaumont Hospital (BH), and two other 
hospitals namely; St. Joseph's Hospital in Raheny, and St. Ita's Hospital in 
Portrane, Dublin. In March 2005, the committee was recognised by the 
Department of Health Ireland, to review applications for clinical trials of 
medicinal products (clinical drugs trials) for the whole of Ireland.  
For a clinical trial to proceed in Ireland, both an Ethics Committee and the 
Health Products Regulatory Authority (HPRA), previously known as the Irish 
Medicines Board (IMB), must approve a clinical drugs trial. In addition, a drugs 
trial must have a European Clinical Trial number, called a EudraCT number, 
and adequate insurance must be in place. An indemnity form must be 
completed with the hospital for academic clinical trials before the study can 
commence.  
Applications were submitted to the Beaumont Hospital Ethics (Medical 
Research) Committee in November 2013 to conduct the study, “Natural Honey 
to Eradicate Nasal MRSA A Randomised Controlled Trial, REC reference 
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number 13/103”. REC approval was granted on  24th January 2014 (appendix –
Ⅳ, copy of the REC approval) 
The advice of the HPRA was sought in relation to the approval required to 
conduct this study at the pilot stage. Consequently, a clinical trial (CT) 
application for a medicinal product was made to what was then the IMB. 
Registration for CT was done in accordance with the European Union (EU) 
clinical trials registry requirements. European Clinical Trial - EudraCT is a 
database of all clinical trials which commenced in the EU from 1 May 2004, and 
also includes clinical trials linked to European paediatric drug development. On 
successful registration, a unique reference for the trial, a EudraCT number 
2010-023408-28, was allocated to the NHNMRSA RCT (appendix Ⅴ, a copy of 
the allocated EudraCT number). 
Subsequent to the IMB review of the CT application, the researcher was 
advised to submit a revised application to the IMB for the study of a medical 
device. The investigative product, Medihoney™ Derma Cream is a CE marked 
licensed medical device bearing the ‘CE number 0120’. The IMB subsequently 
issued the following statement on the review of the application for the study of a 
medical device; 
‘Further to the information you (researcher) have provided on your proposal please be 
informed that clinical research involving CE marked medical devices that is being 
conducted by academic / clinical investigators when there is no commercial intent for 
use of the data do not require review and approval by the IMB prior to commencement’. 
(appendix –Ⅵ copy of the IMB statement) 
The study commenced following receipt of approval from the Beaumont 
Hospital Ethics (Research) Committee, and after insurance and indemnity 
arrangements with the hospital were confirmed. 
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2.2.3 Study settings and location 
Study setting 
The study setting, Beaumont Hospital is a tertiary referral centre and the 
national centre for neurosurgery, renal and pancreatic transplantation, and a 
regional treatment centre for ear, nose and throat, and gastroenterology 
patients. The 820 bed hospital incorporates a twelve-bedded general intensive 
care unit (ICU) and a ten-bedded neurosurgical ICU. The hospital serves a 
population of 1.2 million in North County Dublin and Fingal, (BH Annual report 
2013) as well as patients referred from other parts of the country.  In 2013 there 
were 24,634 admissions, during which 57,968 day cases and 227,958 bed days 
were used. The outpatient department had 181,389 patients attending its 
service in addition to 51,045 patient attendances in the Accident and 
Emergency Department. 
 
Identification of eligible patients based on laboratory surveillance   
Microbiology specimens collected from patients for clinical and screening 
purposes are processed in the BH microbiology laboratory. Test results were 
reported according to the routine reporting protocol and filed electronically in the 
laboratory system ‘Patient Information Profile Explorer (PIPE)’. The Irish 
National Accreditation Board (INAB) accredited diagnostic laboratory in BH and 
the microbiology laboratory utilises systems and processes that safeguard user 
data and that comply with the Data Protection Act 1998 and subsequent Data 
Protection (Amendment) Act 2003.   
Positive MRSA results were routinely notified to the IPC personnel, and this 
data was made available to the researcher. Potential candidates for recruitment 
to the NHNMRSA RCT were initially identified by the researcher from the 
routine clinical microbiological surveillance data. Individual patient test results 
were also available to the clinical supervisor who had access to the password 
protected hospital information technology (IT) system. A preliminary screening 
for eligibility was performed by the researcher for the patients who were 
confirmed with nasal MRSA colonisation, based on the patient’s current location 
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of stay and the episode / health care point of contact where the relevant 
microbiological investigations were ordered.  
 
Target Population 
The target population for the RCT was the adult patient population of the 
hospital. This accounts for a total population of 1.2 million in North County 
Dublin as well as patients referred to BH from the rest of Ireland. The entrants 
for the NHNMRSA study originate from the target population.  
 
Source and eligible population 
Due to confines of this study resources, the source population, a selected group 
based on MRSA screening outcomes was a necessity. In identifying the source 
population, the following criteria were applied. Inpatients or outpatients in BH, 
who are colonised with MRSA on their nose and living with the geographical 
catchment area of BH at a distance not more than 30 kilometres, for patient 
follow up purposes, were considered suitable for recruitment. In addition, it was 
essential that each patient met the specific inclusion and exclusion criteria. For 
the purpose of eligibility in the NHNMRSA study, a detailed inclusion and 
exclusion criterion was developed and presented in the section that describes 
the Participants, Sec 2.2.4 
 
Study entrants 
Study entrants were defined as those patients who consent to and enrol in a 
study. The study entrants at the outset originate from the target population. 
Subsequently the criteria for initial screening and follow up of patients were 
applied to the source population, and thus the eligible population was identified. 
Using this approach the study entrants were identified from the eligible 
population.  
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2.2.4 Study participants 
Patients were recruited for the RCT from BH only. The eligibility criteria were 
patients who were laboratory confirmed with MRSA in their nasal passages, on 
a prospective basis and otherwise suitable according to inclusion and exclusion 
criteria.  
 
Inclusion criteria  
• Age at recruitment, over 18 years. 
• In-patient in Beaumont Hospital at the time of MRSA detection. 
• Able to understand the nature and purpose of the study and provide 
informed consent. 
Exclusion criteria 
• Participating in another clinical trial. 
• Uncontrolled diabetes mellitus. 
• Known hypersensitivity to, or intolerance of, honey or mupirocin.  
• Known to be colonised with strains of S. aureus that were mupirocin 
resistant. 
• Likely to be difficult to follow up due to geographic location; i.e. place of 
residence 30 km or more from BH (see below).  
• Bloodstream infection or active infection in other body site/s. 
• Undergoing acute or elective surgery that involved placement of 
implants. 
• In an intensive care unit. 
Justification of exclusion of a segment of the population  
If the patient’s normal residence was over 30 kilometres away from BH, they 
were excluded from the study due to restrictions on the time and resources 
available to the researcher for adequate follow up of patients on their discharge.  
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2.2.5 Study outcomes 
Primary outcome 
The primary end point of the RCT was ‘the proportion of patients decolonised of 
nasal MRSA after a second course of mupirocin or the nasal honey product, 
regardless of whether re-colonisation occurred later’.  
The primary outcome was assessed based on the microbiology laboratory 
screening of each patient who completed the study. The microbiology laboratory 
screening and reporting were according to established protocols specified in BH 
Laboratory Protocol; LP-MIC-Screens-Revision 4-2013 (appendix-Ⅶ). 
Case definition 
 A current documented microbiological finding of MRSA in the nasal passages 
of a patient, reported by the BH microbiology laboratory, were defined as a case 
of nasal MRSA in the NHNMRSA study. 
 
2.2.6 Available sample 
  In order to estimate the overall prevalence of MRSA among the source 
population, the researcher considered the routinely collected annual 
surveillance data on MRSA at BH for two consecutive years. In 2014, 18,318 
swabs for screening test were processed in BH microbiology laboratory, i.e. for 
MRSA detection, resulting in 274 new cases of MRSA being identified. During 
2013, 13,726 swabs for screening test were processed with 275 new MRSA 
cases detected.  
In addition to new cases of MRSA, previously known patients who were 
colonised with MRSA were also screened on subsequent admissions or for 
other clinical purposes.  Of the 544 unique patient records identified in 2014 
with a new or known MRSA status, 137 patients were classified external cases, 
i.e. the patients were not in-patients but were in nursing homes or in the 
community. Of the remaining 407 patients, 274 were classified as new and 133 
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were known cases of MRSA. In 2013, of the 275 new cases of MRSA, 196 were 
BH inpatients or outpatients and 78 were external cases.  
Based on the microbiology laboratory surveillance data, approximately 500 
cases of MRSA were detected annually of which approximately 30% of cases 
were ineligible i.e. patients not admitted to the hospital. Having also excluded 
those patients with only non-nasal colonisation, i.e. about 30% of MRSA 
patients, the potentially eligible number of patients therefore was 115-120 in a 
calendar year. 
 
Sampling strategy 
In BH, screening of patients for MRSA was based on the hospital ‘Guidelines on 
the control and prevention of MRSA’ (2007), which are based on the National 
Guideline ‘The Control and Prevention of MRSA in Hospitals and in the 
Community’ (2005). (25) In practice, no constraints were applied in BH on the 
screening of patients who otherwise fit the criteria for MRSA screening. Swabs 
were processed according to established laboratory protocols and results were 
reported on an ongoing basis.  
A simple random strategy for sampling patients, where patients had an equal 
chance for allocation into one of the study groups, provided a patient had 
documented nasal MRSA colonisation, was deemed the most appropriate 
sampling approach for the study. 
 
2.2.6.1 Sample size estimation  
The most important consideration in estimating the sample size for a study is 
that, the study should have adequate power to detect a statistical significant 
difference between intervention and control groups, with reference to a defined 
end point. In order to estimate the sample size for the NHNMRSA RCT, the 
researcher investigated studies that evaluated the efficacy of mupirocin for 
nasal decolonisation as well as RCTs that employed honey based products. 
Other comparable studies were also examined for sample size determination. In 
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consultation with an expert methodologist who was part of the RCT team, data 
from the following studies were reviewed to estimate the sample size.  
In a multicentre trial in care homes of 127 residents, intranasal mupirocin 
ointment was compared with a placebo among persistent carriers of S. aureus 
and MRSA with a follow-up period of 6 months. Mupirocin initially eradicated S. 
aureus, including MRSA in 94% (60/64) compared with 86% (54/63) in the 
placebo group, but after 90 days recolonisation occurred in 39% (p=0.003) of 
the mupirocin group. (35)  
In another study of 87 patients, a double-blind, randomized, placebo-controlled 
trial in a tertiary healthcare facility evaluated the efficacy of mupirocin in 
eradicating nasal carriage of MRSA along with body washes using 
chlorhexidine soap for non-nasal sites. At four weeks from the initiation of 
decolonisation, 19/43 (44%) who received mupirocin were free of nasal MRSA 
compared with 11/44 (25%) (p=0.40) in the control group. (24)  
An RCT of 108 patients that employed honey based dressings (n=54) in 
comparison to hydrogel (n=54) for vascular leg ulcers, identified that ulcers 
colonised with MRSA treated with honey based dressings (10) had a 70% 
decolonisation rate in comparison to hydrogel (6) with 16% decolonisation.  
An in vitro study of six CA-MRSA clinical isolates found that all isolates were 
susceptible to natural honey, and bacterial counts were at undetectable levels 
at 24 h. (117)   
Based on the scientific literature review, the efficacy of nasal MRSA 
decolonisation with mupirocin was estimated to be 40-60%. Overall, the 
research team therefore concluded that on the upper side a 60% success rate 
was achievable with mupirocin 2% nasal ointment.  Therefore an estimated 
success rate of 60% was used as the basis for sample size calculation. 
 
2.2.6.2 Power and sample size  
From previous literature it was estimated that the decolonisation rate with 
mupirocin 2% nasal ointment was approximately 60%. Estimation of the sample 
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size in the study was based on the achievement of an 80% decolonisation rate 
(a 33% relative difference), with 80% power at significance level of 0.05%. A 
sample size of 188 would be required to achieve this, i.e. 94 in each group.  
 
2.2.7 Randomisation 
The ability to randomise subjects to treatments that distinguishes experiments 
from surveys is termed randomisation. Randomisation is the method of 
removing selection bias between two groups of patients. Randomisation is 
essential in experiments such as clinical trials as it minimises the chance of a 
biased result. Pocock is of the opinion that randomisation is the best method of 
removing selection bias between two groups of patients. (118) Randomisation is 
therefore fundamental in designing good experiments as it substantially reduces 
the chance of bias. (119)  
 
Methods of randomisation 
For randomisation of subjects, various methods were employed by 
investigators. In practice, computer assisted generation of random numbers and 
random sequences were used for randomisation. Simple and block 
randomisation were the two methods commonly used for randomisation of 
subjects.  
In simple randomisation, each patient’s treatment is determined at random 
independently with no constraints applied. Consequently, there is an equal 
chance of allocation to two treatment groups, which is equivalent to tossing a 
coin. According to Hewitt, simple randomisation is a safe approach as it is 
completely unpredictable and is less prone to technical errors. (120)  
Block randomisation, also called restricted randomisation is another approach 
that keeps the subject numbers in each group very close at all times. The 
generation of randomisation sequence and securing random sequence using 
the block randomisation method is elaborated in the forthcoming section.  
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In the NHNMRSA RCT, block randomisation and remote allocation method was 
used which will be elaborated in the following section. 
 
2.2.7.1 Generation of randomisation sequence  
In the NHNMRSA study, the generation of random sequences was done using 
the block randomisation method. For the purpose of equal block randomisation, 
pre-sealed envelopes and pre-printed labels were used. Pre-printed labels 
entitled, mupirocin 2% and Medihoney™ Derma Cream, were placed in blank 
opaque envelopes and sealed and held in two separate packs. Eight envelopes, 
four with mupirocin and four with Medihoney™ Derma Cream labels, were 
mixed and bundled into a block, and each block of eight envelopes were serially 
numbered in total 24, (8 x 24) blocks.  
 
2.2.7.2 Securing random sequence 
The 24 blocks of eight envelopes each were securely stored in the IPC nursing 
office. Access to the random sequence blocks of envelopes was limited to an 
administrator who was not involved in the study. The researcher did not have 
access to the random sequence blocks. The benefit of the block randomisation 
method used in the study was that, in the event of patient enrolment being less 
than estimated, equal block randomisation approach offered optimal 
comparative analysis of patients in both the investigative and control groups.  
 
2.2.7.3 Allocation concealment  
Once a patient was consented, she/he must be allocated to one of the 
treatment groups; investigative or control. This must be based on the random 
sequence that was generated and held remotely for study rigor and an unbiased 
approach.  
In randomised studies, the process of allocation can be compromised such that 
allocation results in biased groups of patients. Allocation bias may occur when, 
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for example, the investigator holds the random sequence, if there is tampering 
of the envelopes holding the allocation before patient consent, or a number of 
envelopes are opened at the same time. Unconcealed randomisation can lead 
to tampering of envelopes thereby leading to potential bias in allocation. 
Therefore, various methods have been employed by investigators to minimise, 
and where possible, eliminate bias in allocation. One of the most common 
methods employed is the sealed opaque envelope system. (121) In this 
approach, only after a patient is consented to enter a trial is the pre-sealed 
opaque envelope opened and then the patient is allocated to the treatment 
regimen as specified in random allocation obtained from the sealed envelope.   
In this study, once a patient was consented, the researcher telephoned the IPC 
nursing office for the next allocation and the unique study number for the study 
participant. The study number and allocation were recorded by the researcher 
on the case report form (CRF), as well as the proforma study enrolment sticker, 
which were then affixed to the patient’s medical record specifying the date and 
time of enrolment. Access to the pre-sealed block envelopes were restricted to 
one administrator who were not involved in the study. The researcher did not 
have access to the random sequence, i.e. the opaque pre-sealed envelopes 
holding the random sequence. In addition, the researcher was based at a 
remote location from the IPC office during the study period. 
 
2.2.7.4 Blinding  
After allocation, due to the nature of the interventions in the study, both the 
patient and the researcher knew the group that each participant was assigned 
to. As both mupirocin 2% (Bactroban® 2%) nasal ointment and Medihoney™ 
Derma Cream were distinguishable due to packing, the participant and 
researcher were able to recognise the specific product that a patient was 
allocated. Therefore, blinding of the participant or researcher was not 
achievable in the RCT.  
However laboratory analyses were completed without knowledge of treatment 
allocation thus minimising the potential for ascertainment bias. The laboratory 
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personnel in the clinical microbiology department of BH were not able to 
distinguish screening swabs from the study or from other patients screened for 
MRSA. This approach eliminated detection bias in reporting the MRSA 
screening results.  
Statistical analysis of the data was undertaken after completion of the RCT. The 
data of both treatment and control groups were masked, thus blinding the 
statistician.  
 
2.2.8 Patient recruitment  
2.2.8.1 Recruitment process  
For patients admitted to the study hospital and confirmed that they were 
colonised with MRSA based on laboratory results, the researcher liaised with a 
senior nursing staff responsible for the patient and evaluated the patient’s 
suitability for recruitment based on their clinical condition, expected prognosis 
and the criteria for inclusion and exclusion. Prior to taking patient consent, an 
individual patient’s eligibility to enrol in the study was formally assessed, i.e. 
considering each of the inclusion and exclusion criteria by the researcher. 
Patients who fulfil the inclusion criteria were deemed eligible for enrolment. 
Thereafter, a patient who was considered suitable for participation in the RCT 
was approached by the researcher. At the first instance the patient’s awareness 
of their MRSA colonisation and or specimen collected for screening tests were 
assessed. The researcher then discussed with the patient the results of their 
MRSA screening tests and where appropriate, the outcome of past 
decolonisation attempts. The researcher then provided information about the 
NHNMRSA study in detail as listed in the Patient Information leaflet (PIL) 
(appendix - Ⅷ copy of PIL version 3). Patients were encouraged to ask 
questions or clarifications during the subject - investigator interaction. The 
researcher also summarised the key aspects of the RCT to the patients 
recruited, especially the random allocation to either group after consent. 
Patients were advised to consider the study information at the first instance and 
encouraged to make an informed decision on their participation in the study. 
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After sufficient time, usually twenty-four hours from the first contact by the 
investigator, the researcher made a follow-up visit to the patient to address 
queries and provide any clarifications as required. During the follow up visit, the 
patient’s study enrolment and consent was considered. A patient’s consent was 
obtained in triplicate; a copy for the patient, medical record and for the 
researcher. Each patient consented and enrolled in the study was allocated a 
unique case number, which was provided by an administrator through remote 
allocation.  
 
Non-nasal MRSA decolonisation 
The routine practice in BH in the decolonisation of patients who are colonised 
with MRSA at non-nasal sites is concurrent decolonisation using skin 
antiseptics while undergoing nasal decolonisation. This practice continued 
during the RCT for both patient groups. A concurrent nasal and non-nasal 
decolonisation course consisted of daily showering or washing with 
chlorhexidine shampoo for at least two days during the five consecutive days of 
decolonisation and nasal decolonisation. Aqueous chlorhexidine 4% w/v or 
triclosan 2% (Skinsan™) was used for body washing and showering.  
 
2.2.8.2 Patient Recruitment challenges 
The ability of patients to consent, apply the study product, and their geographic 
location, i.e. normal residence, were factors likely to impact upon potential 
patient recruitment. Past experience of the researcher as a specialist IPC 
practitioner and from patient surveys, as well as audits of patient 
communication, indicated that there would be significant challenges in patient 
recruitment. In addition, effective patient communication is another challenge 
that the researcher was cognisant of. A patient awareness survey (2012) 
among inpatients in BH who were colonised with MRSA confirmed that only 
35% of patients were able to consent for an interview or a medical procedure. 
Therefore, the researcher anticipated that no more than one third of all new and 
known cases of MRSA, i.e. approximately 115 of 350 patients per year would 
be eligible for recruitment.  
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Notifying participants of individual results 
Each patient enrolled and completing the study was informed by the researcher 
of their final MRSA screening results. Where feasible, this interaction was a 
face-to-face contact with the patient or by telephone call. A note with the date of 
communication to the patient of their final study outcome was also documented 
in the individual CRF. 
 
2.2.8.3 Dissemination plan  
The results of the RCT will be communicated to the general public and to 
special interest groups such as MRSA and Families, the Irish Patients 
Association as well as North Dublin GP newsletter. National newspapers and 
healthcare periodicals will also be approached to highlight the study outcome. 
The BH Newsletter as well as RCSI outlets will also be contacted for 
communicating the study outcomes to the general healthcare audience. 
The results of the RCT will be disseminated at the conclusion of the study 
through abstracts at professional and scientific meetings as well as through 
articles in peer reviewed professional journals. Scientific meetings such as 
journal clubs, IPC team meetings, national MRSA study days, microbiology and 
IPC conferences, will also be accessed to publicise the results. In addition the 
findings of the study will be presented at internal hospital meetings and a short 
summary of the findings and conclusions will be prepared for the public. The 
researcher will also provide periodic briefings to BH clinical, nursing and 
management team meetings on the study progress as well as the final outcome 
of the study. The findings will also be reported in a thesis that will be submitted 
as part fulfilment of PhD, registered with the RCSI. 
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2.2.8.4 Study protocol  
The ICH defines a protocol as ‘a document that describes the objective(s), 
design, methodology, statistical considerations and organisation of a trial’. The 
study protocol explains the purpose of the study as well as how to carry out the 
study from initiation to the closure of the study. 
The detailed protocol that was applied in the RCT will be listed in the following 
section. 
 
The NHNMRSA RCT Protocol  
Decolonisation regimen 
 Mupirocin 2% (Bactroban® 2% nasal ointment) and Medihoney™ Derma 
Cream were procured and stored in the host facility’s pharmacy in 
accordance with protocols on storage of trial medicinal products.  
 The labelling of mupirocin 2% (Bactroban® 2% nasal ointment) and 
Medihoney™ Derma Cream was done according to good clinical practice 
(GCP) guidelines in the host facility pharmacy.  
 The researcher identified patients colonised with MRSA of the nasal 
passages, from the BH daily microbiology surveillance reports. 
 Potential patients identified from the microbiology surveillance reports 
were then evaluated by the researcher liaising with a senior nurse 
responsible for the care of the patient, to see at the outset if they meet 
inclusion and exclusion criteria. 
 The researcher then discussed the study with potential eligible patients 
including the benefits and adverse events if any, and how they would be 
addressed. A detailed PIL on the NHNMRSA study was provided to the 
patient. The eligibility criteria for each patient’s participation in the 
proposed study were evaluated during the initial patient contact. 
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 Participation of all patients in the study were on a voluntary basis. No 
monetary or other rewards or inducements were offered to participate in 
the study. 
 After approximately twenty-four hours, i.e. the following day, the 
researcher followed up with the patient to address any queries or 
concerns about the study. The patient’s decision to take part, or decline 
the study were noted during this interaction. 
 Explicit written consent was obtained in triplicate from those patients who 
expressed an interest in enrolling in the study. A copy of the signed 
consent form was given to the patient, a copy was held by the researcher 
and a copy was filed in the patient’s medical record. 
 Thereafter allocation of the consented patient was done remotely. The 
researcher initiated a telephone call to the IPC administrator for this 
purpose. A unique case number was allocated by the IPC administrator 
and the researcher recorded this in the CRF, as well as the product 
allocated namely, mupirocin 2% (Bactroban® 2%) or Medihoney™Derma 
Cream. The researcher then completed the study initiation 
documentation and commenced patient data collection which were 
recorded onto the CRF. 
 Mupirocin 2% (Bactroban® 2%) and or Medihoney™ Derma Cream were 
prescribed for patients according to the allocation. A proforma sticker 
was applied onto the patient’s drug Kardex specifying the dose, start and 
end dates. 
 Each study participant was provided by the researcher with a unit of 
mupirocin 2% (Bactroban® 2%) or Medihoney™ Derma Cream. Each of 
these products were a single patient application provided to the patient 
according to his/her allocation. 
 After patient consent, allocation and completion of study initiation 
documentation, the researcher collected the named product from the 
host hospital pharmacy and delivered it to each participant. The 
dispensing and labelling of the prescribed product were done as 
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specified in the pharmacy documentation. (Refer to the pharmacy SOP 
for further details, appendix - Ⅸ). 
 The researcher demonstrated how to self administer the product to the 
patient, and or next-of-kin as appropriate. A repeat demonstration was 
provided where appropriate to ensure the patient was able to administer 
the product correctly.  
 The researcher then assisted the patient to self administer the first dose 
of nasal application to both nostrils. Thereafter the application of 
mupirocin 2% (Bactroban® 2%) or Medihoney™ Derma Cream was 
documented in the relevant notes.  
 The procedure for nasal application was as follows: approximately 2 cm 
(one segment of the little finger OR pea size / head of cotton bud) of 
mupirocin 2% (Bactroban® 2%) or Medihoney™ Derma Cream were 
placed on a disposable sterile cotton bud, and applied on the middle part 
of each nostril.  
 After application to both nostrils, the patient was instructed to pinch and 
rub the nose with two fingers for 10-15 seconds to ensure spread and 
extensive coverage of the nasal epithelium. Following this step, five 
minutes of rest with the head up was advised to facilitate dispersion of 
the ointment / cream into the rear of the nostrils.  
 A printed record sheet was provided to mark the application of the 
prescribed product with the time and the date of application to confirm 
consistent and effective application. For patients in the control group, i.e. 
mupirocin 2% (Bactroban® 2%) the record with the title ‘Directions for 
application of Bactroban® 2% were given. This record is in two pages 
copied onto one sheet, front and back. The directions list the step-by-
step application guide which forms one side of the printed record. In 
addition, a document named ‘Patient record of administration’ which 
includes the day of the week and date, time of application and stop date 
for nasal application, which enables the patient to record self-
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administration of each dose, was provided to patients. This forms the 
second side of the printed record.  
For patients assigned to the investigative group, i.e. allocated 
Medihoney™ Derma Cream, ‘Directions for application of Medihoney™ 
Derma Cream’, were given. This record is in two pages copied onto one 
sheet. The Directions of application of Medihoney™ Derma Cream lists 
the step-by-step application. A table with date and times of application of 
each dose of Medihoney™ Derma Cream is printed on the form which 
allows the patient to record each dose after administration. 
The directions for application of mupirocin 2% (Bactroban® 2%) / 
Medihoney™ Derma Cream were developed in consultation with the 
chief pharmacist, an expert in the field and who is also supervising the 
pharmacy component of clinical trials of medicinal products in BH.  
 The registered nurse(s) responsible for the patient on the relevant ward 
administered the prescribed product for those patients who were unable 
to apply it themselves, and they recorded it in the drug Kardex as is 
standard practice.  
 The directions and record sheets had information specified on the date 
for discontinuing the product, date for collecting of follow up screening 
swabs, contact telephone number for the researcher, to enhance patient 
safety and confidence.  
 The dose and route of application of the products were as follows. 
Medihoney™ Derma Cream or mupirocin 2% (Bactroban® 2%), 
according to allocation, were to be applied to both the nasal passages 
three times a day, for five consecutive days. A flow chart depicting the 
sequence of events is attached as an appendix. (A copy of the screening 
and follow up flowchart appendix –Ⅹ.) 
 Patients were instructed on how to safely store the closed tube (ointment 
/ cream) in its packaging.  
57 
 
 Participants were advised to perform hand hygiene, either washing 
hands with soap and water or using alcohol hand gel based on 
availability and accessibility, before and after nasal application. 
 Patients who were colonised in non-nasal intact body sites, i.e. 
groin/perineum, were instructed to follow the standard decolonisation 
procedure using body wash and shampoo with triclosan 1% (SkinsanTM), 
as per hospital policy. This involves five days of daily washing/showering 
after application, and shampoo for at least two days. This applied to 
patients in both the control and investigative groups. 
 On completion of five days of application, either of the nasal application 
products and or triclosan 1% (SkinsanTM), body wash, the treatment was 
discontinued for two days. 
 Nasal and other body site screening was done two or more days after 
discontinuing the study products, as per the MRSA screening protocol. 
 Swabs were sent to the BH microbiology laboratory and processed 
according to standard testing protocols. 
 Bacterial isolates (MRSA) from the study participants were collected and 
stored by the researcher according to the microbiology laboratory SOP; 
LP-MIC Screens Rev 4 May 2013. (SOP LP MIC Screens is outlined in 
the laboratory aspects methodology chapter), (appendix-Ⅶ). 
 Screening test results were reviewed by the researcher and further 
action; either to rescreen the patient or to start a second course of the 
allocated product took place based on these results. 
 Patients who were negative for MRSA in the nose were rescreened 
between three to seven days after a negative nasal screening result. 
 Patients who were negative for MRSA in the nose, but positive for 
groin/perineum were started on triclosan 1% (SkinsanTM), body wash for 
five days as per the decolonisation protocol. Patients in this category 
were rescreened, both nasal and groin, two or more days after 
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discontinuing the decolonisation products to determine colonisation 
status.  
 Patients who remained positive for MRSA in their nose after one course 
of the nasal application of the allocated product were commenced on a 
second course of the allocated product, which was based on their 
original allocation. A proforma sticker was applied on the drug Kardex 
specifying the dose, start and end dates. Mupirocin 2% (Bactroban® 2%) 
or Medihoney™ Derma Cream were supplied by the researcher to the 
respective patient on commencing a second course of decolonisation. 
Patients in this category were rescreened, both nasal and groin, two or 
more days after discontinuing the products to determine colonisation 
status.  
 A second and third set of nasal and body sites screening were done on 
patients negative for MRSA to verify persistent decolonisation. 
 Patients who were positive for MRSA in the nose after two courses of the 
decolonisation regimen were deemed persistently colonised with MRSA, 
and no further eradication efforts were attempted. The following 
exception applied for first time MRSA cases. 
If a patient who had MRSA identified for the first time in BH was enrolled, 
and allocated to the investigative study group, had two courses of 
Medihoney™ Derma Cream, and had persistent MRSA colonisation, 
then the patient was offered one course of mupirocin 2% (Bactroban® 
2%) nasal ointment. The researcher arranged dispensing of the product 
to the patient. 
 A negative MRSA status was confirmed after three consecutive negative 
MRSA screening samples were obtained after the decolonisation 
intervention. 
Administration of study questionnaires 
 On completion of one course of mupirocin 2% (Bactroban® 2%) or 
Medihoney™ Derma Cream, patients were provided with two 
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questionnaires. The questionnaire development and administration 
methodology is discussed comprehensively in a separate section, 
Chapter Ⅱ section 2.5. 
 The product experience questionnaire (PEQ) was administered in the 
first instance to record patients’ perceptions on the use of mupirocin 2% 
(Bactroban® 2%), or Medihoney™ Derma Cream, based on their 
allocation, (appendix - Ⅺ a, product experience questionnaire 
Medihoney™ Derma Cream version 2, and product experience 
questionnaire mupirocin version 2, appendix - Ⅺ b). 
 A second questionnaire on the perception of being MRSA positive was 
also administered to patients. Both questionnaires were given to the 
patient with a pre-labelled envelope addressed to the researcher. 
Study completion 
 On completion of the study, each patient was informed of the results of 
their MRSA screening, and all study documentation was completed by 
the researcher. This included affixing a proforma sticker in the patient’s 
medical record stating study completion. 
 The relevant laboratory results were recorded in the CRF. 
 Any unused pharmaceutical products were disposed of according to the 
procedure specified in the Pharmacy SOP. 
 
2.2.9 Data collection and management 
2.2.9.1 Variables collected in the NHNMRSA RCT 
Based on evidence based guidelines on the prevention and control of MRSA, 
the following variables were attributed to MRSA colonisation and impinge on 
decolonisation methods, and were decided by the research team as appropriate 
for collecting/recording. This included data on prior hospitalisation, patient’s age 
at enrolment, receipt of antibiotics active against MRSA, history of MRSA 
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colonisation, multisite colonisation, presence of skin wounds, higher assistance 
required with activities of daily living (ADL) (i.e. carer assistance) and the 
presence of invasive medical devices, patients’ compliance with the 
decolonisation protocol, isolation and healthcare worker practice of standard 
and transmission-based precautions (contact), healthcare contact frequency, co 
morbidity and concomitant carriage of drug resistant pathogens.  (45,122) Each 
of the identified variables were coded for recording and data analysis.  
 
2.2.9.2 Patient data collection tools 
The following study specific tools were developed and used throughout the 
study: a CRF, a questionnaire on the product experience, and a questionnaire 
on patient perception of MRSA colonisation. A data dictionary was developed 
which served as a reference point for each of the variables collected and also 
served as the source for systematic coding of data. The data dictionary provides 
the definition for each variable identified in the study, abbreviations and the 
code used to identify the study participants and the database, (appendix - ⅫⅠ 
data dictionary).  
 
2.2.9.3 Patient data collection 
The researcher was primarily responsible for the collection of individual patient 
data. Data were collected and recorded on a CRF that was assigned to each 
study participant at the first instance (appendix Ⅻ).  After quality checks, data 
were entered onto an electronic data base. Primary data were collected by the 
researcher from direct patient interactions in addition to data obtained from the 
interventions over the course of patient participation in the RCT. Data 
(electronic and hard copy) from secondary sources such as the patients’ 
medical records were also collected as appropriate by the researcher. The 
administration of the questionnaires and data collection are addressed in the 
questionnaire methodology, see Chapter Ⅱ, section 2.5. 
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2.2.9.4 Data management 
Data cleaning was completed by the researcher through cross checking each 
patient’s data as entered in the CRF with the database entry, and verified as 
correct. Logical consistency among all parts of a record was validated by cross 
checking the data. There was no alteration or transformation of data and 
laboratory results as reported were captured in the CRF. Coded data from the 
CRF were entered on to a Microsoft (MS) EXCEL data base by the researcher 
for preliminary review and data cleaning. The CRF and the corresponding 
database entry of a random number of patients (10%) were cross checked and 
verified correct by an administrator external to the study.  
For statistical analysis the software package ‘SPSS’ version 20 was utilised. An 
expert methodologist from the Centre for Support and Training in Analysis and 
Research (CSTAR) at University College Dublin (UCD) contributed to the 
methodological aspects of the study. Data analysis was also facilitated and 
supervised by the expert methodologist. 
 
2.2.9.5 Quality control 
In order to minimise bias in data collection, and to ensure conformity between 
source data and the RCT record, a random number of CRFs were audited. 
Conformity to source data and source verification was performed by an external 
auditor. The RCT documents were also audited and adjudged compliant to CT 
standards by a Quality and Regulatory Manager in the RCSI. The audit of 
compliance to CT standards was not originally planned by the research team. 
However, based on the expert advice of the Project Advisory Group (PAG), an 
approach was made to RCSI Clinical Research Centre, where Quality and 
Regulatory Managerial expertise on CTs were available. The results of audits 
were reported to the PAG.  
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2.2.10 Data analysis plan 
Statistical methods 
 Statistical data analyses were conducted using SPSS version 20. Descriptive 
analysis was performed and comparable data were presented in descriptive, 
tabular and graphical forms. The clinical presentation of patients at the time of 
enrolment and outcome on completion of the study i.e. nasal and/or other body 
site MRSA colonisation were summarised using proportions, means and 
standard deviations (SD), or medians and interquartile ranges (IQR), as 
appropriate.  Patients were classified as responders (negative nasal MRSA), or 
non-responders (positive nasal MRSA decolonisation), according to the 
screening test results.  
For comparisons between groups, appropriate inferential statistical tests were 
used. Factors associated with decolonisation response were identified using 
Chi-squared tests or t-tests/Mann-Whitney U tests. Factors considered for all 
analyses included demographic and healthcare factors, age, gender, 
hospitalisation, co-morbidities, healthcare contacts, previous MRSA status etc. 
Both univariate and multi-factorial modelling were conducted to include possible 
confounders in determining the outcome.  To assess homogeneity of 
distribution and to assess any association between the intervention and control 
groups, on specific variables such as gender, age, co morbidities and other IPC 
aspects, Chi-square (χ2) and significance tests were done, the results form part 
of the Univariate analysis.  
Intention to treat analysis (ITT) of all study participants in the study or control 
group they were originally allocated to was done. ITT analysis maintains the 
original comparability of study and control groups with respect to potential 
confounding factors achieved after randomisation of the study participants. Per 
protocol (PP) analysis was also undertaken and included in the results. 
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Multivariate logistic regression 
Logistic regression (LG), a statistical analytical method, is used to predict the 
odds of being a case based on the values of the independent predictors, i.e. 
variables. The ‘odds’ is defined as the probability that a particular outcome is a 
case divided by the probability that is not a case. 
For the purposes of LG, binary data collected in the study had to be re-coded in 
a way that enables seamless data analysis. Variables with multi-level coding 
options had to be grouped into two groups, where an apriori decision was taken 
to apply the code for a variable that denotes risk=1 or no / limited risk=0. 
Clinical IPC knowledge and practices were applied to group the multi-level 
coding options, which are discussed later in this section. The limited number of 
patients in the RCT also necessitated limiting the number of variables that can 
be applied for multivariate regression. Logistic regression necessitates apriori 
decisions by the researcher on the variables that are known or potentially 
contributing to risk or a particular outcome, i.e. in this study failure of the 
intervention leading to persistent nasal MRSA colonisation.  
 
Re-coding of variables for logistic regression analysis 
Gender 
In the RCT data base, participants gender was coded as male=1 and female=2, 
which was re-coded to female=0, and male=1. 
Age category 
Participant’s age in number of years was calculated as date at enrolment, from 
the date of birth of each participant. For LG, age was categorised and coded as 
below 65, y=0, and over 65, y=1. In clinical practice, over 65 y of age is 
considered a high risk category for illness and infections. 
Skin integrity 
Five categories were used to code for the skin condition of the participants 
namely; healthy=1, poor (paper skin) =2, wound=3, ulcer=4, and stoma=5. For 
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LG, healthy and poor category grouped into a single category and coded=0. 
The following categories namely wound, ulcer and stoma were grouped into a 
single group, ‘altered skin integrity’ and coded=1. The limited number of values 
in each category necessitated the collapse of the variable ‘skin integrity’ into two 
groups; where intact skin was considered less risky compared to altered skin 
integrity which was considered at risk. 
Invasive and indwelling devices 
Five categories were also used to code for the presence of invasive and 
indwelling devices; CVC’s/PICC’s=1, PVC’s=2, urinary catheter=3, more than 
one device=4, and participants with no device=9. The categories were coded for 
LG as participants with no device=0 and with any device=1. Similar to skin 
integrity, the device variable had to be grouped in a way that made clinical 
sense. Therefore presence of a device was considered a risk when compared 
with no device.  
Residence during the RCT 
The participant’s residence during the intervention period was categorised into 
four; inpatient=1, outpatient/home=2, nursing home=3, and other healthcare 
facility=4. The categories were collapsed into two groups namely; 
outpatient/home, code=0; inpatient, nursing home and other healthcare facility 
into one category, ‘resident healthcare facilty’ code=1. Patients at their home in 
comparison to those who are resident or admitted to healthcare facilities are 
unlikely to have frequent HCW contact. HCW contact is considered a risk factor 
for transmission of MRSA as well as other MDROs. Therefore residence at a 
healthcare facility was considered a risk and patient’s stay at home was not.  
Isolation of participants 
Isolation of participants during the intervention period in the RCT were 
categorised into four types; single room with CP=1, cohort with CP=2, not 
isolated=3, and not applicable (home) =4. The categories were collapsed into 
two groups; single room with CP, cohort with CP and not applicable into one 
group and applied code=0; and not isolated=1. Isolation of patients with CP is 
recommended for the control and prevention of transmission of MRSA. Single 
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room, cohort isolation and patient stay at home were considered a form of 
isolation for the purposes of LG. The rationale was, if HCW contact occurred CP 
were deemed to be applied, and if at home HCW contact was unlikely, therefore 
the benefit of isolation from other patients reduced the risk for MRSA acquisition 
and transmission, compared to patients colonised with MRSA not isolated. 
Dependency  
The NDS dependency score of the participants were coded in five categories; 
independent=1, minimal assistance=2, moderate assistance=3, dependent=4, 
and specialised nursing care=5. For LG, the dependency categories were 
collapsed into two groups; independent, minimal assistance and moderate 
assistance to a single group, independent to moderate care, code=0; 
dependent and specialised nursing care to a second group, dependent care, 
code=1. Higher dependency of care commands for increased HCW contact with 
sicker patients, which is a recognised risk for acquisition of MRSA and other 
transmissible MDROs. 
History of mupirocin 2% (Bactroban® 2%) use 
The number of courses of past mupirocin use were classified into four groups, 
no previous use=0, one=1, two=2, more than two courses of the antibiotic=3, 
and unknown=9. For LG, three groups were created, one of which included 
participants with one or two courses of mupirocin, code=0, those who had more 
than two courses, code=1, and participants no previous mupirocin use or 
unknown, code=9, i.e. missing data. In clinical practice, the number of 
mupirocin courses is usually limited to two courses, considering increasing MR.  
Multisite colonisation 
Participants who were identified with non-nasal MRSA colonisation on study 
completion, one or more sites, were categorised as multisite colonisation=1, 
MRSA negative cases=2, and if this information was unknown=9. For LG, 
participants who had no documented MRSA colonisation on non-nasal sites or if 
unknown were coded=0; and those with multisite colonisation were coded=1. 
Multisite colonisation is a recognised risk for persistent MRSA carriage. 
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2.2.11. Handling of unexpected or adverse events and emergency care 
Definitions 
Adverse Reaction: An adverse reaction is defined in Article 2(n) of Directive 
2001/20/EC as:  ‘all untoward and unintended responses to an investigational 
medicinal product (IMP) related to any dose administered’. (123) The definition 
implies a reasonable possibility of a causal relationship between the event and 
the IMP.  
Unexpected Adverse Reaction: An adverse reaction, the nature or severity of 
which is not consistent with the applicable product information, e.g. 
investigator’s brochure for an unauthorised investigational product or summary 
of product characteristics for an authorised product. (123)  
Adverse Event (AE). Any untoward medical occurrence in a patient or clinical 
trial subject administered a medicinal product and which does not necessarily 
have a causal relationship with this treatment. (International Conference on 
Harmonisation Good Clinical Practice (ICH GCP) 4.11.2). (124)  
Serious Adverse Event (SAE): Any untoward medical occurrence or effect that 
at any dose results in death, is life-threatening, requires hospitalisation or 
prolongation of existing hospitalisation, results in persistent or significant 
disability or incapacity, or is a congenital anomaly or birth defect (ICH GCP 
4.11.1). (124)  
Monitoring of untoward events 
Patients enrolled in the study were informed that they would be monitored for 
any unexpected or adverse events. Adverse events or SAE were considered 
unlikely, however RCT participants were monitored for AE or SAE. While no 
adverse consequences after the use of honey for medicinal purposes have 
been reported in the healthcare literature, patients were informed that there may 
be a possibility that the honey product used were inferior to the antibiotic used 
to decolonise nasal MRSA. Study entrants were also informed that there were 
no adverse reactions when we conducted our pilot study using the honey 
product, Medihoney™ Derma Cream. However, as honey has not been 
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extensively used for medicinal purposes, study entrants were informed that it 
was possible that there may be other risks which were not known at this time. 
The research team carefully monitored for any unintended effects of honey 
during the course of the study.  It was expected that participants receiving 
Medihoney™ Derma Cream might feel a runny nose based on experience from 
the pilot study. After application of either the control or investigative products, 
patients were monitored for any allergic reactions, itching or rash on the nose or 
face immediately or during the five day course. Study entrants who continued to 
be inpatients were advised to inform the nursing staff assigned for his/her care 
or a doctor who was available at the first instance. Any unexpected event 
information were also elicited from patients by the researcher on follow up visits 
or via telephone contacts. Outpatients were advised to contact the emergency 
care services available in the community at the first instance in the event of an 
unexpected or adverse event. Patients were also provided with a mobile 
telephone contact number to contact the researcher as required. 
In the event of any unpleasant or unexpected patient experience after using 
either control or investigative products, information from the affected patient 
were collected and documented in the AE/SAE record. The clinical team were 
notified and the consultant team continued to manage the patient’s medical 
care. The clinical supervisor was promptly informed of any unexpected or 
adverse events, if they occurred. A record of any unexpected or adverse 
reactions of each patient was maintained by the researcher in the study file and 
was noted in the patient’s CRF. Continuation of the study by a study participant 
in the event of an unexpected or adverse event was carefully considered, and 
the study was discontinued if a patient was unable to continue with the assigned 
protocol. 
On study enrolment, study entrants were informed by the researcher that the 
study was indemnified by the state healthcare insurance applicable for public 
healthcare providers in Ireland, in the very unlikely event that a patient was 
harmed in any way as a direct result of this study. 
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2.2.12. Procurement and storage of pharmacy products 
The investigative product for the experimental decolonisation arm in the 
NHNMRSA study was natural honey, Medihoney™ Derma Cream 50gm in a 
pre-filled tube, manufactured by Derma Sciences Europe Limited. The standard 
product for the control group was mupirocin 2% (20 mg/g) 3gm in a pre-filled 
tube, (Bactroban® 2% (20 mg/g) nasal ointment) manufactured by 
GlaxoSmithKline (GSK), Ireland Limited.  
Medihoney™ Derma Cream and Bactroban® were purchased and stored at 
controlled room temperature according to the product information in the 
Pharmacy Department, Beaumont Hospital. Medihoney™ Derma Cream as 
recommended was stored at room temperature, at 15 - 30 ºC (59-86 F). 
Bactroban® ointment was kept at room temperature, 15 - 30 ºC (59-86 F).   
Temperature logs with daily minimum and maximum temperature readings were 
kept by pharmacy personnel to monitor the storage temperature of the study 
products. The temperature monitoring device included routine calibration 
records, which are managed by the Pharmacy Department. Temperature logs 
were kept in the pharmacy and made available for inspection upon request.  
On receipt of Medihoney™ Derma Cream and mupirocin 2% (Bactroban® 2%) 
in the Pharmacy, the standard practice was to clearly label the items by 
pharmacy personnel and place the stock in the clinical trials area of the 
pharmacy. The study products and documentation were kept in an area with 
restricted access to authorised site personnel only. The researcher dispensed 
the study products in the original packing after completing dispensing details. 
Dispensing details were documented by the researcher in the Product Inventory 
Log for each item dispensed. Each product was dispensed to a named patient 
after printing the relevant patient details onto the pre-approved proforma label 
stickers affixed to the product’s outer cover and product tube, as specified in the 
pharmacy standard operating procedure.  
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2.2.13. Study documents 
In order to conform to good research practice, a number of documents were 
developed and used systematically in the RCT; these are listed below 
(appendix - ⅩⅣ copies of the documents)  
• Patient information leaflet. Version 3. 
• Patient consent form. Version 1. 
• Proforma clinical notes stickers. Version 1. 
• Case report form. Version 2. 
• Data dictionary. 
• Questionnaire; Version 2. 
 Product Experience Questionnaire mupirocin 2% nasal 
ointment. 
 Product Experience Questionnaire Medihoney™ Derma 
Cream. 
• Questionnaire. On MRSA perception; MRSAPQ. Version 1. 
• Standard operating procedure: LP MIC Screens; MRSA screening, 
collection and storage of isolates from colonized patients Lab Protocol. 
Version 1. 
• Standard operating procedures for pharmacy, Version 1. 
• Directions for application of Medihoney™ Derma Cream and patient 
record of application. Version 1. 
• Directions for application of mupirocin 2% (Bactroban® 2%) nasal 
ointment and patient record of application. Version 1. 
• Letter to consultant doctor. Version 1. 
• Letter to family doctor. Version 1. 
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2.2.14. Summary 
Estimating the number of potential participants for a study from the source 
population requires careful consideration by investigators. At the same time, for 
the outcome of a study to be meaningful, the results should be applicable to the 
target population. In the NHNMRSA study the researcher had the advantage of 
having access to microbiology surveillance data for many years before 
conducting the study, in addition to being part of the IPC team in BH involved in 
MRSA prevention and control. Despite this, estimating the potential number of 
participants that could be enrolled in the RCT was challenging. While 
surveillance data can help estimate the eligible population, inclusion and 
exclusion criteria substantially reduces the available and accessible population 
for recruitment. A thorough, well defined step-by-step study protocol was 
essential for the conduct and success of the study.  Its development was a 
significant and useful learning experience for the researcher. The guidance of a 
project team with specialist and subject matter expertise involved in drafting and 
finalising the study protocol was vital. Methodological rigor of protocol 
development cannot be underestimated. The expertise of a methodologist, and 
in the NHNMRSA RCT a reputed methodologist from CSTAR, significantly 
contributed to and complimented the researcher’s learning experience. 
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2.3 Mupirocin susceptibility test methodology 
 
 2.3.1 Introduction 
The overall aim of the NHNMRSA RCT was to investigate the eradication of 
MRSA from the nasal passages in humans with medical grade honey (MGH). 
Two of the five study objectives were pertinent to the laboratory investigation of 
isolates. In this section the methodology that was used to determine mupirocin 
susceptibility of isolates, which includes the collection and storage of bacterial 
isolates as well as the controls that were used, is enumerated. The data 
generated was used to determine the outcome of decolonisation for individual 
patients, as well as to ascertain the prevalence of mupirocin resistance.  
 
2.3.2 Collection of MRSA isolates  
In accordance with routine clinical practice and the BH ‘Guideline for the control 
and prevention of MRSA’ (2007), patients are screened in BH for MRSA and 
specimens are processed through the BH diagnostic microbiology laboratory. 
Nasal MRSA isolates from consenting patients were collected after enrolment to 
the RCT. Collection and storage of MRSA isolates commenced in February 
2014 and continued until the last patient was enrolled on 31st March 2016. The 
sequence of patient screening was as follows: following the first decolonisation 
course, and where applicable the second course, nasal and other body sites 
were screened. Specimens were collected at least 48 h after the last dose of 
the nasal ointment or cream and Skinsan® application using invasive sterile 
collection swabs with transport media (EUROTUBO®, Deltalab, Spain, supplied 
by Premier Scientific Ltd, Belfast).  
Arising from testing during the RCT,  positive MRSA isolates from nasal 
specimens were collected and stored at -20oC on Microbank™ beads (Pro-Lab 
Diagnostics., USA) For previously ‘known MRSA positive’ patients recruited to 
the RCT, the ‘first time detected MRSA’ isolate (historic isolate) was also 
collected if available from stored slope cultures. A sample from stored slope 
cultures (Nutrient agar ) was grown overnight at 37oC on Columbia Blood Agar 
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(CBA) and single isolated colonies were selected and stored at -20oC on 
Microbank™ beads. A patient enrolled in the study may therefore have had up-
to three consecutive isolates; historic, baseline and end of study, if nasal 
decolonisation failed, or only one isolate if only the baseline isolate was 
available and the patient had successful decolonisation. All the baseline and 
end of study isolates were of nasal origin, but the first time isolates included 
nasal as well as those from non-nasal sites.  
 
2.3.3 Bacterial Controls  
MRSA ATCC 43300 was the reference strain used. The reference strain was 
obtained from the BH diagnostic microbiology laboratory.  
 
2.3.4 Media and growth conditions 
MRSA isolates were routinely grown on CBA (Fannin Ltd, Galway, Ireland) 
overnight at 37oC in a static incubator (Gallenkamp, Leicestershire, UK). For 
antibiotic susceptibility testing, isolates were grown on Mueller Hinton (MH) 
(Fannin Ltd, Galway, Ireland) agar. For DNA extraction, single colonies from 
CBA were grown overnight in 5 ml of Brain Heart Infusion (BHI) liquid medium 
in an orbital shaking incubator (Gallenkamp, Leicestershire, UK)  at 37oC and 
150 rpm.  
 
2.3.5 Buffers and solutions 
Milli-Q water (Millipore Ireland, Cork, Ireland) was used for making buffers, 
solutions and agarose gels. Molecular biology reagent water from Sigma-Aldrich 
was used in all PCR reactions, DNA elutions and dilutions. Tris-borate/EDTA 
(TBE) was used at 0.5X concentration as a buffer for agarose gel 
electrophoresis. This was diluted from a 10X stock solution supplied by Sigma-
Aldrich, UK. 
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2.3.6 Sterilisation techniques 
BHI broth and agar media were prepared under aseptic conditions and were 
autoclaved at 121oC for 15 min. All biological laboratory waste was sterilised at 
115oC for 30 min before appropriate disposal. 
 
2.3.7 Mupirocin susceptibility testing 
The susceptibility of MRSA isolates were investigated in accordance with the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) Clinical 
Breakpoints, Bacteria (v3.1) February 2013.  
The MIC was determined using mupirocin E-test strips, (bioMerieux®, UK) 
according to the manufacturer’s instructions. Briefly, a suspension was 
prepared in saline from isolated colonies from an overnight culture and adjusted 
to the density of a 0.5 McFarland standard using the Vitek DensiCHEK™ Plus 
densitometer (bioMerieux®, USA). The suspension was used within 15 min of 
preparation. Using a sterile cotton swab the suspension was inoculated onto 
MH agar in three directions, rotating the plate at 60 degrees each time to 
ensure an even distribution of inoculum.  After air drying for 15 min, a mupirocin 
E-test strip was placed centrally on the agar surface. Plates were incubated for 
16-20 h at 37oC. The MIC was interpreted as the point of intersection of the 
zone of inhibition with the E-strip. Phenotypically, mupirocin susceptibility is 
determined according to MIC breakpoints, with susceptible being ≤4 mg/L. 
MIC’s of 8-256 mg/L are classified as low level mupirocin resistance (LLMR) 
and MIC’s above  >512 mg/L are classified as high level mupirocin resistance 
(HLMR). (46,47) The MIC breakpoints were consistently applied in determining 
susceptibility of MRSA isolates. The data were then used to determine the 
outcome of decolonisation as well as to evaluate bacterial resistance to 
mupirocin. MRSA isolates that were tested for mupirocin susceptibility are listed 
in appendix - ⅩⅤ. 
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2.4 Methodology of Laboratory investigations  
 
2.4.1. Analysis of bacterial isolates 
 
2.4.1.1 Introduction 
The investigation of the MRSA isolates such as the phenotypic and genotypic 
characteristics enables to distinguish the attributes that may potentially 
contribute to the outcome of decolonisation. In this section the methodology that 
was applied in the isolation of bacterial genomic DNA, spa typing and mupA 
polymerase chain reaction (PCR) is catalogued. The MIC and minimum 
bactericidal concentration (MBC) of Medihoney™ Derma Cream were also 
determined as it was considered important.  
 
2.4.1.2 Bacterial molecular genetics techniques 
The identification of bacterial genetic characteristics facilitates the differentiation 
of MRSA colonising strains. Comparison of the Staphylococcus protein A (spa) 
type from a individual patients at multiple time points such as historic, baseline 
and end of study differentiates the colonising spa type, i.e. persistent 
colonisation with same strain or re-colonisation with a different strain. The data 
generated is important to evaluate the outcome of decolonisation attempts for 
an individual patient. Molecular genetics studies helps to classify the 
representativeness of the MRSA isolates with that of local and national 
surveillance data. The data generated was used to determine the colonising 
strains and the outcome of decolonisation. 
 
2.4.1.3 Isolation of bacterial genomic DNA 
Genomic DNA was isolated from overnight cultures of bacteria using the 
Wizard® Genomic DNA Purification Kit (Promega, USA) according to the 
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manufacturer's instructions. Prior to DNA extraction, cells were pre-treated with 
10µl of lysostaphin (1 mg/ml) (Ambi-Products Ltd., USA) in 100µl 50 mM EDTA 
(Sigma-Aldrich., MO, USA. All centrifugation steps were carried out in an 
Eppendorf Centrifuge (5804 R, Hamburg, Germany). 
DNA was eluted with 50 µl DNA rehydration solution (Promega, WI, USA) for 1 
h or overnight at 4oC and stored at -20oC. The concentration of DNA in each 
sample was determined using a Nanodrop 8000 V2.0.0 Spectrometer (Thermo 
Scientific, USA). 
 
2.4.1.4 spa typing 
spa typing is a discriminatory method which distinguishes between strains of S. 
aureus and can be used to infer sequence types (ST). The MRSA isolates were 
prepared for spa typing by the sequencing of a polymorphic 24 base-pair (bp) 
variable number tandem repeat (VNTR) region within the 3’ end of the spa 
gene. The primers used were spa113F (5’-TAAAGACGATCCTTCGGTGAGC-
3’) and spa1514R (5’-CAGCAGTAGTGCCCGTTTGCTT-3’). PCR reactions 
were carried out in a Peltier Thermal Cycler (PTC-200, MJ Research, Bio-rad, 
USA) and contained 25µl of goTAQ green master mix (Promega, WI, USA), 2µl 
of DNA template, 2 µl each of forward and reverse primers (10 pmol/µl), in a 
final volume of 22 µl of sterile water. PCR conditions were: 80oC for 5 min, 35 
cycles of 94oC for 45 s, 60oC for 45 s, and 72oC for 90 s with a final extension 
step for 10 min at 72oC.  
PCR products were cleaned-up using the Promega PCR Clean-Up Kit 
(Promega, WI, USA) according to the manufacturer’s instructions. DNA was 
subsequently prepared for sequencing with the following; 5 µl of DNA mixed 
with 5 µl of primers and both forward and reverse primers in separate tubes 
sent for sequencing to a commercial service provider in labelled tubes. 
LIGHTrun™ sequencing was performed by GATC-biotec, Germany. The spa-
sequence analysis was carried out using the Ridom® StaphType software, 
version 1.3 (Ridom GmbH, Wurzburg, Germany) to identify the spa type.  The 
ST of isolates was inferred from the spa type. The ST and spa type of available 
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sequential isolates from individual patients were compared and analysed to 
generate meaningful results. 
 
2.4.1.5 mupA PCR 
The identification of the presence of mupA in the bacterial genomic DNA is a 
recognised method of confirming mupirocin resistant MRSA. The presence of 
mupA in MRSA isolates were investigated using the PCR method which is now 
discussed. 
DNA was extracted from historic as well as MRSA isolates on study enrolment 
to investigate for the presence of mupA gene by PCR, using ileS forward and 
ileS reverse Primers as previously described by Roth Perez et al.(125) The 
primers used were mupA-F (5’-TATATTATGCGATGGAAG-3’) and mupA-R (5’-
AATAAAATCAGCTGGAAA-3’). The PCR reactions were carried out in a Peltier 
Thermal Cycler and contained 2µl of DNA template, 1 µl each of forward and 
reverse primers (20 pmol/µl), 3 µl of magnesium chloride (25 mM), all in a final 
volume of 18 µl of sterile water. PCR conditions were: 95oC for 5 min, 35 cycles 
of 95oC for 30 s, 60oC for 30 s, and 72oC for 30 s with a final extension step for 
10 min at 72oC. The mupA PCR result of each isolate was listed in order. The 
mupA PCR results of available sequential isolates from individual patients were 
compared and analysed. 
 
2.4.1.6 Agarose gel electrophoresis (AGE)  
Performing AGE detects the presence or absence of bacterial DNA fragments in 
comparison to a representative DNA ladder, such as 1kb ladder, under 
ultraviolet light (UV). Electrophoresis of DNA extracted and PCR products were 
carried out using horizontal 0.8% (w/v) agarose gel containing 10 mg/ml 
ethidium bromide (Promega, WI, USA). Agarose gels were prepared and 
electrophoresed in 0.5X TBE buffer. A 3-6 µL sample of the DNA or PCR 
product containing loading dye was loaded into the test wells.  A 1 kb DNA 
ladder (Promega, WI, USA) was used and 6 µL of the ladder was loaded into 
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the reference well. Horizontal agarose gel tanks (SCIE-PLAS, UK) and Sub-
Cell®, (Bio-rad, USA) were used and electrophoresis performed at 100 - 140 
volts (V) for 30 – 45 min. DNA fragments were visualised by illumination with an 
ultraviolet light source (Ingenius3, SYNGENE., USA) and the images were 
analysed by comparing with the 1 kb DNA ladder, positive control and ‘no-
template’ control. 
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2.4.2 Determination of MIC and MBC of 30% Medical Grade Honey  
 
2.4.2.1 Introduction 
The NHNMRSA study investigated the efficacy of 30% MGH (Medihoney™ 
Derma Cream) the investigative agent, for nasal MRSA decolonisation in 
comparison to mupirocin 2% nasal ointment (control) in a RCT. In this section 
the methodology used to ascertain the antimicrobial properties of Medihoney™ 
Derma Cream is described. 
 
Bacterial Strains 
Eight clinical MRSA isolates (nasal) collected from participants in the RCT, and 
one reference strain, MRSA ATCC 43300, were used. The clinical isolates were 
identified by routine laboratory methods; i.e. detection of staphylocoagulase and 
clumping factor (Staphaurex Plus, Remel, U.K.), and oxacillin resistance (by 
determining oxacillin minimum inhibitory concentrations (MIC)) using the MIC 
Evaluators system (Oxoid, U.K.) and verified MRSA. The reference strain, 
which is routinely used for quality control were obtained from the diagnostic 
microbiology laboratory, BH. 
 
Components of the investigative product 
Table 2.4.2.1 presents the composition of Medihoney™ Derma Cream as 
provided by the manufacturer. The finished product pH is of the range 3.5-5. 
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Table 2.4.2.1 NHNMRSA RCT composition of the investigative product 
Medihoney™ Derma Cream 
Composition Function 
Manuka honey (Leptospermum 
honey, 30%, medical grade) 
Antibacterial component 
Rodi Water (USP) Medium-dilution-filler 
Coconut oil Moisturiser and softener 
natural Triglyceride Prevent loss of water from skin 
Natural wax Barrier function 
Evening Primrose oil Hydrating dry skin 
Aloe Babadenisis (USP) Skin conditioner 
Sodium Benzoate Preservative 
Chamomile Cell regeneration 
Tochenol Acetate Topical nutrients 
Vitamin E Nutrient 
 
2.4.2.2 Dilutions 
Medihoney™ Derma Cream, 50 gm in its original sealed packing were stored at 
room temperature prior to testing and honey dilutions were prepared fresh prior 
to testing. Serial dilutions of Medihoney™ Derma Cream (30% to 0.16% v/v in 
nutrient broth (Oxoid, Fannin, Ireland)) were prepared aseptically for use both 
the agar well diffusion and broth microdilution assays.From the 30% (v/v) 
Medihoney™ Derma Cream, 11 serial dilutions were made, resulting in final 
concentrations of; 30%, 25%, 20%, 15%, 12.5%, 10%, 5%, 2.5%, 1.25%, 
0.62%, 0.31% and, 0.16%. Hereafter, these solutions are referred to as ‘test 
honey’. 
 
2.4.2.3 Agar well diffusion assay  
A previously described screening assay using agar well diffusion were carried 
out with some minor modifications for MIC determination. (126) Bacterial 
suspension were prepared in sterile saline from isolated colonies from an 
overnight culture and adjusted to the density of a 0.5 McFarland standard using 
the Vitek DensiCHEK™ Plus densitometer (bioMerieux®, USA). The 
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suspensions were used within 15 min of preparation. Using a sterile cotton 
swab the suspension was inoculated onto Mueller Hinton (MH) agar in three 
directions rotating the plate at 60 degrees each time to ensure an even 
distribution of the inoculum.  After air drying for 15 min, 5 mm diameter wells 
were cut into the surface of the agar using a sterile bore former. Sixty micro-
litres of test honey, at each of the concentrations stated above, were added to 
each well. Plates were incubated at 37°C for 24 h. A diffusion control of 
methylene blue was used. (127) Zones of inhibition were measured using a 
Vernier calliper (Draper). The diameter of zones, including the diameter of the 
well was recorded. Each assay was carried out in triplicate, and mean values 
obtained. The MIC was defined as the lowest concentration of test material 
which resulted in a measurable inhibition of growth of the test organism based 
on the diameter of the inhibition zone. 
 
2.4.2.4 Determination of MBC of test honey by broth micro-dilution assay 
To establish whether the antibacterial activities of the test honey were 
bacteriostatic or bactericidal, a method previously described were used. (128) 
Ten µl of 0.5 McFarland standardised culture were added to 190 µl of each test 
honey concentration, in the  wells of a 96 well plate and incubated in the dark at 
37°C with shaking at 150 rpm for 24 h. Control wells contained nutrient broth 
only (sterility control), or bacteria and nutrient broth (positive control). Following 
overnight incubation, 10 µl from each well was added to 90 µl sterile saline and 
spread on CBA plates (Oxoid) and incubated overnight. Plates with no visible 
colonies after 24 h growth were recorded as representing bactericidal honey 
activity. 
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2.5  Methodology; Development of questionnaires  
 
2.5.1 Product Experience Questionnaire  
 
The rationale for a Product Experience Questionnaire  
The aim of the NHNMRSA RCT was to compare MGH with mupirocin for nasal 
decolonisation of MRSA. Mupirocin 2% w/w (Bactroban® 2.0% w/w) nasal 
ointment, a licensed medicinal product was the control, and Medihoney™ 
Derma Cream, a licensed medical device, was the investigative product that 
was used in the study.  
Mupirocin 2% nasal ointment has been employed for nasal MRSA 
decolonisation since early 1970’s; however, there is paucity of information on 
patient experience on using the nasal ointment. (51) In the NHNMRSA RCT, it 
was considered important to assess patient experience on application of 
Medihoney™ Derma Cream on nasal passages, as it is a novel approach in the 
nasal eradication of MRSA. Patient compliance for a product prescribed for 
topical application such as an ointment or cream, is potentially influenced by 
patients experience on its use. Therefore, collating patient experience using a 
simple tool that enables the analysis and generation of meaningful information 
was considered important and were incorporated in the study.   
At the first instance, while considering a tool to collate patient experience on 
use of the control and investigative products in the study, an investigation on 
known factors that may contribute to user experience were done.  
 
What are the factors that affect user experience? 
A literature search on assessment criteria for usability identified three general 
themes, namely effectiveness, efficiency and satisfaction.(129-130) Another key 
aspect that was identified in the search was that a participant's reaction in any 
assessment is just one measure of usability. Therefore, in order to get the 
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complete usability picture, investigators should consider effectiveness and 
efficiency. (131) These two dimensions of usability, i.e. effectiveness and 
efficiency, stem from the International Standard Organisation (ISO), ISO 9241-
11 standard, which defines usability as: ‘the extent to which a product can be 
used by specified users to achieve specified goals with effectiveness, efficiency 
and satisfaction in a specified context of use’. (130) The ISO definition reiterates 
that user satisfaction is just one important dimension of usability. People may 
be well disposed to a system but fail to complete critical tasks with it, or in the 
case of a product, they may complete the tasks specified in a roundabout way, 
or for a period or frequency less than specified.  
Based on the outcome of the literature search and the ISO definition, the three 
measures of usability can be deduced as effectiveness, efficiency and 
satisfaction. Effectiveness is the accuracy and completeness with which users 
achieve certain goals. Indicators of effectiveness include quality of solution and 
error rates. Efficiency is the relationship between the accuracy and 
completeness with which users achieve certain goals, and the resources 
expended in achieving them. Indicators of efficiency include task completion 
time and learning time. Satisfaction is the user’s comfort with, and positive 
attitudes towards, the use of the system. User satisfaction can be measured by 
attitude rating scales. (129)  
Investigators are of the opinion that the three measures of usability; 
effectiveness, efficiency and satisfaction are independent, and an investigator 
should measure all three elements to get a rounded measure of usability. 
(129,131) While measuring usability, investigators are alerted on a frequent 
mistake which is to measure satisfaction by using a questionnaire only, either at 
the end of the session or on completion of each task. It is also described that 
once an investigator invites participants to assign a number to their experience, 
their experience suddenly becomes better than it actually was. (131)  
Frokjaer, Hertzum and Hornbaek are of the opinion that while it is tempting to 
assume simple, general correlations between effectiveness, efficiency, and 
satisfaction, any relationship between these factors seems to depend on a 
range of issues such as application domain, context of use, user experience, 
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and task complexity. (129) For routine tasks, Frokjaer is of the opinion that good 
performance depends on the efficient, well-trained execution of a sequence of 
actions which is known to yield stable, high quality results. For such tasks, high-
quality results are routinely achieved, and task completion time may therefore 
be used as an indicator of overall usability. (129)  
 
Tools to measure the user’s experience of the product 
Investigators who have appraised user experience have commented that user 
experience is not only a snapshot of the present usage a product has. It is the 
entire impression a product makes on the user. Furthermore, the user’s 
judgement starts before touching and using a new product. In addition, the 
change of impression carries on during and after the usage of a particular 
product. (132)    
User Experience Questionnaire (UEQ) is one of the tools that is regularly 
quoted by investigators, that is used to assess user experience. (132) The UEQ 
contains six scales; each one of the scales is listed and described in brief. The 
first scale is attractiveness. It is the general impression towards the product. 
The second is efficiency, i.e. it conveys a judgment, is it possible to use the 
product quickly and efficiently.  The third is perspicuity, which conveys the view 
of the user; is it easy to understand how to use the product. The fourth is 
dependability, which elicits users view, does the user feels in control of the 
interaction.  Fifth is stimulation. It is the user judgement that conveys, whether it 
is interesting and exciting to use the product. The final one is novelty, which is 
an impression that communicates to the user that the design of the product is 
innovative and creative.  
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Survey method to measure user experience 
Of the many alternatives that are considered useful to measure user 
experience, survey is one of the methods that are frequently employed by 
investigators.  Survey methods are broadly classified into two; the first method 
utilises a personal approach, which can consist of face to face structured 
interviews as well as telephone interviews. The second method is a self 
administered approach; which can be through a paper and pencil survey, online 
as well as mail surveys. The benefits of the traditional survey administration 
method, using the paper and pencil survey is that it is ideal for respondents who 
are not computer literate or do not have access to the internet. The limitations of 
this method are; the paper and pencil self administered technique usually 
requires the researcher to be present during the administration; it also 
necessitates doing the expensive reproduction of survey questionnaires and the 
tiring manual distribution of the questionnaires to the respondents. Typically, a 
questionnaire is a paper and pencil instrument that is administered to the 
respondents.   
 
Response rates to questionnaire surveys 
The response rates to surveys can be influenced by the method that is utilised. 
As outlined in the earlier section, each type of survey method has its 
advantages and disadvantages. However, there are various ways by which the 
researcher can encourage participants to respond and complete the survey, 
thereby improving response rates. One of the approaches is compensation; to 
compensate the participant’s effort by means of providing an incentive. Another 
approach is by ensuring confidentiality and anonymity, (if it applies) of the 
participant. This can be an assurance to the participants that all their answers 
will be kept confidential and their responses will only be used for the purpose of 
the survey. The third approach is by following the KISS principle; Keep It Short 
and Simple. (133) Higher response and completion rates to questionnaire 
surveys are associated with concise, simple, and easy to answer survey 
questionnaires. (133) By portraying the tool as professional, courteous and 
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polite, an investigator can influence the return rates. Saying please and thank 
you as well as guiding the respondent politely, are also helpful in motivating the 
participant to complete the survey. Finally, participants are more likely to 
cooperate if the researcher practices professionalism, whether in appearance or 
their behaviour. 
 
How to address potential bias in a survey questionnaire  
A well developed questionnaire is imperative to gather the most appropriate 
data on the subject matter that is investigated. Therefore, in developing a good 
questionnaire there are many issues that investigators should consider. The 
basic tenant while developing questions or statements are the use of neutral 
wording when introducing questions and avoiding leading questions. Along with 
this one should make the questions as simple as possible, avoid too many open 
questions, and ask general questions before specific questions.  
While developing user experience questionnaires investigators should  avoid 
introduction of potential bias, this includes ‘acquiescence bias’, i.e. the fact that 
people are more likely to agree with a statement than disagree with it, stated by 
Cronbach 70 years ago, applies even today. (134) This means that one needs 
to balance positively phrased statements, such as ‘I found this interface easy to 
use’ with negative ones, for example ‘I found this interface difficult to navigate’. 
From questionnaires that are positively phrased, the results are more likely 
biased towards positive respondence and vice versa.  
Questionnaires that avoid acquiescence bias often suffer from other sources of 
bias such as reliability and validity. Reliability bias means that the same 
questionnaire may yield different results at different times. This can be checked 
by measuring the questionnaire's test-retest reliability. The third is validity bias. 
If validity is poor, there is no guarantee that the questionnaire actually measures 
what it is intended to measure, i.e. user satisfaction.  
A good positive user experience is central for the success of investigative as 
well as novel and interactive products. To improve a product’s quality aspects, it 
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is important to be able to measure user experience in an efficient and reliable 
way. But measuring user experience is not sufficient in itself.  
How the user is able to record his/her most appropriate response to a statement 
or question, and the method to be employed, was the next consideration by the 
researcher while developing the questionnaire survey tool. The next section will 
consider the tools that were used to record user response, for example rating 
scales. 
 
Rating scales for survey questionnaires 
A response format to a statement or questions in assesment tools can vary in 
form to suit the investigator requirements; however, it should be user friendly. 
The response formats used in surveys vary depending on the type of question 
being asked. Responses can be as simple as a choice between yes and no or 
choosing an answer among several response options, which is complex and 
may puzzle users. In a survey the response options for each question may 
include a dichotomous, a three, five, seven point scale or more, or a semantic 
differential scale. Each of these response scales has its own advantages and 
disadvantages.  The rule of thumb is that the best response scale to use is the 
one which can be easily understood by respondents and interpreted by the 
researcher. (133)  
A dichotomous scale is a two-point scale which presents options that are the 
opposite of each other, for e.g. yes or no. This type of response scale does not 
give the respondent an opportunity to be neutral on his/her answer in a 
question. A semantic differential scale is generally used in specialist surveys in 
order to gather and interpret data based on the connotative (the emotions and 
associations connected) meaning of the respondent’s answer. A semantic 
differential scale uses a pair of clearly opposite words, and can either be 
marked or unmarked. A rating scale that provides more than two options, in 
which the respondent can answer in neutrality over a question being asked, e.g. 
good, fair, poor in a three point scale, or in a five point scale the options for a 
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response may range from  strongly agree, agree, neutral i.e. neither agree or 
disagree, disagree, or strongly disagree. (133)  
 
Designing rating scales  
Rating scales are used for making an appropriate response to a statement or a 
question by the respondent. In devising rating scales the following four factors 
are considered important for a good outcome. Firstly, to use scales with equal 
options for positive and negative replies, e.g. five point scales should have two 
positive and two negative options with a neutral middle choice. Secondly, to use 
scales whose end points are equally positive and negative, e.g. scales going 
from very good to very poor or from good to poor, but not from very good to 
poor. Thirdly, to use scales that measure only one thing at a time i.e. a specific 
question or statement; and the fourth, to give people a do not apply or ‘N/A’ 
option if that is appropriate. 
Likert scale rating is a rating scale frequently discussed by investigators who 
employ survey questionnaires. Likert scale question itself was invented by the 
educator and psychologist Rensis Likert. (129) Likert scaling is a bipolar scaling 
method, measuring either positive or negative response to a statement. In a 
good Likert scale, the scale is balanced on both sides of a neutral option, 
creating a less biased measurement. For example, scales from positive to 
negative with five point scales; strongly agree, agree, neither agree or disagree, 
disagree and strongly disagree. The actual scale labels, as well as the numeric 
scale itself, may vary. Sometimes an even-point scale is used, where the middle 
option, neither agree nor disagree is not available. Likert scale is an ordinal 
scale, not an interval or ratio scale. A survey using a Likert scale rating is 
designed to measure an underlying construct of interest, so a numeric value 
may not be applied to the rating scale, in addition if a numeric rating scale is 
applied it is unlikely to represent a correct of the construct appraised. 
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Development of the NHNMRSA Product Experience Questionnaire  
For the purpose of constructing the product experience questionnaire (PEQ) in 
the NHNMRSA study, the researcher considered the six UEQ scales and the 
suitability of each of the scales in the PEQ. Of the six UEQ scales, 
attractiveness, dependability, stimulation and novelty scales were not 
considered of primary importance while considering user experience on the 
application of Medihoney™ Derma Cream, or mupirocin 2% w/w (Bactroban® 
2%), in the study. The logic was that, a medical device or a medicinal product is 
used in general for a medicinal purpose, prescribed by a practitioner, where, a 
necessity rather than a choice that determines the need to use a medicine, or a 
medical device. In order to assess user experience on a product, it is also 
important to determine that a user is able to comprehend how to use the 
product. Therefore, perspicuity was identified as the scale that was most 
applicable in the study.  
A self administered survey questionnaire method using paper and pencil to 
record user experience was considered optimal for use in the NHNMRSA study. 
The PEQ was developed through an iterative process involving supervisors for 
face and content validity. A statement or a question’s face and content validity 
can influence a respondent in making a correct response. Face validity 
describes the degree to which an assessment measures what it appears to 
measure. Content or logical validity refers to how accurately an assessment or 
measurement tool taps into the various aspects of the specific construct in 
question i.e. are the responses by the person answering the questions 
influenced by other factors. Four statements were developed by the researcher 
that elicited elements of perspicuity. These four statements were neutral 
statements that elaborated on perspicuity, that the user experienced on 
application of the allocated product. Each of the four statements measured only 
one aspect of the user experience. The fifth statement was a personal 
preference question, to record patients’ own preferences, where an option was 
given to patients to choose.  
A Likert scale rating was used in the PEQ. Scaling of four of the Likert 
statements in the questionnaire were with equal options, scales from positive to 
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negative with five point scales; which ranged from strongly agree, agree, neither 
agree or disagree, disagree and strongly disagree. A do not apply option was 
not used in the PEQ, as it was not appropiate. The fifth item in the PEQ, to 
record patients’ own preference where an option was available to the patient to 
choose between an antibiotic and a natural product, to eradicate MRSA from 
the nose. The fifth statement therefore had a scale with two options, to record 
the choice of the product. The PEQ incorporated a comment section which 
offered users with an option to place a free text if they wished, in addition to the 
response to five Likert statements.  
The PEQ was initially administered to 10 patients during the pilot study to 
evaluate its suitability for patients and their ease of registering a response. 
Completed questionnaires from 10 participants’ and their responses were 
evaluated to ascertain user encounter with the PEQ.  
While the PEQ was developed initially to evaluate the user experience of the 
investigative product, i.e. Medihoney™ Derma Cream, the research project 
team considered the merit of administering the PEQ to all study entrants, i.e. in 
both arms of the RCT. This was based on the evidence of limited scientific 
literature on patient experience on use of mupirocin 2% (Bactroban® 2%), nasal 
ointment for MRSA decolonisation. The research team deliberated on the 
potential merit of generating comparable data from control and study groups by 
administering the PEQ to all eligible study entrants. The decision to administer 
the PEQ to all study entrants necessitated modification of the questionnaire title 
to reflect the product allocated to the patient. The title of the PEQ for patients in 
the investigative group was labelled ‘Experience with Medihoney™ Derma 
Cream’. In addition, where the product name was specified in the questionnaire, 
the term ‘Derma Cream’ was used consistently. The title of the PEQ for patients 
allocated in the control group was labelled ‘Experience with Mupirocin nasal 
ointment’. In the PEQ for the investigative group where the product name was 
specified, the term mupirocin was consistently used. 
The amended PEQ was then administered to a group of ten patients, five in 
each arm who were enrolled in the RCT to evaluate their responses and ease of 
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use. The informal feedback received was satisfactory and the questionnaires 
were completed in full.  
PEQ amendments 
A NHNMRSA RCT project governance body ‘Project Advisory Committee’ 
(PAC) was set up to advice on the research study. The PAC at its first meeting 
(held in May 2014) considered the study instruments including the PEQ. The 
PAC were of the opinion that the wording of the PEQ statement five, ‘If given a 
choice between an antibiotic and a natural product to eradicate MRSA from the 
nose, I would prefer the natural product’ may influence a patients opinion in 
favour of the natural product thus generating a potential bias. Based on the 
suggestion of the PAC the wording of the statement was revised to reflect 
statement neutrality.  The revised statement which the PAC agreed with is as 
follows; ‘If given a choice between an antibiotic and a natural product to 
eradicate MRSA from the nose, which would you prefer’. The amendment to the 
PEQ necessitated a change of rating scale to record patients’ response to the 
specific statement, as well as approval by the Ethics (Medical Research), 
Committee (ERC), Beaumont Hospital. For the revised statement in the PEQ, a 
scale was not applicable and the option was not positive or negative rating, but 
to record patients’ choice of the product. Therefore the option provided was to 
choose ‘antibiotic’ or ‘natural product’. A submission was made by the 
researcher to the ERC, Beaumont hospital seeking the committee’s approval for 
the amendment to the wording of the PEQ. The ERC approved the proposed 
amendment of the wording in the PEQ approval date 23/05/2014. The revised 
version (V2) of the PEQ was used in the study thereafter (appendix - ⅩⅣ). 
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2.5.2 Development of the MRSA Perception Questionnaire 
 
Background 
In the past, the researcher was instrumental in developing and implementing a 
‘patient communication service on MRSA’ in Beaumont hospital. The provision 
of this service involved the following; a specialist nurse in infection prevention 
and control (IPC) providing detailed information to patients colonised or infected 
with MRSA. This began with a process of IPC written notification of MRSA 
colonisation in the patient’s medical record. Subsequently the respective clinical 
team provided initial information to the patient about the microbiological finding. 
This service was audited at planned intervals, (appendix - ⅩⅣ, proforma 
sticker patient notification of alert organisms). The insight gained from 
implementing and auditing the patient communication service encouraged the 
researcher to investigate patients' illness perception on MRSA colonisation 
while taking part in the RCT. With this aim, the researcher carried out literature 
reviews and electronic searches for pre-existing validated questionnaires that 
might be considered for use in the RCT.  
 
Assessing Illness Perception of patients 
Illness affects a person in a multitude of ways. The impact of an illness and 
coping with the illness of each individual can vary. An understanding of the 
patient’s perception of an illness, and how it impacts them psychologically and 
manifests in their behaviour, may assist healthcare practitioners and social 
therapy professionals to inform and develop appropriate responses to patients’ 
needs. (135)  
The illness perception approach can be best understood in the context of wider 
changes in psychology. Since the emergence of contemporary cognitive 
psychology during the mid 19th century, the focus on cognition and cognitive 
approaches has dominated all areas of psychological research and theory. At 
the core of the cognitive approach is the view that individuals construct models, 
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internal representations, or schema, which reflect their pooled understanding of 
previous experiences and are used for interpreting new ones and planning their 
behaviour. (135)  
Studies by Leventhal showed that patients' emotional responses to changes in 
tumour size following chemotherapy for lymphoma were a function of their own 
personal cognitive model of the illness. From this and other studies, Leventhal 
developed a self-regulatory model whereby patients construct their own 
representations or models which help them make sense of their experience and 
provide a basis for their own coping responses. (135) The self regulatory model 
developed by Leventhal contains core components, beliefs about the etiology of 
the illness, its symptoms and label, the personal consequences of the illness, 
how long it will last, and the extent to which the illness is amenable to control or 
cure. These components show logical interrelationships. For example, a strong 
belief that the illness can be cured or controlled is typically associated with 
shortly perceived illness duration and relatively minor consequences. 
Until the early 1990’s, the assessment of illness perceptions has been by open-
ended interviews designed to encourage patients to elaborate their own ideas 
about their illness. Weinman and colleagues has developed a new scale called 
the Illness Perception Questionnaire (IPQ) that can be used in a variety of 
physical illnesses which according to the architects of the IPQ should make 
patient assessment more efficient for researchers. (136)  
Weinman is of the opinion that in healthcare, cognitive approach offers an 
opportunity for researchers to identify the critical factors in patients' adaptation 
to illness. (136) Furthermore, this approach can facilitate the development of 
interventions that modify or take account of specific patient cognitions such as 
beliefs about the cause or potential for control/cure of an illness. Cognitive 
approach in healthcare influenced the development of a collaborative 
relationship with patients in which their beliefs and expectations are 
acknowledged in consultations and treatment, thereby patients are encouraged 
to take a more active and informed role. Early exploration and identification of 
patients' perceptions also offers the opportunity of minimising or avoiding later 
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difficulties such as non-adherence to treatment or recommended behaviour 
changes. (136)  
 
The Illness Perception Questionnaire  
The IPQ is a widely used multifactorial pencil and paper questionnaire which 
assesses cognitive illness representations of patients on a five-point Likert 
scale. (136) There are five dimensions of cognitive representation of illness in 
the IPQ. The first is identity, i.e. the label the person uses to describe the illness 
and the symptoms they view as being part of the disease. The second is 
consequences, the expected effects and outcome of the illness. The third is 
cause, the personal ideas about the cause of the illness. The fourth is timeline, 
i.e. how long the patient believes the illness will last, and the fifth is cure or 
control, the extent to which the patient believes that they can recover from or 
control the illness. The emotional representation in the IPQ incorporates 
negative reactions such as fear, anger, and distress. The importance of illness 
representations to patient behaviour has been demonstrated by research over 
four decades. (137) Changing patients’ illness perceptions has been shown to 
improve recovery following myocardial infarction (MI) (138), and other self-
regulatory interventions in illnesses as diverse as diabetes and AIDS, have also 
improved patient outcomes. (139)  
A revised version of the IPQ scale, the Illness Perception Questionnaire–
Revised (IPQ-R), extended the original scale by adding more items, splitting the 
control dimension into personal control and treatment control, and incorporating 
a cyclical timeline dimension, an overall comprehension of illness factor, as well 
as an emotional representation. (140) Based on the IPQ, a single-item scale 
approach to assess perceptions on a continuous linear scale was constructed 
by the research team who constructed the IPQ. This tool allowed the recording 
of short and simple measures of illness perceptions, as well as measuring with 
an alternative format such as the multifactorial Likert scale approach used in the 
IPQ and IPQ-R. The Brief Illness Perception Questionnaire (BIPQ) is 
copyrighted. (141) (Appendix - ⅩⅥ) The BIPQ incorporates nine items, each 
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item assesses one dimension of illness perceptions such as; consequences, 
time line, personal control, treatment control, identity, coherence, emotional 
representation, concern and the final aspect is a casual item which asks 
patients to list the three most important causal factors that caused their illness. 
The BIPQ has been used for studies of conditions such as asthma, renal 
disease, diabetes, myocardial infarction and a group of patients with chest pain 
undergoing stress exercise testing prior to diagnosis. The BIPQ authors claim 
that the tool is a valid and reliable measure of illness perceptions in a variety of 
illness groups. The evaluation of BIPQ in the above mentioned conditions report 
good test–retest reliability and concurrent validity with relevant measures. The 
results also indicate that there are moderate to good associations between the 
BIPQ and the IPQ-R on all of the equivalent dimensions. The main advantage 
offered by the BIPQ is the brevity and speed of completion for patients, as well 
as the easy interpretation of scores. The BIPQ authors assert that the tool is 
most useful for ill and elderly populations who would find completion of a long 
questionnaire difficult. It also offers advantages when researchers are already 
using a number of other pencil and paper measures, but wish to also include an 
assessment of illness perceptions over a relatively short period, to reduce the 
burden on research participants. The results from the scale can be easily 
scored and are readily interpretable by researchers and clinicians. 
 
Development of the patient MRSA Perception Questionnaire  
In order to gather patients’ perception on their MRSA colonisation, the 
researcher considered the merits of using a validated IPQ. With this purpose 
the BIPQ was assessed for its advantages such as the ease and speed of 
completion for users, brevity, as well as the easy interpretation of scores. For 
BIPQ to be employed in the NHNMRSA study, it was deduced that the 
terminology required modification for contextualisation and describing the 
condition evaluated i.e. MRSA colonisation. With the permission of the copyright 
holder (lizbroadbent@clear.net.nz) the BIPQ was adapted to suit the 
NHNMRSA study. The researcher amended the BIPQ, with the term illness 
changed to MRSA colonisation in the adapted questionnaire, MRSA perception 
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questionnaire (MRSA PQ). Similar to the BIPQ, the MRSA PQ incorporates all 
the nine items as in the BIPQ, with each item assessing one dimension of 
illness perceptions. The MRSA PQ also follows the same sequence of items as 
in the BIPQ; starting with consequences, time line, personal control, treatment 
control, identity, coherence, emotional representation and concern. The final 
item in the MRSA PQ is a casual item which invites patients to list the three 
most important causal factors that caused their MRSA colonisation.  
 
The MRSA PQ rating scale 
The original BIPQ response scale consists of an 11 point scale, from 0 to 10, 
the scale 0 representing a neutral or positive view of the item to the maximum 
score of 10 that corresponds to the individual patients’ views. The MRSA PQ 
followed the same11 point scale from 0-11in each of the eight Likert statements. 
The ninth, an open question was to list in rank order, the three most important 
factors that the patient believed caused his/her MRSA colonisation. The MRSA 
PQ was initially administered to healthcare volunteers. The purpose of which 
was to evaluate the user’s ability to understand the questions and response 
scores listed in the adapted questionnaire, i.e. MRSA PQ. Based on feedback, 
the format of the MRSA PQ was changed from portrait to landscape, without 
any change of content.  
 
Administration of the PEQ and MRSA PQ 
The NHNMRSA RCT research team considered the best possible opportunity to 
administer the questionnaires to study entrants for optimal return, to obtain an 
informed and correct opinion on the product experience as well as their 
perceptions on MRSA. The PEQ was administered to study entrants based on 
their allocation.  The investigative group was administered with the PEQ titled 
‘Experience with Medihoney™ Derma Cream’ and the control group was 
administered the PEQ titled ‘Experience with mupirocin nasal ointment’. The 
PEQ and the MRSA PQ were printed without any respondent identifiers and 
held with the researcher. Patients were handed a copy of the PEQ according to 
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the group each patient was allocated to, in addition to a copy of the MRSA PQ. 
Patients were provided with both the questionnaires, i.e. the PEQ and the 
MRSA PQ on the last day of the first course of Medihoney™ Derma Cream or 
mupriorcin 2% nasal application, or a at a later date. The researcher guided 
each patient who was provided with the questionnaires on how to complete 
each of the questionnaires, in addition to how and where to record their 
responses.  The study participants were encouraged to complete the 
questionnaires and the anonymous nature of the tool and responses were 
reiterated. A pre-labelled envelope addressed to the researcher was also 
provided to patients along with the questionnaires to facilitate return of 
completed questionnaires. The returned questionnaires were stored in a secure 
location in the host facility for analysis. 
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Chapter Ⅲ Results 
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3.1 Literature review 
 
3.1.1 Introduction  
The aim of the literature review was to determine the prevalence of MR and its 
clinical consequences, as well as measures to control MR. By undertaking the 
review the researcher also aimed to gather the evidence if any, that supports 
the use of new agents as potential therapeutic alternatives for the prevention 
and control  of MRSA. 
 
3.1.2 Results 
3.1.2.1 Types and prevalence of mupirocin resistance 
Phenotypically, mupirocin susceptibility is determined according to minimum 
inhibition concentration (MIC) breakpoints with susceptible being ≤4 mg/L, 
LLMR 8–256 mg/L and HLMR >512 mg/L. (142,47) Mupirocin MICs of 8–64 
mg/L are usually due to non-synonymous changes in the native isoleucyl-tRNA 
synthetase gene. S. aureus isolates with an MIC of 128 or 256 mg/L are 
uncommon but are considered to demonstrate LLMR; these isolates have 
acquired base changes in the native isoleucyl RNA synthetase gene, ileS. 
(39,142,51) MICs of ≥512 mg/L reflect HLMR and this is mediated by the 
acquisition of a conjugative plasmid containing mupA (ileS2), which encodes an 
alternative isoleucyl-tRNA synthetase. (47,48)  Although ileS2 does not encode 
resistance to other antibiotics, the presence of ileS2-carrying plasmids has been 
associated with resistance to antibiotics such as clindamycin, tetracycline, 
erythromycin and levofloxacin. (143)  
 
Among S. aureus isolates MR ranges from 1% - 81%. (39,144) In a Canadian 
hospital MR increased from 2.7% to 65%, between the beginning of the first 
year of the epidemic (1990) and the end of the third year. (145) In Brazil (1996) 
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in two tertiary care university hospitals, in one of which there was extensive use 
of mupirocin, 62/114 (63%) of isolates were MR. (43)  
 
In Shanghai and Wenzhou (China), during a three year surveillance program 
(2005 – 2008), HLMR was identified in 53/803 (6.6%) isolates that were MR 
MRSA. (146) In Singapore, HLMR was reported from 34/307 (11%) isolates; 
14% from screening isolates and 10% from clinical isolates during 2009 - 2010. 
(147) In Korea in 2011, HLMR was also reported from a neonatal ICU where 
101/223 (45%) of admissions were MRSA positive; of these, 70% had isolates 
that were MR. (148)  
 
In the USA, in a multicentre study in care homes over 30 months (2008 - 2011), 
MR was detected in 101 (12%) isolates; HLMR in 78 (9%) isolates and LLMR in 
23 (3%) isolates. (122) In Taiwan, in a review of 240 MRSA isolates recovered 
between 1990 and 2005, from patients who had failed decolonisation, MR was 
identified in 63% of the isolates. (149) In a nested case-control study conducted 
in an acute hospital in Switzerland (2011) MR ranged 9% - 81%. (144)  
 
Amongst staphylococcal isolates generally MR ranges from as low as 10.3% to 
as high as 97%. (150,151) In a French study in 2011 of  staphylococcal isolates 
a MR rate of 10.3% was reported amongst 708 isolates of CoNS, mainly HLMR 
(5.6%). (150) In a Dutch study of 238 CoNS BSI isolates, S. epidermidis was 
most prevalent, i.e. 150 isolates (63%) and it was also the most common 
species expressing HLMR isolates, i.e. 25 isolates (78%). In another study from 
the Netherlands in 2015 of 607 CoNS isolates collected from 469 patients after 
decolonisation with mupirocin, 588 (97%) were HLMR. S. epidermidis was most 
prevalent species with HLMR, i.e. 568 (94%). (151)  
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3.1.2.2 Chlorhexidine resistance 
Bacterial resistance to chlorhexidine was initially reported in 1995. (38) 
Resistance to chlorhexidine is conferred by two gene families, qacA/B and smr. 
(152) The plasmid mediated qacA/B genes encode proton-dependent multidrug 
efflux pumps, expression of which results in high-level resistance to antiseptics, 
whereas the smr gene confers low-level resistance. (144,38,153)  
Chlorhexidine resistance, i.e. qacA/B and smr ranges from 0.6% - 91%. 
(122,144) In Taiwan where chlorhexidine has been used for 20 years for hand 
hygiene, the proportion of MRSA isolates with a chlorhexidine MIC of ≥4 mg/L 
increased from 1.7% in 1990 to 50% in 1995 to  40% in 2000 and then to 46.7% 
in 2005. Among these isolates, 46/83 (55.4%) carried the qacA/B gene. In 
addition, qacA and/or qacB were identified in 91% of MRSA isolates from 
patients who had failed decolonisation. (149)  
In Korea among MR MRSA isolates collected between 2006 and 2009, the 
qacA/B and smr genes were detected in 65% of isolates. (154) In a nested 
case-control study of MRSA decolonisation from Switzerland, qacA/B was very 
prevalent among 68/75 cases (91%) and 51/75 of controls (68%). (144) The 
same study also found that combined LLMR and the presence of chlorhexidine 
resistance significantly increased the risk of persistent MRSA carriage. (144) It 
appears that chlorhexidine resistance is increasingly reported and the presence 
of qacA and/or qacB is associated with persistent MRSA colonisation.  
 
3.1.2.3 Controlling mupirocin resistance 
Three approaches were proposed by Patel et al. in controlling MR. (142) First, 
additional studies are needed to quantify the efficacy and unintended 
consequences of mupirocin use as a prevention strategy. Second, a strategy for 
monitoring the prevalence of resistance should be in place whenever mupirocin 
is routinely used. Third, monitoring should not only focus on MR itself, but also 
should help determine whether mupirocin use might amplify the spread of other 
MDR via its linkage to other resistance determinants. (142)   
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Incorporating MR surveillance as part of ongoing surveillance programmes such 
as EARSS-Net, which monitors antibiotic resistance amongst invasive isolates 
of MRSA, i.e. in BSI, may be beneficial as these are representative of isolates 
responsible for serious infection from a population in which many have had or 
will be undergoing MRSA decolonisation. 
For persistent MRSA carriers, mupirocin MIC testing should be repeated to 
assist in informed decision making and provide the potential opportunity to 
impact on the control of resistance. Point prevalence surveillance is also 
indicated in centres where mupirocin is widely used and / or resistance is 
reported. 
Control of mupirocin use, i.e. targeted decolonisation in selected patients based 
on risk assessment rather than the decolonisation of all MRSA-positive patients, 
has proved an effective strategy to combat MR. (44) There was a precipitous 
decline in the number of isolates with HLMR (from 31% to 4%) and also LLMR 
(from 26% to 10%) after measures were introduced to control or limit the use of 
mupirocin over 2 years (1996 - 1998), in a mixed healthcare setting that 
included acute, domiciliary and nursing homecare. 
In the Netherlands reductions in MR following the control of mupirocin use were 
reported from a neonatal unit in 1992 where the routine application of mupirocin 
to central vascular catheter insertion sites was discontinued. (155) In Western 
Australia, restricted mupirocin use for nasal decolonisation led to reductions in 
MR from 6.4% (n=16) in 1994 to 0.3% (n=3) in 1997. (156)   
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3.1.2.4 Alternative agents for decolonisation 
The alternative agents investigated by researchers for MRSA decolonisation 
include other antimicrobials, non-antimicrobials as well as natural agents. The 
review findings on the use of various alternative agents for decolonisation are 
now discussed. 
Antimicrobial agents 
Bacitracin ointment, usually in combination with polymyxin B and neosporin 
(e.g. polysporin), has been studied as a potential MRSA decolonisation agent. 
In an RCT that compared mupirocin with polysporin and daily chlorhexidine 
gluconate (CHG) washes, only 15/49 (30.6%) patients in the polysporin arm 
were MRSA negative at all body sites at 48 h, compared with 35/54 (64.8%) of 
those treated with mupirocin. (157)  
Retapamulin is a pleuromutilin and a new class of antibiotic that exhibits activity 
against various skin bacteria including MSSA and MRSA. An in vitro study 
reported that retapamulin had good activity against 15/16 (94%) of MR isolates. 
(158) However, a double-blind RCT concluded that the clinical success rate in 
the treatment of secondarily infected traumatic lesions amongst patients with 
MRSA was significantly lower with retapamulin compared with linezolid. (159)  
The antimicrobial options such as polysporin and retapamulin appear less 
effective when compared with mupriocin for decolonisation. 
Octenidine dihydrochloride 
In the decolonisation of extra-nasal sites in a study using octenidine 
dihydrochloride body washes a successful outcome was recorded in 18/32 
(56.3%) of patients. (160) In another study where CHG or povidone-iodine was 
contraindicated, success with vaginal MRSA decolonisation has also been 
reported using octenidine solution. (161)  
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Polyhexanide 
In a study that retrospectively evaluated polyhexanide (Prontoderm) Gel Light 
nasal ointment, body foam and mouthwash for decolonisation, persistent MRSA 
was identified among 51/72 (71%) of those who underwent the Prontoderm 
regimen. Pooled cultures of nasal, perineal and throat samples were used, 
which limits conclusions on the components that resulted in an inferior rate of 
decolonisation. (162) A double blind placebo controlled RCT that evaluated a 
single 10 day course of polyhexanide nasal application has reported sub-
optimal success in nasal MRSA decolonisation. (163) Polyhexanide therefore 
compares unfavourably with mupirocin nasal application for MRSA 
decolonisation. 
Ethanol 
The nasal application of 70% ethanol combined with emollients and a 
preservative (Nozin Nasal Sanitizer), resulted in a 98.8% reduction in colony 
counts at the end of the normal (10 h) workday. (164) My search did not retrieve 
other studies that used ethanol for nasal decolonisation. Therefore, further 
studies are needed before this approach can be safely recommended.  
Sodium hypochlorite 
An RCT comparing three decolonisation regimens using mupirocin, 
chlorhexidine and bleach on patients with community-based skin and soft tissue 
infections and multisite S. aureus colonisation revealed that the highest rate of 
successful S. aureus eradication (71%) occurred in patients with a combination 
of nasal mupirocin and daily bleach baths. (57) In skin conditions there may be 
role for concurrent nasal and skin/soft tissue decolonisation/treatment using 
sodium hypochlorite, however, there is paucity of information on its use in 
routine practice.  
Lysostaphin 
Lysostaphin is a glycylglycine endopeptidase that cleaves the cross-linking 
pentaglycine bridges in the cell walls of staphylococci. In an animal model, a 
single application of 0.5% lysostaphin cream eradicated MSSA and MRSA from 
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the nares of animals more effectively than mupirocin. (165) In 24 h time–kill 
studies, lysostaphin has also been found to be superior to mupirocin and tea 
tree oil. (166)   
Omiganan pentahydrochloride 
Omiganan pentahydrochloride is a novel topical cationic peptide active against 
a broad spectrum of bacteria and yeast. An in vitro study has demonstrated 
potent activity against S. aureus regardless of the underlying resistance 
mechanism, at a concentration significantly below the concentration that would 
probably be used in clinical practice (1% gel). (167)  
Natural honey 
Honey is of interest to healthcare practitioners involved with wound 
management and reductions in the number of MRSA colony counts in open 
wounds have been demonstrated. (92,106-108,113) An in vitro study of four 
types of honey (botanic origin), three sourced from Northern Ireland and one 
from Suisse Normande, France, found that they reduced the bacterial count of 
community acquired MRSA isolates. (117) Similar findings on MRSA 
eradication are reported elsewhere when medical-grade honey was applied to 
chronic wounds. (113,99)  
Tea tree oil 
A study of a tea tree (Melaleuca alternifolia) oil-based regimen was compared 
with standard treatment consisting of mupirocin, chlorhexidine or silver 
sulfadiazine. (54) Of the patients who received the tea tree oil regimen, 46/110 
(42%) were decolonised in comparison to 56/114(49%) the patients who 
received standard treatment, 14 days after a five day course. Mupirocin was 
significantly more effective at clearing nasal carriage than the tea tree oil 
preparation (78% versus 47%; P=0.0001). A RCT in two ICUs evaluated the 
effect of daily washing with tea tree oil (Novabac 5% skin wash) compared with 
standard care with a baby soft wash (Johnson’s Baby Softwash) on the 
incidence of MRSA colonisation and found that there was no statistical 
difference between the two approaches. (55)  
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Silver 
The successful topical application of silver agents (Acticoat 7w®, Smith & 
Nephew) in treating patients with MRSA surgical site infection (n=2) without 
systemic antibiotics as well as with gentian violet (0.5%) for skin lesions (n=28) 
and for the eradication of nasal carriage (n=9) has been described. (168) Silver 
impregnated dressings are indicated in the management of certain type of 
wounds. 
Bacteriophages 
Bacteriophage therapy is an alternative to antibiotics for the treatment of chronic 
MRSA infections, as success has been reported both in treating infections (n=6) 
as well as in the eradication of MRSA carrier status in a healthcare worker. 
(169) The potential for an engineered staphylococcal-specific phage lysin (ClyS) 
to be used for topical decolonisation was investigated in a mouse model. (170) 
ClyS eradicated a significantly greater number of MSSA and MRSA with a 3 log 
reduction compared with a 2 log reduction with mupirocin. (170)  
Another agent, P128 a chimeric protein that combines the lethal activity of two 
enzymes, consists of a phage tail-associated muralytic enzyme of phage K and 
the staphylococcal cell wall-targeting domain (SH3b) of lysostaphin. In time–kill 
assays, P128 reduced cfu by 99.99% within 1 h and inhibited growth for up to 
24 h. (171) Evidence that phages can effectively combat experimentally induced 
S. aureus infections in animals, warrants further study in clinical trials. (172)  
 
3.1.3 Discussion  
Bacterial resistance to mupirocin initially identified in S. aureus, in recent 
years has also been identified amongst other staphylococci. Increasing MR 
among S. aureus as well as other staphylococcal isolates, either alone or 
combined with chlorhexidine resistance means that, ongoing monitoring of 
resistance is necessary. Surveillance of MR and chlorhexidine resistance is 
especially important where there is widespread and even indiscriminate use of 
decolonisation regimens using mupirocin and chlorhexidine.  
110 
 
The emergence of HLMR amongst CoNS isolates indicates an expanding 
reservoir of plasmids encoding MR, which can be transferred to other CoNS 
strains as well as to S. aureus including MRSA. (173) HLMR and resistance to 
other antibiotics amongst CoNS may result in a reduction in oral antibiotic 
options for prolonged treatment of prosthetic infections with CoNS.  
Resistance to mupirocin and chlorhexidine, the commonly used decolonising 
agents limits the options for patients who may benefit from MRSA suppression 
or decolonisation therapy. Before application, LLMR is significantly associated 
with persistent MRSA carriage. In addition, there is a strong association 
between previous mupirocin exposure and both LLMR and HLMR. An 
association exists between HLMR (mupA carriage) and multidrug resistance 
(MDR). The presence of qacA and/or qacB and MR is another factor associated 
with failed decolonisation. (174)  
Cross-sectional studies have found that chlorhexidine resistance alone did not 
predict persistent carriage, suggesting that the combination of LLMR and 
chlorhexidine resistance may be necessary for clinical failure, i.e. persistent 
colonisation. (144) Therefore, among persistent colonisers it is logical to 
investigate for MR and chlorhexidine resistance before attempting additional 
courses of suppression or decolonisation therapy if ongoing monitoring of 
resistance is not performed. Therapeutic trials of alternative agents such as 
honey and bacteriophages show some promise but need to be further evaluated 
in clinical trials.  
 
3.1.4 Summary 
• Among S. aureus isolates, MR ranges from 1% - 81%. 
• Among other staphylococcal isolates, MR ranges from 10.3% - 97%, 
mostly in S. epidermidis.  
• The emergence of HLMR amongst CoNS isolates indicates an 
expanding reservoir of plasmids encoding MR.  
• Among MRSA isolates, chlorhexidine resistance ranges from 0.6% - 
91%. 
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• The genetic determinants of MR either alone or combined with 
chlorhexidine resistance, i.e. qacA/B or smr,  presents a significant 
challenge for the control and prevention of MRSA. 
• Alternate antimicrobial agents such as polysporin and retapamulin are 
less effective in comparison to mupirocin for MRSA decolonisation.  
• Agents such as octenidine dihydrochloride, polyhexanide, ethanol (70%), 
sodium hypochlorite, lysostaphin, omiganon pentahydrochloride, natural 
honey, tea tree oil, silver and bacteriophages have been investigated 
with varying success for MRSA decolonisation. 
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3.2. Results of the Randomised Control Trial 
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3.2 Patient characteristics and RCT outcome  
3. 2.1 Introduction  
MRSA colonise different body sites, nasal colonisation being very common. In 
healthcare, MRSA screening programs usually incorporate nasal screening in 
addition to other sites such as groin/perineum, wounds, ulcers, device insertion 
sites as well as the throat. Decolonisation of the nasal passages of MRSA is 
attempted as part of prevention of infection, as well as control of transmission.  
Nasal as well as non-nasal decolonisation efforts may be influenced by many 
factors, of which patient risk factors are significant. The overall aim of the 
NHNMRSA study was to determine the comparative efficacy of 30% MGH 
(Medihoney™ Derma Cream) the investigative product, to mupirocin 2% 
(Bactroban® 2%) nasal ointment (control), to decolonise the nasal passages of 
MRSA, in a RCT. In executing the RCT, a number of patient characteristics 
(hereafter termed variables) were collected to determine the impact if any, on 
the outcome of nasal MRSA decolonisation. The patient variables and the study 
outcome is enumerated in detail. 
 
3.2.2 Results; Participants and baseline characteristics 
Participants 
During the study period (1st March 2014 to 31st March 2016) there were 457 
patients with nasal MRSA positive swab that were reported from BH 
microbiology laboratory. Of the 457 patients, 74 swabs were from external 
patient specimens, and where therefore not eligible for recruitment to the study. 
All the remaining 383 patients were assessed for eligibility. Following the 
preliminary assessment and application of the exclusion criteria, 108 (28%) 
were eligible and 100 (93%) patients consented to participate in the study, and 
were then allocated randomly to intervention and control groups. All the 100 
participants had a positive MRSA nasal swab at baseline. The study groups and 
reason for non-inclusion are shown in Figure 3.2.1. 
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Figure 3.2.1 Natural honey for nasal MRSA RCT enrolment flow diagram 
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Follow-up 
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Analysed in ITT (n=50)  
Analysed in PP (n=44) 
Not included (n=6) 
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Demographic, clinical and microbiologic characteristics 
Statistical analysis 
The characteristics of the study participants are described using frequencies, 
percentages, measures of central tendencies and measures of dispersions as 
appropriate. The homogeneity of the intervention and control groups such as 
the basic socio-demographic and clinical characteristics was assessed using 
Chi-square (χ2) tests. In the analysis of data if any cell had a frequency less 
than 5, then Fishers Exact test values in the 2 x 2 contingency table were used 
to assess for any significant difference between the intervention and control 
group.  
As a rule of thumb for statistical analysis and reporting of results, χ2 value is 
used as the preferred option (where a 2X2 table was available), and if the value 
is less than five in any column, then likely hood ratio is used instead of the χ2 
value. In addition, the p-value and significance is recorded.  
 
Baseline characteristics 
The baseline characteristics of the study participants and comparisons between 
the intervention and control groups are presented in Table 3.2.1 
 
  
116 
 
Table 3.2.1 Natural honey for nasal MRSA RCT comparison of the baseline 
characteristics of the intervention and control groups 
 
 
Intervention n=50 Control n=50 
 
 
Age at enrolment 
  
 
 
Mean (Sd)a 71.7    (13.2) 74.7    (11.0) 
 
 
Gender       n               %          n            % p-value Sigb 
   Male 36 (72.0) 28 (56.0) 0.096         nsc 
   Female 14 (28.0) 22 (44.0)    
Medical Specialty 
     
 
   Medicine 34 (68.0) 36 (72.0) 0.866 ns 
   Surgery 9 (18.0) 7 (14.0)    
   Renal 6 (12.0) 5 (10.0)    
   Neuroscience 1 (2.0) 2 (4.0)    
Comorbidity 
     
 
   Diabetes mellitus 16 (39.0) 13 (33.3) 0.597 ns 
   Prosthesis 0 (0) 2 (5.6) 0.151 ns 
   Liver disease 0 (0) 1 (2.7) 0.321 ns 
   COPD# 13 (32.5) 18 (45.0) 0.251 ns 
   Malignancy 4 (10.5) 4 (10.5) 1 ns 
   Vascular disease 17 (44.7) 15 (35.7) 0.411 ns 
   Immuno- suppression 10 (27.0) 14 (38.9) 0.281 ns 
   Renal disease 8 (20.0) 11 (28.2) 0.394 ns 
   Heart disease 11 (26.2) 11 (24.4) 0.851 ns 
Normal residence 
     
 
   Nursing home 2 (15.4) 3 (18.8) 0.523 ns 
   Other HCF* 1 (7.7) 0 (0)              ns 
   Unknown 10 (76.9) 13 (81.2)              ns 
Health care contact pre enrolment 
    
 
   High (>6/ year) 41 (82.0) 37 (74.0) 0.87 ns 
   Medium (3-5/ year) 5 (10.0) 12 (24.0)    
   Low (<2/ year) 4 (8.0) 1 (2.0)    
Recruitment location 
    
 
   Inpatient 42 (84.0) 44 (88.0) 0.564 ns 
   Outpatient 8 (16.0) 6 (12.0)    
a- Standard deviation, b- Significance, c-Not significant, #COPD - Chronic obstructive pulmonary disease,  
* HCF- Health care facility 
 
The mean age and standard deviation (Sd) of the study entrants was 73.2 y 
(12.1). In the intervention group the mean age of the participants was 71.7 y, 
and in the control group 74.7 y. The age ranged from 34.7 years to 91.6 years.  
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A preponderance of males was observed in the intervention group, however, in 
the control group the distribution of both genders were comparable. The 
distribution of patients according to their medical specialty was also comparable 
in the intervention and control groups, refer Table 3.2.1. 
Various co-morbidities were identified in our study participants, refer Table 
3.2.1. Among the 100 study participants the most prevalent pre-existing 
conditions was diabetes mellitus (DM) 39%, vascular disease 32%, chronic 
obstructive pulmonary disease (COPD) 31%, immunodeficiency 24%, chronic 
heart disease (CHD) 22% and end stage renal disease (ESRD) 22%.  
Of the 100 patients, 5% were nursing home residents, one patient was a 
communal facility resident and the remaining 94% patients lived at home prior 
to the RCT enrolment. The distribution of patients based on their location of 
residence prior to study enrolment was comparable between the two groups. In 
a similar manner, the location of recruitment was also comparable between the 
intervention and control groups.  
 
Overall, there were no significant differences between the intervention and 
control groups at baseline, as presented in Table 3.2.1.  
  
Risk factors 
In Table 3.2.2 the baseline risk factors of the study participants collected such 
as the acuity of care recorded, using the nursing dependency information 
system (NIS), their skin condition, and the presence of invasive and indwelling 
devices, are presented. 
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Table 3.2.2 Natural honey for nasal MRSA RCT, comparison of baseline risk 
factors between the intervention and control groups 
Variable 
 
Intervention Control Univariate analysis 
n=50 n=50 P-value Siga 
Nursing dependency (NIS)*            n  % n % 
 
 
   Low-medium 37 (74.0) 36 (72.0) 0.822 nsb 
   High-specialised care 13 (26.0) 14 (28.0)    
Skin integrity 
     
 
   Skin - Healthy 25 (50.0) 28 (56.0) 0.816 ns 
   Wound 14 (28.0) 13 (26.0)    
   Ulcer 11 (22.0) 9 (18.0)    
Device in situ            
   CVC**/PICC# 5 (13.9) 5 (15.6) 0.411 ns 
   PVC$ 19 (52.8) 21 (65.6)    
   Urine catheter 3 (8.3) 3 (9.4)    
   More than 1 device 9 (25.0) 3 (9.4)    
 a -Significance, b- not significant, * - Nursing dependency score, ** CVC - Central vascular catheter, #-
Peripheral inserted central catheter, $-PVC - Peripheral vascular catheter 
The NIS score is a weighted cumulative score that is applied following nursing 
assessment and is updated regularly. NIS is composed of five elements; 
personal care, feeding, mobility, nursing attention and the fifth item is other; 
which includes involuntary drainage, major intervention and specialist 
intervention. Three levels of care apply to each of the first four NIS elements. A 
weighted score applies for each of the five elements which generate a 
cumulative NIS score, range 1-5. The NIS score of each of the participants in 
the study was transcribed from the NIS system to the database. 
Of the 100 participants, 19% had a NIS score of 5, that signifies they needed 
specialist nursing care, 8% had a NIS score=4, which means they were nursing 
dependent, 19% had a NIS score=3, who required moderate assistance, 53% 
had a NIS score=2, who only required minimal assistance, and one participant 
was independent. For statistical analysis, independent, low and medium NIS 
scores (scores 1-3) were  grouped into a single group as low-medium, and the 
remaining two categories high dependency and specialised care (scores 4-5) 
into  high-specialised care. Overall 27% of the participants were of the high 
dependent and specialised care category (NIS scores=4-5), which denotes a 
high level of healthcare contact among such patients.  
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Of the 100 participants 47% had altered skin integrity of which 24% participants 
had wounds, 20% ulcers and 3% stoma.   
Overall, 68 participants had an invasive device in situ. Of the 100 
participants,10% had a central vascular catheter (CVC) or a peripherally 
inserted central catheter (PICC), 40% had a peripheral vascular catheter (PVC), 
6% had a urinary catheter (UC) and 12% had more than one invasive device 
during their participation in the study. 
 
The distribution of participants in the intervention and control groups was 
comparable for their acuity of care, skin condition; i.e. integrity, wounds and 
ulcers, as well as the presence of invasive devices. There were no statistically 
significant differences between the intervention and control groups in terms of 
their nursing dependency, skin condition and the presence of invasive and 
indwelling devices. 
 
Baseline microbiological characteristics  
Microbiological characteristics such as MRSA status; whether first time 
identified in BH or previously known and past decolonisation attempts were data 
of clinical significance in the study. In Table 3.2.3 the baseline microbiological 
characteristics of the study participants including MRSA status on study 
enrolment, colonisation with multi drug resistant organisms (MDRO) Clostridium 
difficile Infection (CDI) and past decolonisation attempts are presented. 
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Table 3.2.3 Natural honey for nasal MRSA RCT comparison of the baseline 
microbiological characteristics of the intervention and control groups 
 
Variable 
 
Intervention Control Univariate analysis 
n=50  n=50  P-value Siga 
MRSA history n % n % 
 
 
First time identified 4 (8.0) 3 (6.0) 0.695 nsb 
Previously known 46 (92.0) 47 (94.0)    
MDRO* CDI status 
     
 
VRE" 8 (80.0) 11 (84.6) 0.772 ns 
C difficile# 2 (20.0) 4 (80.0) 0.793 ns 
ESBL£ 6 (75.0) 7 (100) 0.155 ns 
CRE$ 2 (100) 1 (100)    
MRSA decolonisation history 
H/o€ decolonisation 45 (90.0) 44 (88.0) 0.749 ns 
Past mupirocin nasal  use  
Yes 43 (86.0) 44 (88.0) 0.766 ns 
 Mupirocin number of courses 
1-2 26 (60.4) 27 (61.3) 0.869 ns 
3& > 17 (39.5) 17 (38.6)    
Past non-nasal decolonisation 
Yes 45 (90.0) 43 (87.8) 0.722 ns 
a- Significance, b-Not significant, *- multi drug resistant organisms, CDI - Clostridium difficile infection,       
" VRE - vancomycin resistant enterococci, # Clostridium difficile, £ESBL - Extended spectrum beta 
lactamase organisms, $CRE - Carbapenem resistant enterobacteriacae, ~NA – Not applicable, € - History 
of. 
 
Of the 100 participants, 93% were previously identified with MRSA colonisation 
/ infection, i.e. known cases. The remaining 7% were first time identified MRSA 
in BH, during their current episode of admission to the hospital.   
Cumulatively, 89% (89/100) of patients had a history of attempted nasal 
colonisation, and 88% (88/100) had non-nasal decolonisation. Among the 
patients who had attempted nasal decolonisation, 60% (53/89) had up to two 
courses of mupirocin, 38% (34/89) three or more courses of nasal mupirocin2% 
ointment before study enrolment.  
Ten patients (10%) had a laboratory confirmed Clostridium difficile infection in 
the current episode of hospital admission, 19% (19) had history of VRE 
colonisation and 13% (13) ESBL colonisation, refer Table 3.2.3. 
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The distribution of participants in the intervention and control groups were 
comparable for their MRSA status, colonisation with MDROs CDI, past history 
of decolonisation, both nasal and non-nasal body sites, as well as the use of 
mupirocin  for nasal decolonisation of MRSA, refer Table 3.2.3. There were no 
significant statistical differences in their MRSA status, colonisation with MDROs 
CDI as well as past decolonisation attempts between the two groups. 
 
Infection prevention and control characteristics  
Decolonisation of patients of their MRSA carriage is attempted while in hospital 
settings, and isolation of patients along with practice of CP is recommended 
and practised where feasible and appropriate. Multisite colonisation, i.e. MRSA 
colonisation of non-nasal sites is also of clinical significance and affects nasal 
decolonisation attempts.  
In Table 3.2.4 the comparison of the concomitant IPC characteristics that were 
relevant to the study, such as place of residence of the study participants along 
with the application of CP and patient isolation where appropriate, along with 
MRSA colonised sites, are presented. 
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Table 3.2.4 Natural honey for nasal MRSA RCT concomitant infection 
prevention and control (IPC) characteristics in the intervention and control 
groups 
Variable 
 
Intervention Control Univariate 
analysis 
 
n % n % p-value Sigb 
Residence during the study 50 (100) 50 (100) 
 
 
Inpatient 42 (84.0) 44 (88.0) 0.564 ns
a
 
Out patient 8 (16.0) 6 (12.0)    
Isolation of patients        
 
Single room CP* 22 (44.0) 25 (50.0) 0.747 ns 
Cohort CP 6 (12.0) 4 (8.0)    
Not isolated 10 (20.0) 13 (26.0)    
Not applicable 8 (16.0) 6 (12.0)    
MRMRSA** on enrolment 
Yes 3 (6.0) 0 (0) 0.079 ns 
MRSA positive sites on enrolment 
Nasal 50 (100) 50 (100)    
Groin 19 (38.0) 20 (40.0) 0.904 ns 
Urine 0 (0) 1 (2..0) 0.248 ns 
Respiratory 1 (2.0) 0 (0) 0.157 ns 
Wound 13 (26.0) 5 (10.0) 0.844 ns 
Ulcer 5 (10.0) 4 (8.0)    
Other site/s 3 (6.0) 1 (2.0)    
a -not significant, b -significance *Contact precautions, ** Mupirocin resistant MRSA 
 
On commencement of the study, 86% of the participants were inpatients and 
57% of the patients were isolated, either in a single room or cohort with CP.  
Current nasal colonisation was an essential prerequisite for RCT enrolment and 
all of the 100 participants had documented MRSA nasal colonisation at study 
enrolment. Non-nasal colonisation was identified cumulatively at one or more of 
the sites screened among 72% of the participants. Groin/perineum was the 
most common site colonised 39%, followed by wounds 18% and ulcers 9%.  
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The distribution of participants in the intervention and control groups were 
comparable for their location of residence and IPC practices such as isolation 
and CP during study commencement, refer Table 3.2.4. MRSA colonisation of 
non-nasal sites was also comparable between the two groups. There were no 
significant statistical difference in the location of residence and IPC practices, 
as well as MRSA colonised sites between the intervention and control groups. 
 
3.2.3 RCT outcome, nasal MRSA screening 
In Table 3.2.5 the microbiological outcome of the attempted nasal MRSA 
decolonisation, on an intention to treat (ITT) of all the 100 consented and 
randomised patients, irrespective of whether a final outcome was available, is 
presented. This includes patients who deviated from the allocated protocol, 
were lost to follow-up as well as withdrew from the study, 14 (14%) in total; 
eight (8%) in the intervention and six (6%) in the control group. Per protocol 
analysis of participants who completed the study according to the allocated 
protocol is also presented. Data on MRSA colonisation of non-nasal sites where 
available, at the end of the study, were also compared between the two groups. 
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Table 3.2.5 Natural honey for nasal MRSA RCT microbiological outcome in the 
intervention and control groups 
MRSA 
 
Intervention Control         Univariate analysis 
 
n           % 
 
n           % Chi-square p-value Sig
a
 
Nasal  negative (ITT basis) 18 (36.0) 25 (50.0) 1.999 0.157 nsb 
 
Nasal negative (PP basis) 
 
18 (42.9) 25 (56.8) 1.675 0.196 ns 
 
 
Positive on any non-nasal 
site/s 
34 (85.0) 34 (79.1) 0.492 0.483 ns 
a - Significance, b - not significant 
 
On an ITT analysis, of the 100 participants, 18 (36%) in the intervention group 
and 25 (50%) in the control group were decolonised of nasal MRSA by the end 
of the study. A χ2 test was performed to assess the difference in the rate of 
decolonisation of MRSA between the intervention and control group. There was 
no statistically significant difference between the two groups (χ2=1.999, df=1, 
p=0.157), Table 3.2.5. On a PP analysis, the final outcome i.e. nasal screening 
results were available for 86 (86%) of the participants; 42 (84%) from the 
intervention group and 44 (88%), from the control group. In the intervention 
group 18 (43%) participants and in the control group 25 (57%) participants were 
decolonised of their nasal MRSA, however, a χ2- test showed no significant 
difference (χ2=1.675, p=0.196).  
MRSA colonisation was identified at one or more non-nasal sites in 68% (68) of 
the participants on study completion. 
The outcome of the intervention and control groups were comparable on their 
outcome, nasal MRSA, refer Table 3.2.5. In a similar way, outcome of non-
nasal sites MRSA screening was also comparable for both groups.  No 
significant statistical association or significance was identified based on the 
nasal screening outcome between the intervention and control groups, as for 
non-nasal screening results. 
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Univariate analysis of the data confirms robust comparability of the study 
participants in the intervention and control groups. In addition, none of the study 
variables were of statistical significance on the outcome, i.e. nasal MRSA. 
Based on the ITT and PP analysis, there was no statistical significance in the 
outcome of nasal MRSA decolonisation, between the intervention and control 
groups. Therefore, the NHNMRSA RCT null hypothesis is not rejected. 
However, a particular concern is the impact of the less than anticipated number 
of patients enrolled in the study on the power to detect significant differences 
between the intervention and control groups. 
 
Multivariate logistic regression 
For logistic regression analysis binary data were re-coded, details itemised in 
the RCT methodology section, and multivariate logistic regression analysis 
undertaken. In order to perform multivariate analysis, from a statistical point of 
view a rule of thumb is that 10 subjects is the minimum number required for 
each dependent variable. Therefore, based on elements of clinical risk and 
importance previously described by others, and variables with a p- value of up 
to 0.2 in univariate analysis, were included in the model constructed for 
sensitivity analysis.  
  
The best fitting model for multivariate sensitivity testing was developed based 
on the convention that the lowest -2log likelihood and Nagelkarke R2 (NR2) 
scores, whereby the lowest -2log likelihood and NR2 highest explains the best fit 
of the model used. 
 
Table 3.2.6 presents the results of the multivariate logistic regression analysis. 
Eight variables were initially considered for the logistic regression analysis; age, 
gender, skin integrity,  presence of invasive devices, location of patient 
residence during the RCT, patient isolation, nursing dependency, past 
mupirocin use and MRSA colonisation of non-nasal sites. Table 3.2.7 that 
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follows presents the Hosmer and Lemeshow test results, the model that was 
used to perform logistic regression analysis. 
 
Table 3.2.6 Natural honey for nasal MRSA RCT multivariate logistic regression 
analysis on the outcome of nasal MRSA decolonisation 
Variable p OR 
95% CI 
L             U 
Siga 
Age category >65 y 0.433 1.805 0.413 7.888 ns
b
 
Gender, Male 0.776 1.177 0.382 3.627 ns 
Skin, non-intact 0.115 0.391 0.122 1.256 ns 
Invasive device present 0.884 0.915 0.280 2.989 ns 
Residence, HCFc 0.451 0.531 0.102 2.755 ns 
Isolation, HCF 0.349 1.908 0.493 7.382 ns 
NDSs dependent care 0.529 1.507 0.420 5.410 ns 
Mupirocin >2 course 0.101 2.625 0.830 8.308 ns 
Multisite MRSA colonisation 0.008 4.707 1.496 14.815 s
d
 
a - significance, b - not significant, c - Health care facility, d- significant 
The test model summary is further explained using the model coefficients and 
the significance (p) values derived, in Table 3.2.7 
Table 3.2.7 Natural honey for nasal MRSA RCT LG results of the model using 
the Hosmer and Lemeshow test 
Model summary Hosmer and Lemeshow Test 
-2 Log 
likelihood 
Cox & Snell R 
Square 
Nagelkerke R 
Square Chi-square df p 
85.398 0.216 0.288 7.241 8 0.511 
 
Multisite i.e. concomitant non-nasal MRSA colonisation, was significantly 
associated, (χ2=7.241, p=0.008) with persistent nasal MRSA colonisation.  
 
Table 3.2.8 presents the results of logistic regression analysis of the outcome of 
the intervention, compared to four variables that displayed significance or close 
association, and Table 3.2.9 displays the test model summary results. 
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Table 3.2.8 NHNMRSA RCT results of logistic regression (LG) of four variables 
of association. 
Variable p OR 
95% CI 
L             U 
Skin non-intact 0.070 0.354 0.116 1.087 
Isolation, HCFa 0.305 1.946 0.545 6.952 
Mupirocin >2 course 0.081 2.652 0.886 7.935 
Multisite MRSA colonisation 0.003 5.186 1.736 15.489 
a - Health care facility 
 
Table 3.2.9 Natural honey for nasal MRSA RCT LG analysis, model summary 
using Hosmer and Lemeshow test, on nasal MRSA decolonisation outcome 
Model Summary Hosmer and Lemeshow Test 
-2 Log 
likelihood 
Cox & Snell R 
Square 
Nagelkerke R 
Square Chi-square df p 
86.859 0.2 0.268 2.391 6 0.88 
 
Logistic regression analysis using four variables that potentially showed 
relevance indicates that non-nasal MRSA colonisation was significantly 
associated with persistent nasal MRSA colonisation, p=0.003. Altered skin 
integrity and the application of more than two courses of mupirocin 2% nasal 
ointment prior to RCT enrolment were also associated with persistent nasal 
carriage of MRSA. 
 
3.2.4 Summary 
• Univariate analysis confirms the homogenous allocation of study 
participants between the intervention and control groups on their 
baseline demographics, risk factors, microbiologic characteristics, as well 
as concomitant IPC practices. 
• Most study participants (94%) lived at home prior to the study enrolment. 
• The dependency of care were of the high and specialised care category 
for 27 (27%) of the participants. A high level of healthcare contact to 
increased the potential risk of transmission and colonisation with 
MDRO’s.  
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• One half of the participants had altered skin integrity, 47 (47%), of which 
27 (27%) had wounds/ stoma and 20 (20%) chronic ulcers.   
• Of the 100 participants who had invasive devices, PVC’s were most 
common, 40%. 
• Most of the patients who enrolled in the study were previously known to 
be MRSA colonised 93 (93%).   
• Previous decolonisation attempts were recorded for 87 (87%) of the 
study participants, both nasal as well as non-nasal decolonisation. 
• On study enrolment, 57 (57%) of the patients were isolated, either in a 
single room or cohort with CP. 
• A high prevalence of non-nasal MRSA colonisation was evident, 
cumulatively 72 (72%) among study participants, of which groin/perineum 
39% (30) was the most common colonised site.  
• On an ITT analysis, a negative nasal MRSA screen was identified among 
18 (36%) of the participants in the intervention group and 25 (50%) in the 
control group. However, using a PP approach, negative nasal screening 
was evident among 18 (43%) of the participants in the intervention group 
and 25 (57%) in the control group.  
• Logistic regression analysis confirms that non-nasal MRSA colonisation 
was significantly associated with failure of nasal MRSA decolonisation. 
• There was an association with failed nasal MRSA decolonisation and 
altered skin integrity; wounds/stoma/ulcer were identified by LG analysis. 
• On LG analysis, the application of more than two courses of mupricoin 
was associated with failure to eradicate nasal MRSA. 
• The RCT null hypothesis is not rejected based on the statistical test 
results. 
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3.3 Mupirocin susceptibility test results 
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3.3.1Introduction  
MRSA isolates can be classified according to mupirocin susceptibility. The aim 
of determining mupirocin susceptibility (MS) is to determine the susceptibility of 
isolates to mupirocin, which is used for nasal MRSA decolonisation. Two 
methods were employed to determine MS, namely the antibiotic disc diffusion 
test and the minimum inhibitory concentration (MIC) using the E test method. In 
our study the E test method was used. The MIC is defined as the lowest 
concentration inhibiting bacterial growth. 
In clinical practice, MS of MRSA isolates is usually determined on the first time 
MRSA is recovered from clinical or screening specimens of a patient. 
Determination of MS in previously known MRSA colonised / infected patient 
varies.  Comparison of MS from multiple isolates from the same patient over 
time facilitates determining when MR was acquired, and to estimate the 
prevalence of MR.  
Prior mupirocin exposure is identified as a potential risk factor for the acquisition 
of MR. The use of the MIC E test to characterise MRSA isolates is discussed in 
this chapter and test results are compared for each patient at sequential time 
points. 
 
3.3.1.1 Methods used to collect isolates 
MRSA isolates from the RCT participants were collected prospectively. Purity 
cultures were prepared from the chromogenic agar plates (MRSAid®; 
Basingstoke, U.K.), which is the current method employed in BH microbiology 
laboratory for MRSA identification. The isolates were frozen on beads and 
stored for future tests.  The susceptibility of the following clinical isolates were 
assessed; historic (first time identified in BH) where available, baseline on study 
enrolment and isolates from persistent colonisers at the end of the study.  Purity 
plates were prepared from specimens processed in BH, isolates sloped and 
archived. 
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3.3.1.2 Prognostic variable; prior mupirocin use 
A history of prior mupirocin exposure was enumerated from each participant at 
study enrolment. Mupirocin exposure is associated with potential acquisition of 
MR. In clinical practice mupirocin 2% nasal application is limited to two 
consecutive courses at a given time period. However, practice on the use of 
mupirocin 2% varies, from target to universal decolonisation such as in ICU 
patients in some countries. (56) 
 
3.3.2. Category of bacterial isolates investigated 
Historic, baseline and final isolates 
Of the 100 study participants, historic isolates were obtained from archived 
isolates for 66 cases. These isolates includes clinical as well as isolates derived 
from screening specimens. The source of collection of the 66 historic isolates 
are as follows; nose 34, and the remaining from wound/skin soft tissue, groin, 
sputum/bronchial lavage/respiratory , ulcer, urine and from blood. Baseline 
isolates (nasal) were available from all the 100 participants; 50 each from the 
investigative and control groups, and 43 isolates from persistent colonisers 
(nasal), on study completion. Of the 43 persistent colonisers, 24 isolates were 
from the investigative group and 19 from the control group. 
 
3.3.3 Results 
3.3.3.1 Comparison of mupirocin susceptibility  
The susceptibility of MRSA isolates to mupirocin was investigated using the 
phenotypic method i.e. MIC E test, test kits supplied by bioMerieux®, 
Basingstoke, UK. MS was determined according to MIC breakpoints with 
susceptible being ≤4 mg/L, LLMR 8–256 mg/L and HLMR ≥512 mg/L.  (142)  
The MS results for the historic, baseline and final isolates were categorised 
according to the respective MIC breakpoints and are tabulated in Table 3.3.1. 
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Table 3.3.1 NHNMRSA study mupirocin susceptibility of historic, baseline and 
final isolates 
MRSA  
isolates 
Susceptibility range - MIC 
≤4 mg/L % 8 - 256 mg/L % 
≥ 512 mg/L 
% 
Total No 
of isolates 
Historic 91 
 
3 
 
6 
 
66 
 
Baseline 88 
 
4 
 
8 
 
100 
 
Final 77 
 
2 
 
21 
 
43 
 
 
Of the 66 historic isolates, 65 (91%) were MS, two (3%) were LLMR and four 
(6%) HLMR. Of the 100 baseline isolates, 88 (88%) were MS, four (4%) LLMR 
and eight (8%) HLMR. Of the 86 participants who completed the study and 
where a final outcome was available, 43 (50%) participants had persistent nasal 
MRSA colonisation. Of the 43 persistent colonisers, 33 (77%) were MS, 23% 
MR; of which one (2%) was LLMR and nine (21%) HLMR.  
 
3.3.3.2 Prevalence of mupirocin resistance 
In the RCT, of the 100 patients enrolled 11 (11%) had no documented evidence 
of prior mupirocin use or could not confirm use of nasal mupirocin. Of the 
remaining 89 patients, 13 (13%) had one course, 41 (41%) two courses and 35 
(35%) had more than two courses of intra nasal mupirocin. 
At baseline, eight cases were HLMR but for none of these were MS results 
available on enrolment. Of these eight isolates with HLMR at baseline, MS was 
unchanged subsequently for six, one became susceptible and one participant 
discontinued from the study. Table 3.3.2 displays the MIC’s of the HLMR cases 
at baseline and on completion of study. 
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Table 3.3.2 NHNMRSA RCT, prevalence of high level mupirocin resistance at 
baseline and the corresponding MIC for final isolates  
Isolate no 
Susceptibility - MIC mg/L 
Baseline  
MIC 
Final isolate  
MIC 
xx36 >1024 >1024 
xx97 >1024 >1024 
xx79 >1024 0 
xx54 >1024 >1024 
xx57 >1024 0 
xx61 >1024 >1024 
xx62 >1024 >1024 
xx66 >1024 >1024 
 
A comparison of the MIC’s of the historic, baseline and final isolates of the 
patients who acquired MR was undertaken. Four patients acquired MR; three 
HLMR and one case of LLMR. Of the four acquired MR cases an historic isolate 
was available for three and a final isolate was available for all four. The 
acquisition of MR; LLMR and HLMR is displayed in Table 3.3.3.  
Table 3.3.3 NHNMRSA RCT, mupirocin resistance amongst historic, baseline 
and final isolates 
Isolate no 
Susceptibility range - MIC mg/L 
Historic Baseline Final 
xx22 NA 0.19 >1024 
xx84 0.38 32 >1024 
xx95 0.25 0.75 >1024 
xx08 0.38 0.5 32 
NA – Isolate not available 
 
3.3.3.3 Outcome of intervention of MR cases 
The final outcome i.e. nasal MRSA screening results of 86 participants are 
available. Among the participants who had MR identified on study enrolment, 
three patients cleared MR MRSA carriage. One participant each in the 
investigative and control groups with LLMR were decolonised, as well one with 
HLMR in the investigative group. The successful decolonisation outcome of the 
MR cases is provided in Table 3.3.4. 
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Table 3.3.4 NHNMRSA RCT, MICs amongst mupirocin resistant MRSA cases 
who were cleared of MRSA 
Isolate no 
Susceptibility range - MIC mg/L 
Historic Baseline Final 
xx28 16 32 0 
xx77 NA 16 0 
xx57 >1024 >1024 0 
NA – Isolate not available 
 
3.3.4 Discussion 
Mupirocin susceptibility of the isolates investigated 
A comparison of MS of isolates from the same patient at sequential time points 
enabled us to evaluate the MS of isolates and the probable time of MR 
acquisition. Most of the isolates were MS; 91% historic, 88% at baseline and 
77% at the end of the study. However, MR progressively increased from the 
point of first time identification, from 8% to 23% at the end of study.  
A comparison of MS at baseline and at the end of the study, between the 
Medihoney™ Derma Cream (investigative) and mupirocin 2% (control) groups 
demonstrates that, in the control group the rate of MR acquisition was 10% (4); 
HLMR 8% and LLMR 2%. MS was unchanged for all the persistent colonisers in 
the investigative group, i.e. for the baseline and final isolates. 
The incidence of MR acquired is similar to that reported elsewhere. The rate of 
HLMR was 6% following an intensive MRSA nasal eradication program. (34) In 
an RCT that compared different eradication regimens for MRSA decolonisation, 
the rate of MR was 5%. (175) Another study found that MR increased 
exponentially from 2.7% (1990) to 65% (1993) during a three year period where 
mupirocin was used extensively. (145)    
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Prevalence and acquisition of mupirocin resistance comparing historic, baseline 
and final isolates 
Overall the prevalence of MR progressively increased from the time initially 
identified to the end of the study, i.e. MR was 8% on first time identification, 
12% at study enrolment and 23% at the end of study. Of all the cases who 
newly acquired MR, 75% were HLMR. 
The prevalence of MR identified in the RCT is comparable with findings 
previously described. A national prevalence survey from France reported 2.2% 
MR (2013) (150), a surveillance study from Singapore, 11% MR (42), an RCT 
from Switzerland, 23% (1999) (24), a surgical ICU surveillance program from 
USA, 13.2% (2007) (176), a four year surveillance program from China, 6.6% 
(2010) (146), a 10 year surveillance program from Canada, 4% (2007) (39), and 
finally in an observational study from USA, 47.5% of isolates were reported as 
resistant (2003). (36) 
 
Decolonisation of MR MRSA cases 
Three cases of MR were decolonised; two cases had LLMR and one had HLMR 
at baseline. 
 
3.3.5 Summary  
• Of the historic, baseline and final isolates, MS was 91%, 88% and 77%, 
respectively. 
• Among historic MRSA clinical isolates, MR was 8%. 
• At baseline, the proportion of nasal isolates that were MR was 12%. 
• On completion of the study the proportion of nasal isolates that were MR 
was 23%. 
• New acquisition of MR amongst RCT participants was 10%. 
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3.4 Results of Laboratory investigations  
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3.4.1 Genotypic investigation of MRSA isolates 
 
3.4.1 Introduction 
Genotyping of bacterial isolates is undertaken to differentiate and characterise 
isolates and can reveal molecular similarities and differences between isolates 
that can support epidemiological studies. The genotypic characterisation of the 
clinical MRSA isolates was undertaken here to investigate stability of the MRSA 
genotypes before, during and after nasal decolonisation.  
 
3.4.1.1 Results spa typing 
Bacterial molecular genetic analysis  
Table 3.4.1 presents the genotypic characterisation of the MRSA isolates based 
on spa types. The ST of the isolates, where available, was inferred from the spa 
type. At baseline 100, and on study completion 43, nasal MRSA isolates were 
available from 100 study participants for spa typing.  
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Table 3.4.1 Natural honey for nasal MRSA study comparison of spa types at 
baseline and after attempted decolonisation from nasal MRSA isolates collected 
from 100 study entrants 
 
 
MRSA isolates 
spa type Baseline  Final  
t008 0 0 
t020 5 2 
t022# 4 0 
t032# 40 19 
t040 1 0 
t045$ 1 0 
t084 0 0 
t1214 0 0 
t127* 10 7 
t1370 1 0 
t1499 1 0 
t15373@ 1 1 
t15959~ 1 0 
t1612 3 3 
t190£ 1 0 
t223# 0 0 
t2436 2 1 
t379 1 0 
t4599# 9 1 
t515# 12 7 
t557# 0 0 
t578 1 0 
t6764 1 0 
t7636 1 1 
t8046 1 0 
t9570 1 0 
Failed spa test 1 0 
Unknown 1 1 
Total 100 43 
#ST22, *ST1, £ST8, $ST5, @ new spa type - a, ~ new spa type - b 
From the 143 MRSA isolates tested, 26 different spa types were identified. The 
common spa types were; t032, 59 (41%), t515, 19 (13%), t127, 17 (11.8%) and 
t4599, 10 (7%). A spa type could not be assigned for two isolates. Two new spa 
types were identified and spa type t15373 and t15959 were assigned by spa 
type curator, website (http://www.seqnet.org). 
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Based on the spa types, a ST could be inferred from 110 (77%) isolates. The 
common STs were ST22, 91 (63.6%) followed by ST1, 17 (11.8%), and one 
isolate each of the ST5 and ST8 types. 
Historic MRSA isolates  
Of the 100 study participants, historic isolates were available from 66 
participants and they were investigated for their spa type. Table 3.4.2 and 
Figure 3.4.1 present the spa types for the historic and baseline isolates from the 
66 participants. 
Table 3.4.2 Natural honey for nasal MRSA study spa types of the historic and 
baseline nasal MRSA isolates collected from 66 study participants 
 
 
MRSA isolates 
spa type Historic Baseline  
t008 1 0 
t020 2 5 
t022# 3 4 
t032# 33 40 
t040 0 1 
t045$ 0 1 
t084 1 0 
t1214 1 0 
t127* 6 10 
t1370 1 1 
t1499 0 1 
t15373@ 1 1 
t15959~ 0 1 
t1612 3 3 
t190£ 1 1 
t223# 1 0 
t2436 2 2 
t379 1 1 
t4599# 0 9 
t515# 6 12 
t557# 1 0 
t578 0 1 
t6764 0 1 
t7636 0 1 
t8046 1 1 
t9570 0 1 
Failed spa test 0 1 
Unknown 1 1 
Total 66 100 
#ST22, *ST1, £ST8, $ST5, @ -new spa type - a, ~ new spa type - b 
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Figure 3.4.1 Natural honey for nasal MRSA RCT spa types of the historic and 
baseline isolates from the 66 participants 
 
 
Of the 166 historic and baseline MRSA isolates, the common spa types were; 
t032, 73 (44%), t515, 18 (11%), and t127, 16 (10%). The most prevalent ST 
type was ST22 109 (66%), followed by ST1, 16 (10%).  
 
Comparison of historic, baseline and final isolates based on spa type 
Table 3.4.3 presents the comparison of the spa types from all of the study 
participants where available, at multiple time points; historic and baseline for 66 
participants, and baseline and on study completion for 43 persistently colonised 
participants.  
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Table 3.4.3 Natural honey for nasal MRSA study comparison of spa types of 66 
historic and baseline isolates and 43 baseline and final MRSA isolates 
 
spa type 
Historic and baseline isolates 
n=66 (%) 
Baseline and final isolates 
n=43 (%) 
Indistinguishable  45 (68) 39 (91) 
Distinguishable 21 (32) 4 (9) 
 
The spa types of the 100 study participants, historic, baseline and on study 
completion are listed in appendix - ⅩⅤ.  
 
Duration of MRSA carriage  
Table 3.4.4 outlines the duration of carriage for the 100 study participants since 
the first time they were confirmed as MRSA positive until RCT enrolment. 
Table 3.4.4 Natural honey for nasal MRSA RCT duration of MRSA colonisation 
in years prior to RCT enrolment 
Duration of MRSA 
colonisation No of cases 
0 <1 Yr  40 
1-2 Yr 17 
3-5 Yr 27 
6-10 Yr 10 
11-15 Yr 6 
 
Of the 100 study participants, 40% were colonised for less than one year, 44% 
between1-5 years and the remaining 16% between 6 and 15 years. 
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Duration of MRSA colonisation and comparison of spa types 
A comparison of the duration of MRSA colonisation of the 66 study participants, 
where the historic and baseline isolates, were available was done. Figure 3.4.3 
shows the duration of MRSA carriage since first identification of MRSA to RCT 
enrolment of the 45 participants where the spa type was indistinguishable. 
Figure 3.4.4 illustrates the duration of MRSA carriage of the 21 cases where the 
spa type was distinguishable. 
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Figure 3.4.3 Natural honey for nasal MRSA RCT duration of MRSA carriage of 
45 participants who had an indistinguishable spa type, both historic and at 
baseline 
 
 
Figure 3.4.4 NHNMRSA RCT duration of MRSA carriage of 21 participants 
where a distinguishable spa type was evident 
  
Of the 66 study participants where a historic and baseline isolate was available 
for spa type comparison, 45 (68%) had an indistinguishable spa type on first 
identification and on RCT enrolment. For 21 (32%) participants the spa type 
was distinguishable at two time points. Of the 21 cases where a distinguishable 
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spa type was evident, the duration of MRSA colonisation was less than one 
year for 14 (67%) cases, refer Figure 3.4.3. 
Table 3.4.5 presents the RCT outcome comparison of the 43 participants who 
had successful nasal MRSA decolonisation, intervention and control groups, 
and their baseline spa types. The percentage success is calculated based on 
the 43 (100%) patients who were decolonised, and compared between the 
intervention and control groups. 
Table 3.4.5 Natural honey for nasal MRSA RCT comparative analysis of the 
baseline spa types of the 43 participants who had successful nasal 
decolonisation 
 
Baseline MRSA 
isolates 
Successful 
decolonisation 
Intervention 
group 
Control  
group 
spa type n n % n % n % 
t008 0 0  0  0  
t020 5 1 20.0 0  1  
t022# 4 2 50.0 1 50.0 1 50.0 
t032# 40 19 48.0 7 37.0 12 63.0 
t040 1 1 100 1 100 0  
t045$ 1 0  0  0  
t084 0 0  0  0  
t1214 0 0  0  0  
t127* 10 3 30.0 2 67.0 1 33.0 
t1370 1 1 100 0  1 100 
t1499 1 1 100 0  1 100 
t15373@ 1 0  0  0  
t15959~ 1 1 100 1  0 100 
t1612 3 0  0  0  
t190£ 1 1 100 0  1 100 
t223# 0 0  0  0  
t2436 2 1 100 0  1 100 
t379 1 1 100 1 100 0  
t4599# 9 5 56.0 3 60.0 2 40.0 
t515# 12 3 25.0 2 67.0 1 33.0 
t557# 0 0  0  0  
t578 1 1 100 0  1 100 
t6764 1 1 100 0  1 100 
t7636 1 0  0  0  
t8046 1 0  0  0  
t9570 1 0  0  0  
Failed spa test 1 1 100 0  1 100 
Unknown 1 0  0  0  
Total 100 43  18  25  
#ST22, *ST1,£ST8, $ST5, @new spa type – a. ~new spa type - b 
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The spa type of the carriage isolates did not appear to influence the outcome of 
the nasal decolonisation. Persistent colonisation with the same spa type was 
evident even over relatively long time-spans.  However, replacement of the 
colonising spa type was also identified. In summary, no pattern according to the 
spa type/s was evident that influenced the nasal decolonisation outcome among 
the intervention and control groups. 
 
3.4.1.2 mupA PCR test results 
Table 3.4.6 presents the cumulative mupA PCR test results of the 100 baseline 
and 66 historic MRSA isolates investigated. 
Table 3.4.6 Natural honey for nasal MRSA RCT, mupA PCR test results of the 
100 baseline and 66 historic isolates.  
mupA 
           Historic isolates 
       n=66 (%) 
           Baseline isolates  
         n=100 (%) 
Positive 52 (79) 83 (83) 
Negative 14 (21) 17 (17) 
 
 
Figure 3.4.5 shows the percentage comparison of the of mupA PCR test results 
of the 166 historic and baseline MRSA isolates from 100 study participants. 
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Figure 3.4.5 Natural honey for nasal MRSA RCT mupA PCR test results of the 
66 historic and 100 baseline MRSA isolates 
 
 
Determining the presence of mupA gene using PCR is a standard method 
employed for ascertaining genotypic mupirocin resistance amongst S. aureus 
isolates. When amplifying a 310 bp fragment of the mupA gene by PCR 
followed by agarose gel electrophoresis and DNA band visualisation under UV 
light, 17 (17%) of baseline and 14 (21%) of historic MRSA isolates were mupA 
negative. This suggests that these MRSA isolates do not harbour the mupA 
genes that confer low (ileS-1) and high level mupirocin resistance (ileS-2). 
However, this does not exclude the potential for non-ileS-1 or ileS-2 genes that 
confer mupirocin resistance previously described by others. (49,46,50) 
 
3.1.4.3 Summary 
The genotypic investigation demonstrates extensive diversity of the MRSA 
isolates with 26 spa types. The findings are similar to the diversity of MRSA 
isolates reported by the others nationally in Ireland, according to spa type. (177-
178)  
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3.4.2 Results of the MIC and MBC determination of 30% Medical 
Grade Honey  
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3.4.2 Results of the MIC and MBC determination of 30% Medical Grade 
Honey  
 
3.4.2.1 Introduction 
In order to demonstrate the antibacterial property of the investigative product, 
the MIC and MBC of 30% MGH were performed. The results of the agar well 
diffusion assay for MIC, and MBC by broth culture and micro-dilution are 
presented. 
 
3.4.2.2 MIC by agar well diffusion assay  
In table 3.4.2.1 the agar well diffusion assay results are presented. The zone of 
inhibition measured in mm, which is attributed to the antibacterial activity of the 
test honey, is also displayed in figure 3.4.2.1.  
Table 3.4.2.1 Mean zones of inhibition* to determine antibacterial activity of test 
honey 
 
MRSA Test honey concentration 
Isolate No 30% 25% 20% 15% 12.5% 10% 5% 
mm mm mm mm mm mm mm 
ATCC43300 12 10 9 9 6 0 0 
1112 12 10 9 9 8 0 0 
1113 10 10 10 8 9 6 6 
1115 10 9 9 9 8 6 0 
1117 13 10 9 9 6 6 0 
1123 10 10 9 7 0 0 0 
1124 10 10 9 8 6 6 0 
1127 10 10 8 7 0 0 0 
1129 11 9 8 7 6 0 0 
*Including well diameter 5 mm 
A zone of inhibition was observed from 15% of the test honey against all eight 
clinical isolates and the reference MRSA isolate, demonstrating antibacterial 
activity, refer Table 3.4.2.1.  
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Figure 3.4.2.1 Mean zones of inhibition* to determine antibacterial activity of 
test honey 
 
A clear zone of bacterial inhibition was observed for test honey concentrations 
starting from 5% for the nine isolates investigated, as displayed in Table 3.4.2.1 
and Figure 3.4.2.1. 
 
3.4.2.3 MBC by broth micro-dilution method 
In Table 3.4.2.2 the results of MBC of test honey to clinical and reference 
MRSA isolates are presented.  
Table 3.4.2.2 MBC of test honey and determination of antibacterial activity 
 
Isolate number 
Test 
honey 1112 1113 1115 1117 1123 1124 1127 1129 43300 
5% TNTCa TNTC TNTC TNTC TNTC TNTC TNTC TNTC TNTC 
10% 1b 33 0 0 0 0 0 0 0 
12.50% 0 0 0 0 0 0 0 0 0 
15% 0 0 0 0 1 0 0 0 0 
20% 0 0 0 0 0 0 0 0 0 
25% 0 0 0 0 0 0 0 0 0 
30% 0 0 0 0 0 0 0 0 0 
Positive 
Control TNTC TNTC TNTC TNTC TNTC TNTC TNTC TNTC TNTC 
Negative 
Control NGc NG NG NG NG NG NG NG NG 
a - TNTC - Too numerous to count, b - colony forming units (cfu), c- NG - No growth 
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No bacterial growth was observed after 24 h from test honey of concentrations 
of 12.5% and higher for all the eight clinical and one reference MRSA isolates. 
The MBC values correlates with MIC values, therefore providing supporting 
evidence of bactericidal rather than bacteriastatic action of test honey. 
 
Comparison of MIC and MBC of test honey  
In Table 3.4.2.3 the observed MIC and MBC of test honey for the eight clinical 
and one reference MRSA isolates tested are compared. The bactericidal 
concentration was in concordance with the bacteristatic concentration for most 
isolates. 
Table 4.3.2.3 Comparison of MIC and MBC of test honey 
MRSA isolate 
No 
Test honey 
conc: 
MIC 
(mm) 
MBC* (honey 
conc:) 
Bacterial 
growth 
ATCC 43300 12.5% 6 12.5% NG
a
 
1112 12.5% 8 12.5% NG 
1113 12.5% 9 12.5% NG 
1115 12.5% 8 12.5% NG 
1117 12.5% 6 12.5% NG 
1123 15% 7 15% NG 
1124 12.5% 6 12.5% NG 
1127 15% 7 12.5% NG 
1129 12.5% 6 12.5% NG 
*The MBC of test honey to inhibit 100% of microbial growth in vitro, expressed in % v/v solution for clinical 
isolates (n = 8) and reference (n=1) , ATCC 43300 isolate. a -no growth 
 
3.4.2.4 Conclusion 
Antibacterial activity of test honey was demonstrated using the agar well 
diffusion assay and broth micro-dilution methods using clinical and reference 
MRSA isolates. The MIC using the agar well diffusion method, demonstrated 
antibacterial activity of test honey at 5% and higher concentrations. Using the 
broth micro-dilution method to differentiate bactericidal from bacteriostatic 
action, it was established that the MBC of the test honey was 12.5%. From a 
comparison of MIC and MBC values, it can therefore be deduced that the MIC 
and MBC of the test honey is in the range of 12.5% to 15% for the MRSA 
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isolates tested. Other investigators have reported MICs of 4% and higher to 
antibacterial honey. (70,179)  The bactericidal action of test honey observed is 
in concordance with findings reported by others. (110,117) 
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3.5 Questionnaire survey results 
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3.5.1 The Brief Illness Perception Questionnaire 
 
3.5.1.1 Introduction  
In the RCT, the participants beliefs and perceptions on MRSA colonisation 
(illness) was collated using the modified BIPQ; MRSAPQ. The MRSAPQ was 
administered to participants on completion of a course of mupirocin 2% or 
Medihoney™ Derma Cream nasal application. The response rate was 87.5% 
(n=35). The BIPQ questionnaire survey results are discussed. 
 
3.5.1.2 Results 
The Likert style rating questionnaire (MRSAPQ) used an ordered continuum of 
response categories, with a balanced number of positive and negative options, 
a neutral option and each category was labelled. This facilitated balanced 
response options as well as assigning an even number scale for analytical 
purposes. Each item of the modified BIPQ items assessed one dimension of 
illness perception. Eight dimensions and a causal item on causation of MRSA 
were gathered using the questionnaire. Individual scores relative to each item 
were distributed throughout a full scale range (0-10), 11 scales. The numeric 
values assigned to the response categories were consistently applied for all 
questionnaires received and analysed. The results of each of the dimensions 
are listed in the same order, and cumulatively displayed in Table 3.5.1. 
Consequence  
Of the 35 respondents, for 23 (66%) MRSA colonisation had little or no affect on 
their daily lives.  However, for nine (26%), MRSA colonisation had a moderate 
impact on their daily lives. For three (8.5%) participants, it did not have an 
impact at all. Therefore it can be construed that MRSA colonisation had limited 
or no impact for 26 (74%) participants. 
Timeline 
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A clear majority 29 (83%) of the participants believed that their MRSA 
colonisation would continue forever, three (8.5%) participants believed that it 
would continue for a short duration, while another three (8.5%) participants 
believed that it would be for a medium time period. 
Personal control 
Most participants 33 (94%) deemed that they did not have any control on their 
MRSA colonisation. The remaining two (6%) felt they had some control over it. 
Treatment control 
All the participants 35 (100%), were in agreement that decolonisation of MRSA 
will be extremely helpful. 
Identity 
Of the 35 participants, eight (23%) experienced moderate or major symptoms 
related to MRSA. However, the overwhelming number of participants 27 (77%) 
did not experience any symptoms they attributed to MRSA colonisation. 
Concern 
This item reflects a combination of emotional and cognitive representation of 
participants. Of the 35 participants, a significant proportion, 28 (80%), were 
concerned about their MRSA colonisation but for seven (20%), this was not a 
matter of concern.  
Coherence 
While 20 (57%), of participants stated that they had moderate to good 
understanding of MRSA, 15 (43%) stated that they had only minimal or limited 
information on MRSA. 
Emotional representation 
Of the 35 participants, 27 (77%), were emotionally detached from their 
colonisation status. However, for eight (23%), participants MRSA colonisation 
had an impact on their emotional wellbeing. 
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Casual item 
The participants attributed the following causes or factors as being responsible 
for their positive MRSA status; hospitalisation 16 (34%), surgery 10 (21%), poor 
hospital hygiene eight (17%), chronic illness six (13%), use of antibiotics five 
(11%) and contact with health care workers two (4%). 
 
Table 3.5.1 NHNMRSA RCT results of the eight BIPQ dimensions.  
BIPQ items Mean (Std Dev) Median (IQR) Mode 
Consequences 2.94 (3.5) 1 (0) 0 
Timeline 8.69 (2.32) 10 (8.5) 10 
Personal control 0.77 (2.37) 0 (0) 0 
Treatment control 9.69 (0.9) 10 (0) 10 
Identity 2.09 (3.05) 0 (0) 0 
Concern 6.83 (2.91) 7 (5) 7 
Coherence 4.77 (2.21) 5 (3) 5 
Emotional representation 2.74 (2.39) 2 (1) 0 
 
3.4.1.3 Discussion  
Descriptive statistics pertinent to the eight BIPQ items showed that, in general, 
the participants tended to view their MRSA carriage as a chronic condition 
(timeline mean score = 8.69), and perceived that if cleared with appropriate 
treatment (treatment control mean score = 9.09), it was significantly beneficial. 
However, participants were firmly convinced that they had limited or no control 
over MRSA colonisation (personal control mean score = 0.77). Most participants 
perceived that their MRSA colonisation did not have serious consequences or 
negative impact on their lives (consequences mean score = 2.94). However, 
participants were deeply concerned (concern mean score =6.83) due to their 
colonisation. Participants in general were emotionally detached (emotional 
response mean score = 2.74) from the condition. Most participants did not have 
MRSA-related symptoms (identity mean score =2.09), but participants 
understanding of MRSA was moderate to low (coherence mean score = 4.77). 
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Consistently low scores for consequences; 26% standard deviation (Sd) 2.94, 
identity; 23% (Sd 2.09) and emotional response; 23% (Sd 2.74) are associated 
with good psychological, social and physical functioning which implies good 
illness outcomes. (180) However, a high score for concern 71% (Sd 6.83) is 
associated with poor psychological functioning which contradicts the earlier 
assumption based on consequences, identity and emotional responses. Low 
personal control 6% (Sd 0.77) and very high treatment control 100% (Sd 9.69) 
are associated with suboptimal psycho-social and physical functioning which 
implies poor illness outcome.  A longer perceived time line 83% (Sd 8.69) with 
MRSA colonisation is associated with poor outcome and quality of life. Most of 
the study participants were chronic carriers of MRSA and the survey results 
should be interpreted in this context. 
 
3.4.1.4 Summary 
• Participants perceived that MRSA colonisation was a chronic condition 
and that it did not have serious consequences on their daily lives. 
• Participants were in general emotionally detached from the condition and 
few had MRSA related symptoms.  
• Most participants felt they had limited or no control over carriage, but 
decolonisation was considered beneficial, indicating the importance 
attached to treatment/control of MRSA. 
Understanding of the disease can lead to more favourable health behaviours 
and disease outcomes. A sub-optimal understanding of MRSA among 40% of 
patients necessitates measures to target improving knowledge about MRSA. 
This should enable patients to understand MRSA acquisition and transmission 
as well as adherence to treatment/decolonisation potentially leading to better 
outcome. 
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3.5.2. Product experience questionnaire  
Patients experience on the use of medical grade honey and mupirocin 
 
3.5.2.1 Introduction 
The NHNMRSA RCT employed a PEQ to collate patient’s experience on the 
use of the investigative and control products. The PEQ was developed by the 
researcher through an iterative process. A Likert scale type rating was used in 
the PEQ for four of five questions. The PEQ scaling of four of the Likert 
statements ranged from strongly agree, agree, neither agree or disagree, 
disagree and strongly disagree. The fifth item was to record the patients’ own 
preference where an option was offered to the patient; to choose between an 
antibiotic and a natural product, to eradicate MRSA from the nose. This fifth 
statement therefore had a scale with two options, i.e. to record the product 
choice. Patients in the investigative group were provided with the PEQ labelled 
‘Experience with Medihoney™ Derma Cream’ and the control group with the 
PEQ labelled ‘Experience with mupirocin nasal ointment’. The PEQ was 
administered to study participants on completion of a course of Medihoney™ 
Derma Cream (investigative) or mupirocin 2% (control) nasal application. The 
cumulative response rate was 87.5%, details are now considered.  
 
3.5.2.2 Results 
Analysis of the Likert style PEQ was done assigning numeric values to each of 
the five point scale. Numeric values were assigned as follows; strongly agree 
=1, agree =2, neither agrees or disagree =3, disagree =4 and strongly disagree 
=5. The fifth item; a choice of an antibiotic or natural product was analysed as 
recorded by respondents. The results of each of the items are listed in the same 
order. For the investigative group, the cumulative results are displayed in Table 
3.5.2, followed by the statistical analysis in Table 3.5.3. For the control group 
the results are displayed in Table 3.5.4, followed by statistical analysis for the 
same group in Table 3.5.5. 
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Of the 35 respondents, 20 PEQ’s were returned from the investigative group 
and 15 from the control group. 
Medihoney™ Derma Cream 
Of the 20 respondents who had Medihoney™ Derma Cream nasal application, 
19 (95%) agreed that it was easy to apply to their nasal passages, and one 
(5%) neither agreed nor disagreed. Most, 18 (90%) agreed that Derma Cream 
was not sticky to the nasal passages but one (5%) found it was sticky, and the 
remaining one respondent neither agreed nor disagreed to this statement. 
Likewise 17 (85%) respondents did not experience a runny nose after Derma 
Cream application, one (5%) did experience runny nose and two (10%) neither 
agreed nor disagreed to the statement. Almost all, 19 (95%) did not experience 
any unpleasant sensation but one (5%) patient did state that they experienced 
an unpleasant sensation following Medihoney™ Derma Cream nasal 
application. 
If a choice was available for patients, most of the respondents 17 (85%) in the 
investigative group preferred a natural product an antibiotic in one (5%) and two 
(10%) had no preference. One of the respondent stated that the aroma of 
Medihoney™ Derma Cream was similar to that of ‘Heather’ - a plant that grows 
in acid soil and abundant in mountains of Ireland. 
 
Table 3.5.2 NHNMRSA RCT patient’s experience on the use of Medihoney™ 
Derma Cream 
Abbreviated Statement Agree / strongly 
agree n (%) 
Neither agrees / 
disagree n (%) 
Disagree / strongly 
disagree n (%) 
Ease of application 19 (95) 1 (5) 0 
Sticky on nose 1 (5) 1 (5) 18 (90) 
Runny nose on 
application 
1 (5) 2 (10) 17 (85) 
Unpleasant nasal 
sensation 
1 (5) 0 19 (95) 
 
 Antibiotic No preference Natural product 
Patients preferred option 
if a choice was available 
1 (5) 2 (10) 17 (85) 
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Table 3.5.3 NHNMRSA RCT c results of statistical analysis of the PEQ, 
Medihoney™ Derma Cream  
PEQ items Mean (Std Dev) Median (IQR) Mode 
Ease of application 1.5 (0.6) 1 (1) 1 
Nasal stickiness 4 (0.6) 4 (4) 4 
Runny nose 3.9 (0.5) 4 (4) 4 
Unpleasant nasal 
sensation 4 (0.7) 4 (4) 4 
Note: Numeric values: 1= strongly agree, 2= agree, 3= not agree or disagree, 4= disagree, 5 = 
strongly disagree. 
 
Mupirocin 2% (Bactroban® 2%) group 
Of the 15 respondents who had mupirocin 2% nasal application, 13 (87%) 
agreed that it was easy to apply the ointment to their nasal passages, two 
(13%) neither agreed nor disagreed. In response to the statement on nasal 
stickiness, 10 (67%) responded that mupirocin was not sticky but three (20%) 
found it was sticky, and the remaining two respondents neither agreed nor 
disagreed. Many patients, five (33%) experienced a runny nose after mupirocin 
2% application but nine (60%) did not experience this, and the rest one (7%) 
neither agreed nor disagreed. Almost all, 14 (93%) respondents did not 
experience any unpleasant sensation following mupirocin 2% application but 
one (7%) patient did state that they experienced an unpleasant sensation 
following the nasal application. 
If a choice was available for patients, the antibiotic option was preferred by four 
(27%), a natural product by eight (67%) and three (20%) had no preference. 
Table 3.5.4 NHNMRSA RCT patient experience on the use of mupirocin 2% 
nasal ointment  
Abbreviated Statement Agree / strongly 
agree, n (%) 
Neither agrees / 
disagree, n (%) 
Disagree / strongly 
disagree, n (%) 
Ease of application 13 (87) 2 (13) 0 
Sticky on nose 3 (20) 2 (13) 10 (67) 
Runny nose on 
application 
5 (33) 1 (7) 9 (60) 
Unpleasant nasal 
sensation  
1 (7) 0 14 (93) 
 
 Antibiotic No preference Natural product 
Patients preferred option 
if a choice was available 
4 (27) 3 (20) 8 (53) 
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Table 3.5.5 NHNMRSA RCT results of statistical analysis of the PEQ, mupirocin 
2%  
PEQ items Mean n, (Std Dev) Median n. (IQR) Mode, n 
Ease of application 1.6 (0.7) 1 (1) 1 
Nasal stickiness 3.6 (0.9) 4 (3) 4 
Runny nose 3.3 (1) 4 (2) 4 
Unpleasant nasal 
sensation 4 (0.9) 4 (4) 4 
Note: Numeric values assigned: 1= strongly agree, 2= agree, 3= not agree or disagree, 4= 
disagree, 5 = strongly disagree 
 
3.5.2.3 Discussion  
 PEQ Medihoney™ Derma Cream 
Most patients (95%) concurred that Medihoney™ Derma Cream was easy to 
apply, not sticky (90%), did not lead to a runny nose (85%) and they did not 
experience an unpleasant sensation (95%). Based on the survey results it can 
therefore be inferred that Medihoney™ Derma Cream is safe to apply to the 
nasal passages, with minimal undesirable effects. Medihoney™ Derma Cream 
is a CE marked medical device, and the manufactures claim is a sophisticated 
emollient for skin application. Considering the user experience and observations 
from the RCT, Medihoney™ Derma Cream may be used judiciously for nasal 
application. 
 
 PEQ mupirocin2% (Bactroban®2%) 
Although mupirocin 2% nasal ointment has been used for nasal MRSA 
decolonisation for over four decades, there is limited information on patients’ 
experience of its use. In our study, most respondents (87%) concurred that 
mupirocin 2% nasal ointment was easy to apply, but it was sticky (20%), and a 
runny nose was experienced by 33% of respondents. Almost all (95%) 
respondents agreed that they did not experience any unpleasant sensation 
following its application. 
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3.5.2.4 Summary 
• Medihoney™ Derma Cream may be applied to the human nasal 
passages with minimal undesirable effects. 
• The application of Medihoney™ Derma Cream and mupirocin 2% nasal 
ointment by participants to their nasal passages was easy. 
• A runny nose may be experienced by some patients following mupirocin 
2% nasal application. 
Patients’ preferred choice is a natural alternative to an antibiotic, if that 
was available for MRSA decolonisation.  
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Chapter Ⅳ Discussion, conclusions, reflections 
and future research  
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Discussion, conclusions, reflections and future research  
 
In the final chapter the researcher aims to bring the essence of the study to a 
meaningful conclusion. The discussions in this chapter are condensed under 
the themes which follow the introduction; study rationale, results, how it 
correlates, as well as contrasts, with the findings of others. The crucial 
discussion revolves around the clinical and economic implications which will 
also consider the advantages and limitations of the study, and concludes with 
recommendations for future work.  
 
4.1 Introduction 
Why did I take this path? To conduct a clinical trial with no previous hands on 
experience is a demanding and challenging project? Having reflected on this 
point in depth the following quote strikes me as appropriate ‘It is not so 
important what you do, but, be the best in what you do’. I believe that this neatly 
summarises why I chose this path and what contribution it has made. 
Now let me tell my story. I remember a patient who I looked after during my 
nursing training, which was an experience which deeply affected me, and 
instilled in me the importance of preventing infection. A moment of weakness 
left a young woman with more than 70% burns. Twenty five years ago in a 
resource constrained health system, there was little hope that she would 
survive. Then I saw in her eyes a plea to live. Was it possible, we could have 
done something better? A unique bond developed between the trainee nurse 
and the patient, until she succumbed to infection and was freed from all her 
pains. This had a profound impact on me and my future professional career. 
There were many other incidents which I recall, about preventable infection that 
left a mark on me.  
 
Why did I do this RCT? Reflecting on a little over two decades of my 
professional IPC career, what I value is the basics, which if we can get right, we 
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can prevent many infections and save lives. I lived through many phases of 
MRSA prevention and control. From the 1980s when MRSA was not so 
common to the 2000s when it became endemic, and in epidemic proportions in 
some health systems. I recall the change from search and destroy, to horizontal 
prevention, and the dramatic fall in MRSA BSI when basic IPC practices were 
aggressively implemented.  
However, our approach to patient decolonisation of MRSA using antibiotics and 
antiseptics remains a battle. When pathogens are adapting for survival we need 
to think outside the box and to look to mother nature. Is there an answer in 
nature? Perhaps there is, however, we need to search with an open eye and a 
curious mind. Scientifically it has been proven that bacteria survive and multiply 
where there is water. How then, does honey, derived from bees, stay stale-free 
for 1000s of years? Over the centuries many traditional health systems used 
honey for many ailments, and as late as 2015, modern medicine has 
scientifically proven that honey treated burns and infected wounds heal quicker 
than with antiseptic and antibiotic based treatment.  
Can honey eradicate MRSA? Before we can come to a conclusion, one must 
enquire with an inquisitive mind. One may find an answer, and disprove or 
generate more questions during the journey. That is what I have done and 
largely answers why I embarked on this research. 
 
4.2 Study findings 
Literature review 
Undertaking the review of the literature on MR and alternatives for the 
eradication of MRSA was a unique learning experience. The review findings 
confirmed the necessity for alternative MRSA decolonisation options other than 
the conventional antibiotic route, thereby affirming the principle and the basis for 
the NHNMRSA RCT. The review presented a composite picture on MR and 
CHZ resistance, such as a strong association between previous mupirocin 
exposure and both low-level and HLMR as high as 81%. (174) Widespread 
acquisition among CoNS of MR, especially HLMR from surveys in Europe, 
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following nasal decolonisation with mupirocin, have been as high as 97% 
(588/607), which is alarming. (181,151) Along with MR and CHZ resistance, 
HLMR (mupA carriage) is also linked to MDR, which signifies the extent of the 
antimicrobial resistance challenge faced by modern health systems. The review 
also showed that among MRSA isolates, the presence of the qacA and/or qacB 
genes encoding resistance to chlorhexidine, ranges from 65% to 91%, which 
along with MR is associated with failed decolonisation. Therefore, for safe 
clinical practice the optimal use of mupirocin and CHZ for MRSA decolonisation 
must be deduced from up to-date scientific evidence. This point will be further 
elaborated in the discussion of the RCT results.  
 
Randomised Clinical Trial 
Considering the body of work involved in obtaining regulatory and ethical 
approval for the conduct of the RCT, competing for research funding was 
probably the less challenging part in the entire project. The study opened many 
avenues of learning, which the researcher, prior to commencement of the study 
was not so knowledgeable about. Laboratory based learning such as bacterial 
molecular investigation methods, MIC and MBC assays were complemented 
with scientific communication techniques, scientific leadership skills, research 
methods and statistical analysis, with the overall management of the project as 
the lead investigator and administrator.  
The regulatory requirements necessitated the researcher to select a product 
that met the criteria for use in humans for medicinal purposes. The researcher 
investigated any licensed off-the-shelf honey based product/s if that was 
available that was antibacterial, considering the challenges in locally formulating 
a MGH product. The enquiry ultimately narrowed to Medihoney™ Derma 
Cream, a medical device, for which the manufacturers claim antibacterial 
activity with 30% MGH. The RCT results substantiate the potential for MGH as 
a viable alternative for MRSA decolonisation. However, studies must be done 
using higher concentrations of MGH. In clinical practice, honey based dressings 
at concentrations of 50% and higher are used for the management of infected 
wounds and ulcers. The dilution effects of a cream or ointment when applied 
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topically such as in moist nasal passages, could potentially be overcome by the 
application of higher concentrations of MGH. The MIC and MBC investigations 
demonstrated antibacterial properties of the MGH product at 5% and higher, i.e. 
MIC, and MBC at 12.5% and higher, after 24 h at 370 C. In theory, higher 
concentrations of MGH should demonstrate higher antibacterial properties. 
Investigators have reported that the antibiotic mupirocin demonstrated a slow 
bactericidal action in time-kill tests, resulting in 90 to 99% killing after 24 h at 
370 C when tests of bactericidal activity were performed. (173) In another study 
that investigated the concentration of mupirocin, sterile cultures were obtained 
when S. aureus strains were exposed to 1.0 mg/l or more of mupirocin for 120 
h. The investigators concluded that mupirocin has slow bactericidal activity 
against S. aureus and that 2% mupirocin may well be effective for topical 
treatment of skin infections. (182)  Similarly, dose concentration investigations 
of MGH must be performed to determine the optimal bactericidal concentration 
for safe clinical use. 
I concluded that at best 30% of the eligible participants could be enrolled in the 
RCT, whereas in actuality 28% of the eligible patients consented for the study. 
A 10% drop out rate was predicted for various reasons, and on study 
completion, a final outcome was not available for 14% of patients due to loss of 
follow up, protocol violation and attrition from the study. I followed up patients 
up in their residential home or other HCF, which was easier for some patients 
as they said ‘it was less demanding’. Moreover, the IPC expertise of the 
research team and the academic nature of the study encouraged patients and 
families to take part. Overall, the strategies employed by the researcher 
benefitted in optimal patient recruitment. Researchers may consider the 
successful strategies the NHNMRSA team employed while planning further 
similar studies. 
Sub-optimal patient compliance with medications has been previously reported. 
Although Medihoney™ Derma Cream and mupirocin 2% (Bactroban® 2%) was 
prescribed in the Drug Kardex, in some instances I saw poor medication 
compliance on the administration of prescribed medication. Various strategies 
were employed to ascertain patient medication administration. A simple count of 
the remaining cotton buds in the pack, direct patient interaction enquiring about 
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smell or patient discomfort, prompted me to investigate this vital aspect further. 
A note of self-administration in the Drug Kardex was another challenge to 
address. For inpatients during their study period, the researcher visited them at 
least once a day to administer the prescribed product. This opportunity was also 
used to interact with the staff nurse assigned and or nurse manager, and to 
reiterate administration of the intervention product as prescribed. Patients at 
home or in another HCF were followed up by telephone and supported on 
optimal administration. Clear directions on the application and recording of 
Medihoney™ Derma Cream or mupirocin 2% (Bactroban® 2%) were provided 
to participants. Patients were requested to mark a tick ✓after each dose in the 
appropriate box in the sheet provided, which to some extent benefitted in 
enhancing compliance. 
Many patients who required minimal assistance for self care and who were 
assessed as competent for self administration of medications, in practice 
experienced nasal application as challenging. The demand on nursing staff to 
prioritise available time for dependent patients may also have influenced their 
decision to direct patients to self administer and record accordingly in the drug 
Kardex. Both these were also probable factors that influenced medication 
compliance. In future, consideration must be given to the form of medication 
such as a nasal ointment/cream, which might be preferred. While compliance 
on injectable and oral medications may be addressed by the HCW and patient 
education, for local application of medications, user versatility is an important 
factor that may potentially influence its administration. The MRSAPQ results 
confirm patients’ perception of MRSA as a chronic condition and that treatment 
control is optimal. Therefore before enrolling any patient for a decolonisation 
program, there must be active engagement with the patient and family to 
augment compliance with the protocol. During the decolonisation course, good 
hygiene practices are paramount especially daily washing and showering along 
with the use of clean personal clothing for its success. All these measures must 
be communicated and patients should be assessed on their ability to actively 
engage with the protocol. If not, we may inadvertently contribute to 
decolonisation failure as well as anti-microbial resistance.  
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Patients with non-nasal MRSA colonisation should be carefully evaluated before 
enrolling in a decolonisation program. As evident from the statistical analysis, 
non-nasal MRSA colonisation was significantly associated with failed nasal 
MRSA decolonisation. Therefore where appropriate, non-nasal MRSA 
decolonisation such as wounds and ulcers should be addressed first, followed 
by nasal decolonisation. However, if suppression therapy is planned such as in 
the case of ITU patients or before high risk surgery, consideration should be 
given on the potential merit of this strategy before a decision to repeat courses 
of nasal mupirocin is made. 
Other formulations such as single use pre-soaked sponge/swabs or aerosols 
are another option for ease of medication administration. In recent years certain 
anti-tuberculosis medications are used in the aerosolised form which provides 
optimal target drug delivery as well as limited adverse effects. (184) The 
potential for an aerosolised preparation of both MGH and mupirocin is worth 
investigating for decolonisation of the respiratory passages including nasal 
MRSA decolonisation. In the case of patients with COPD and other pulmonary 
conditions, respiratory MRSA colonisation is difficult to eradicate, therefore an 
aerosol may offer the potential for pulmonary and nasal decolonisation. In such 
patients attempting nasal MRSA decolonisation alone is not sufficient as re-
colonisation from the patients’ airways is inevitable.  
 
Mupirocin susceptibility  
I collected MRSA isolates at sequential time points where possible, i.e. historic, 
baseline on recruitment and from persistent nasal MRSA carriers, at the end of 
the study. The baseline and final isolates were collected prospectively and 
historic isolates from archived isolates, where available. A comparative analysis 
of mupirocin susceptibility at multiple time points provided a robust picture of 
MR among the clinical isolates, historic as well as new acquisition. This 
approach enabled me to make meaningful conclusions on the risks of the 
administration of multiple courses of mupirocin.  
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The comparative analysis of MS between the clinical isolates from the same 
patient at sequential time points facilitated the evaluation of the probable time of 
acquisition of MR. While most of the isolates were MS; 92% historic, 88% at 
baseline and 77% at the end of the study, MR progressively increased from the 
point of first time identification, from 8% to 23% at the end of the study. The 
incidence and the acquisition of MR is comparable to that reported by others, 
such as HLMR of 6% following an intensive MRSA nasal eradication program 
and 5% in an RCT that compared different eradication regimens for MRSA 
decolonisation. (34,175) The increasing incidence of MR, 23%, when multiple 
courses of mupirocin were administered identified in this study, that compares 
with the surveillance findings reported by others, for example in Canada where 
an exponential increase in MR from 2.7% to 65% (1990-1993) was recorded 
during a three year period where mupirocin was used extensively. (145) In 
Taiwan (149), a case control study also confirmed that previous mupirocin 
exposure was an independent predictor for LLMR and HLMR. (41) The 
mounting evidence underlines the necessity for stewardship measures to 
conserve this valuable antibiotic option for nasal MRSA decolonisation, to 
prevent infection, and in clinical situations such as prosthetic device implants for 
optimal patient benefit.     
 
Phenotypic and genotypic analysis of the isolates 
Initially I acquired competence in performing these laboratory tests, which in 
itself was exciting. The complexities involved in the identification and 
classification of the isolates along with the presence of resistance genes helped 
me to better understand the clinical aspects of IPC in MRSA control.  
All of the 209 clinical isolates collected in the RCT were investigated. A spa type 
was assigned for 205 isolates. In total, 26 spa types and an unknown type were 
identified. The predominant spa-types were t032, t515, t127 and t4559. Two 
new spa types which had a unique DNA-sequence, not previously reported, 
were identified; t15373 and t15959 were assigned to these two spa types by the 
SeqNet curator. The predominant ST was ST22 (65%), followed by ST1 (11%). 
Of the 66 patients where a historic and recruitment isolate were available, 45 
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(68%) had an indistinguishable spa type on both occasions.  Among persistent 
MRSA carriers (n=46/100), 42 patients had an indistinguishable spa type on 
recruitment and at the end of study. In decreasing order, hospitalisation, 
surgery, poor hospital hygiene, chronic illness, antibiotic use and contact with 
health care workers, are amongst the factors probably causing MRSA 
acquisition.  
The comparative genotypic analysis demonstrated the diversity of MRSA 
colonising strains, thereby emphasising the necessity of surveillance and 
molecular analysis to identify new and resistant strains. Among persistent 
carriers where MRSA decolonisation is indicated such as during ITU admission 
and before high risk surgery, molecular and genetic analysis of the isolates 
directs the optimal decolonisation choice as well as treatment if necessitated  
Identification of an indistinguishable spa type among two thirds of persistent 
MRSA carriers supports the widely held view that most persistent carriers are 
colonised with the same strain, rather than with new strains. This informs the 
interpretation of molecular and genotypic analysis of isolates from at risk 
patients when there is a considerable time lapse from when the patient was 
confirmed MRSA positive. 
  
Patient MRSA perception questionnaire 
A dearth of pre-existing IPQs necessitated the development of an instrument 
from pre-existing IPQs. This led to the modification of the BIPQ, an instrument 
that is tested for its content and logical validity, to the MRSAPQ, which was 
used to record patients’ perceptions on their MRSA carriage.  
The literature review on IPQs provided a new learning experience as well as 
insights into the psychological domain that impacts illness perception and 
patient outcome. This experience enabled me to acknowledge that an 
understanding of the disease can lead to more favourable health behaviours 
and disease outcomes. The analysis of the completed MRSAPQ shows that the 
study participants perceived MRSA colonisation a chronic condition and that it 
did not have serious consequences on their daily lives. In addition, participants 
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were in general emotionally detached from the condition and few had MRSA 
related symptoms. Interestingly, most participants felt they had limited or no 
control over carriage, but decolonisation was considered beneficial, indicating 
the importance attached to treatment/control of MRSA. 
Most of the study participants, 93%, were previously known to be colonised with 
MRSA, and had experienced previous decolonisation attempts, some with 
success and subsequent re-colonisation, and others were not decolonised at 
all. The results must be considered in the context that most participants were 
known MRSA carriers, which would have influenced the participants’ responses. 
A sub-optimal understanding of MRSA among nearly one half of the patients 
necessitates measures to improve knowledge about MRSA among patients and 
the public. Such measures should engage patients and their care givers so that 
patients attain a robust understanding of MRSA, acquisition and transmission, 
as well as the necessity for adherence to treatment/decolonisation, potentially 
leading to better patient outcomes. 
 
Product experience questionnaire 
A Likert style response PEQ, developed through an iterative process, was used 
to record patient perception on nasal application of Medihoney™ Derma Cream, 
and mupirocin 2% (Bactroban® 2%).  
The results of the PEQ showed that patients perceived the nasal application of 
the MGH as pleasant, 19 (95%), not sticky on their nasal passages 18 (90%) 
and 17 (85%) did not have a runny nose. Concurrently, the control group, 13 
(87%), were of the opinion that mupirocin 2% was easy to apply. However, 5 
(33%) experienced a runny nose sensation after its application. This compares 
with unpleasant user experience of 39% previously reported, subsequent to 
nasal mupirocin use. (183)  
In the intervention group, if a choice were available for patients, most of the 
respondents 17 (85%) preferred a natural product to an antibiotic. In the control 
group, if a choice was available, the antibiotic option was preferred only by 4 
(27%), and a natural product was the preferred option for 8 (67%). Patients’ 
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perception on the use of a non-antibiotic alternative in both the groups provides 
further ammunition to look for alternative treatment options.  
 
4.3 Strengths and limitations of the study 
Strengths 
There are some strengths which facilitated the successful conduct of the 
NHNMRSA study. Firstly, the investigator’s familiarity with the study setting as 
an IPC practitioner, and the investigating team’s working relationship with 
clinicians as well as other stakeholders, provided a buy-in which contributed 
enormously to the success of the study. Investigator rapport with the IPC team, 
nurse managers and frontline staff facilitated optimal patient recruitment. 
Patients were recruited from a heterogenous population in a real world clinical 
setting. Scientifically sound randomisation and patient allocation principles were 
applied and patients were followed up as planned. The RCT results were 
reported in conformity to the consolidated standards for reporting of clinical 
trials (CONSORT) statement. 
The findings substantiate previous findings supporting the antibacterial 
properties of honey and its potential for clinical use. For the first time in a RCT, 
honey was investigated for nasal MRSA eradication with a large sample size, 
well designed and meeting Cochrane and CONSORT reporting criteria in 
addition to independent statistical analysis.  
 
Limitations  
Clinical setting – tertiary acute/referral 
Patients were recruited from a tertiary care hospital which is also a national 
referral centre. The wide geographic origin of patients in the study population 
limited recruitment to those the investigator could follow up for home/care 
centre visit. Therefore, many patients were excluded from recruitment, 
especially in the renal and neuroscience specialities.  
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Sample size 
The number of study participants recruited was less than what was anticipated 
before study commencement. A sample size of 88 patients in each group was 
planned, but 50 in each group were enrolled within the time and resources that 
were available for the study. The less than planned sample size enrolled 
impacted on the statistical significance of the findings. 
Single centre, time and resources 
The study was limited to a single centre due to time and resources issues. In 
future, larger studies involving multiple centres should be conducted to confirm 
the results in order to recommend or dissuade the use of MGH as a valid choice 
for nasal MRSA decolonisation.  
Concealment of products 
One of the limitations of the study specifically is that the NHNMRSA was an 
open label study. After remote allocation the patient and the researcher were 
aware of the product allocated and the group the patient was assigned to. 
Therefore performance bias may have occurred. However, within the 
constraints of the study, allocation concealment and avoidance of detection 
bias, were the best that could be achieved in the RCT. 
Generalisability of the RCT results 
Limited options for decolonisation of MRSA necessitate the investigation of 
potential alternatives that demonstrate clinical benefit. The bactericidal action of 
the investigative product, i.e. 30% MGH, was established in vivo. The outcome 
of in vitro nasal MRSA decolonisation among a heterogenous population 
showed no statistical difference between the investigation and control groups. 
However, this may be due to the sample size, which was less than anticipated. 
Therefore, the results lack statistical power, even though the clinical outcomes 
do not show wide variation. 
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4.4 Clinical implications 
The limited alternate options for nasal MRSA decolonisation place mupirocin at 
the cornerstone for most eradication programs to date, despite MR as well as 
suboptimal rates of successful decolonisation. Decolonisation approaches vary 
from search and destroy to universal decolonisation, as well as the 
management of individual clinical cases. The extent of MR in the wider context 
of antimicrobial stewardship has been well explored and presented in this 
thesis. The researcher will now consider the long-term impact of MR on three 
areas of mupirocin use: clinical cases, screen and treat and universal 
decolonisation, to estimate the relative transmissibility of MR and MSSA strains, 
and MRSA control policies. 
A simulation model that evaluated the total prevalence of MR in colonised and 
infected MRSA patients in two London hospitals found that after 5 years of 
simulation MR was 9.1%, with the screen and treat mupirocin policy but this 
increased to 21.3% (95% CI  20.9%–21.7%) with universal mupirocin use. The 
modelling provides evidence derived from a real clinical setting of a fitness cost 
associated with MR in MRSA strains. Even under conservative estimates of 
relative transmissibility, the investigators predict long-term increases in the 
prevalence of MR where universal decolonisation policies apply. (185) What 
does this therefore mean? Should we limit MRSA prevention to screen and treat 
only? If so, what about persistent MRSA carriers. I will now consider these two 
scenarios and how the RCT results may provide direction in translating the 
evidence into practice. 
MRSA screening strategies in many health systems now focus on targeted 
rather than universal screening of patients, such as in at risk patients, for 
example ITU admissions as well as before high risk surgery. Where MRSA 
decolonisation is ultimately unsuccessful, suppression therapy may be of short 
term benefit, if the patient becomes initially MRSA negative as it reduces the 
microbial load and thus potentially reduces the risk of infection. Is it safe to 
administer multiple courses of mupirocin? Stewardship as well as evidence of 
increasing MR does not support this approach. However molecular diagnosis 
and genotypic data on AMR resistance genes and or gene expression may help 
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direct therapeutic decisions. In certain patients, additional decolonisation 
courses or suppression therapy may be beneficial if bacterial susceptibilities are 
known, especially among persistent MRSA carriers. Increasing AMR and the 
prevalence of MDRO particularly in the high risk patient population, 
necessitates clinicians to target and therefore limit antibiotic use, i.e. conserve 
the antibiotic armoury to treat infections that are susceptible to that antibiotic. If 
a non-antibiotic choice is available it is a win-win situation for patients and 
society as the needs of the patient are met and antibiotics are preserved for 
society’s use. The BIPQ results confirm user preference for non-antibiotic 
options, if that is clinically beneficial. However additional work is required before 
MGH can be safely recommended for MRSA decolonisation, which is further 
explored in the recommendations that follow.  
 
4.5 Economic implications 
The fitness cost model explored in the clinical implications section (Sec 4.4) 
neatly summarises the long-term impact of MR where universal decolonisation 
policies are applied. (185)  
In Ireland (2012) the overall hospital acquired infection (HAI) prevalence was 
5.2% (95% CI 4.7-5.6), highest in tertiary hospitals 7.5%, and in the host 
hospital it was 10.9%. Of the microorganisms that were implicated in HAI, S. 
aureus was the second most frequent pathogen detected (n=46; 15%), of which 
37% were MRSA. (186) In Ireland in 2012, the average length of stay (LOS) for 
a hospital inpatient was 5.7 days, compared with an estimated LOS of 22 days 
when the HAI was contracted. The Health Service Executive (HSE) published 
figures for the cost of a day of stay in a public hospital (2010) as €899/day. An 
additional 16 days of inpatient stay translates to an extra €14,384.00. This does 
not include all other costs, such as productivity loss, as well as the pain and 
distress caused to the patient and family. 
An independent review on AMR commissioned by the UK (2014), supported by 
the Wellcome Trust, commissioned RAND Europe (a not for profit research 
institute whose mission is to help improve policy and decision making through 
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research and analysis) to examine the likely global cost of AMR by the year 
2050, if the AMR problem is not tackled. (187) Using a theoretical model called 
'a dynamic general equilibrium model' the research team explored different 
global scenarios for AMR from now until 2050, to see what effect they would 
produce on the global economy. Five AMR organisms were considered in the 
model namely; MRSA, resistant Escherichia coli, Klebsiella pneumoniae, multi 
drug resistant-tuberculosis and human immuno-deficiency virus (HIV), from 
published data. The team considered the effects that AMR has on the economy 
through disruption of the supply of labour, by estimating the impact that an 
increase in resistance would have on the labour force through two mechanisms: 
increased morbidity that reduce the size of the working age population, and 
increased mortality that temporarily reduces the size of the workforce, and in 
severe cases to permanent reductions in labour productivity. 
Failing to tackle AMR will mean that by 2050 the world population will be 
between 11 million to 444 million lower than it would otherwise be in the 
absence of AMR. The reduction in population and the morbidity impact would 
also reduce the level of world gross domestic product (GDP). That means by 
2050 the world economy would be smaller by between 0.06% and 3.1%, a 
cumulative loss that ranges between $2.1 trillion and $124.5 trillion in the best 
and worst case scenarios. By 2050, failing to tackle AMR is expected to cause 
10 million deaths attributable to AMR every year compared to other major 
causes of death, including cancer.  
Delaying the development of widespread resistance by just 10 years could save 
65 trillion US$ of the world’s output between now and 2050, as estimated by the 
researchers. (187) Therefore the independent review calls policy and decision 
makers to look carefully at how to conserve the world’s existing antibiotics and 
those developed in the future.  
Sir Alexander Fleming in his address on receiving the coveted Nobel prize in 
1945, reminded the world; 
The time may come when penicillin can be bought by anyone in the shops. Then there 
is the danger that the ignorant man may easily under-dose himself and by exposing his 
microbes to non-lethal quantities of the drug make them resistant'. (188) 
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Methicillin resistance was first reported in 1961. Was the common man able to 
buy penicillin in shops in the 1960s? Was it under dosing or broad antimicrobial 
cover that led to resistance? There may be many plausible answers, however, 
the logical and simple answer directs one to the reasons for the abuse of the 
antibiotic and non-lethal concentrations.  Survival and the evolution of bacteria 
to adapt to the most challenging environments made them potentially the most 
successful living organisms. Bacteria adapt to external threats and have 
survived for long periods of time, and that will continue. Humanity must accept 
the fact that for bacteria, antibiotic exposure is no different to other threats 
which makes these living organisms able to adapt and survive. Therefore the 
principle of conservation and the conservative use antimicrobials should be the 
fundamental principle in our approach to containing resistance. Where 
alternatives are available, they should be used in the prevention and treatment 
of health conditions, and society must invest in research and development. 
 
4.6 Reflections  
The complexities involved in the conduct of an RCT opened many avenues of 
learning for me. Approvals and permissions such as those from the HPRA, 
Ethics Committee and indemnity provided administrative learning experience, 
which was complimented by that from setting up and conducting the RCT, 
patient interaction, data collection and data management aspects, enabled me 
to develop skill in niche areas. The skills development was complimented by 
academic learning in research methods and statistical analysis, scientific writing 
and leadership, publication, along with presenting results to scientific as well as 
other audiences. In comparison with multi centre RCTs the single centre 
NHNMRSA study offered me the opportunity to conceive, setup and conduct all 
aspects of the study. On reflection it was a challenging long journey that I 
walked through patiently, generously supported by the supervisors and many 
others who were experts in their own field.  
To gain a comprehensive understanding on the antibiotic susceptibility testing 
methodology and the reporting of susceptibility, I wanted hands-on laboratory 
experience, i.e. to test mupirocin susceptibility, MIC and MBC assays. The 
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laboratory experience provided me with an opportunity to comprehend the 
complexities involved in specimen processing and results reporting. Performing 
these tests under the supervision of senior microbiology scientists using 
approved laboratory protocols was an invaluable learning experience, especially 
as such opportunities are seldom available for non-scientists outside of the 
research settings. The controls employed for media, storage, buffers, solutions, 
reference bacterial strains as well as in the interpretation of results provided a 
unique insight into the quality assurance methods utilised in diagnostic 
laboratories. The skill gained in performing these tests and the knowledge 
acquired undertaking the scientific study have enabled me to attain a profound 
understanding of the multifaceted aspects of MRSA prevention and control, and 
to correlate this with clinical scenarios. 
In this journey, on reflection I recognise that every difficult situation was a 
learning experience, which reaffirmed me that the light is near and near, and to 
stick to the fight and not to quit. 
 
4.7 Recommendations 
The NHNMRSA RCT was ground breaking. To date, there are no studies 
published where MGH was used to investigate its potential for nasal MRSA 
decolonisation. I believed in the medicinal properties of honey and pursued the 
idea using the best possible approach, an RCT, the gold standard for clinical 
studies. To overcome the limitations outlined in this thesis, in future, larger 
studies involving multi-centres, acute hospitals as well as non-acute care 
settings, should be conducted, to replicate the results as well as to enrol a large 
heterogenous population so that the results can be applied to a wider 
population.  
The potential for an aerosolised preparation for MGH and mupirocin 
administration should also be further investigated, in addition to further in vitro 
studies. Pharmaceutical and industry engagement is worth investigating for the 
aerosolised product development. This approach may offer future potential, 
both for pulmonary and nasal decolonisation.  
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Mupirocin 2% ointment is used either alone or with skin antiseptics as part of a comprehensive MRSA decolon-
ization strategy. Increased mupirocin use predisposes to mupirocin resistance, which is significantly associated
with persistent MRSA carriage. Mupirocin resistance as high as 81% has been reported. There is a strong associ-
ation between previous mupirocin exposure and both low-level and high-level mupirocin resistance. High-level
mupirocin resistance (mupA carriage) is also linked to MDR. Among MRSA isolates, the presence of the qacA and/
or qacB gene, encoding resistance to chlorhexidine, ranges from 65% to 91%, which, along with mupirocin resist-
ance, is associated with failed decolonization. This is of significant concern for patient care and infection preven-
tion and control strategies as both these agents are used concurrently for decolonization. Increasing bacterial
resistance necessitates the discovery or development of new antimicrobial therapies. These include, for example,
polyhexanide, lysostaphin, ethanol, omiganan pentahydrochloride, tea tree oil, probiotics, bacteriophages and
honey. However, few of these have been evaluated fully or extensively tested in clinical trials and this is required
to in part address the implications of mupirocin resistance.
Background
Staphylococcus aureus is a leading cause of healthcare-
associated infections worldwide and is associated with increased
morbidity, mortality and higher healthcare costs, including infec-
tions caused by MSSA and MRSA.1 Colonization with MRSA
increases the risk of adverse health outcomes and it is estimated
that 10%–30% of carriers subsequently develop infection.2 The
nose as well as extranasal sites such as the throat and perineum,
skin ulcers and skin lesions are frequently colonized.3 – 5 A meta-
analysis concluded that MRSA colonization conferred a 4-fold
increased risk of infection as compared with MSSA colonization.6
Eradication of MRSA carriage from the nose and other body sites
forms an integral part of strategies to prevent and control MRSA in
many countries.7 – 9 Mupirocin is an important component in MRSA
prevention and specifically for the eradication of nasal MRSA.
However, reports of increasing mupirocin resistance (MR) are of
serious concern.
This review aims to determine the prevalence of MR and its clin-
ical consequences as well as measures to control MR. It also
reviews the evidence supporting the use of new agents as poten-
tial therapeutic alternatives for the prevention and management
of MRSA.
Search strategy
The following databases were searched (date of last search: 30
March 2015): PubMed, CINAHL, Scopus and Web of Science. The
search was limited to humans and English language publications
from 1985 to March 2015. Search terms included multiple var-
iants of the following terms: “Staphylococcus aureus, nose/
nasal, colonisation/colonization, honey, infection control or pre-
vention and control, wound, ulcer, surgical wound infection, top-
ical, treatment, chlorhexidine, mupirocin and drug resistance”
alone or in combination and/or ‘infection’. Medical subject head-
ings (MeSH) terms where available were used. Additionally, the
reference lists of retrieved articles were scanned to identify any
further studies. The titles and abstracts identified were screened
for relevance by one author. The list of potential articles was
reviewed to remove duplicates and full-text versions were
obtained. Further articles were eliminated following review. The
original articles were obtained and assessed in detail for inclusion.
Articles included in this review are those that addressed mupiro-
cin, i.e. infections associated with S. aureus, MRSA, decolonization,
resistance, surveillance reports, systematic reviews or meta-
analyses where the search terms appeared in the article title or
abstract. From a total of 499 articles initially found, after exclusion
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for reasons of unsuitability or duplicates, 88 articles remained for
inclusion, including those identified from reference lists. The
search process is illustrated in Figure 1.
Mupirocin use
The antibiotic mupirocin (pseudomonic acid A) is produced by the
bacterium Pseudomonas fluorescens. Mupirocin calcium ointment
was clinically introduced in the late 1980s and has proved to be
one of the most successful topical antibiotics for the clearance
of nasal S. aureus, both MSSA as well as MRSA.5,10 – 12 Mupirocin
is a competitive inhibitor of bacterial isoleucyl-tRNA synthetase
and is active against most ‘Gram-positive’ and some ‘Gram-
negative’ bacilli. Mupirocin-mediated inhibition of isoleucyl-tRNA
synthetase impedes protein and RNA synthesis, ultimately leading
to bacterial death. There is very little systemic absorption following
the topical application of mupirocin. After systemic administration,
mupirocin has a short half-life (15 min) and is rapidly converted
into inactive monic acid, which is excreted principally through
the kidneys.
The therapeutic indication for mupirocin is the elimination of
nasal carriage of staphylococci, including MRSA. The method of
application is nasal ointment, usually 2%, applied to the anterior
nares two to three times daily. Nasal carriage is then normally
cleared within 5–7 days of commencing treatment.12,13 A system-
atic review that included 23 trials concluded that mupirocin applied
two or three times daily for 4–7 days to both nostrils showed excel-
lent efficacy and eradicated S. aureus in 90% of patients as
assessed 1 week after treatment.13 A meta-analysis in 2008 con-
cluded that mupirocin appears to be cost-effective only in those
patients who are proven nasal carriers, where a significant and
strong reduction in S. aureus infection was confirmed.12
A significant limitation to the use of mupirocin is resistance,
which reportedly ranges from 1% to 81%.14 – 21 Mupirocin is also
used by some clinicians for the treatment of local skin and soft
499 records identified through database searching, screened
for title and abstract
304 excluded including duplicates and
those not meeting the inclusion and 
exclusion criteria
195 articles reviewed 
107 excluded; not relevant to the review
88 articles included in the review 
13 RCTs
2 case–control studies
10 non-controlled cohort studies
3 observational studies
19 diagnostic/laboratory studies
12 surveillance reports
8 reviews
4 guideline, expert opinion, consensus reports
9 qualitative reports
7 investigation/in vitro studies
1 mixed methods
Figure 1. Search process and the number of relevant references.
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tissue infections caused by S. aureus and streptococcal species,
which also contributes to MR.22
Mupirocin 2% ointment is used for nasal decolonization alone
or as part of a comprehensive MRSA decolonization strategy along
with skin antiseptics such as chlorhexidine. The impact of the
application of mupirocin to the nose has been investigated by vari-
ous researchers with varying success, in terms of immediate as
well as medium- to long-term sustained nasal MRSA decoloniza-
tion.5,23 – 25 In a multicentre trial in care homes, intranasal mupir-
ocin ointment was compared with a placebo among persistent
carriers of S. aureus and MRSA (n¼127) with a follow-up period
of 6 months. Mupirocin initially eradicated S. aureus, including
MRSA in 60/64 (94%) compared with 54/63 (86%) in the placebo
group, but after 90 days recolonization occurred in 39% of the
mupirocin group.24 In a study of 40 hospitalized patients, it was
found that MRSA clearance was more common amongst patients
with mupirocin-susceptible isolates (91%) than in those patients
colonized with low-level MR (LLMR) and high-level MR (HLMR).25 A
double-blind, randomized, placebo-controlled trial in a tertiary
healthcare facility evaluated the efficacy of mupirocin in eradicat-
ing nasal carriage of MRSA with body washing using chlorhexidine
soap for other sites. At the end of follow-up, i.e. 4 weeks from the
initiation of decolonization, 19/43 (44%) who received mupirocin
were free of nasal MRSA compared with 11/44 (25%) in the control
group.5
Mupirocin resistance
MR is very important for infection prevention and control person-
nel who are engaged in MRSA control efforts and also in the man-
agement of individual patients such as before major surgery to
minimize post-operative MRSA infection, as the presence of resist-
ance significantly reduces the likelihood of MRSA eradication.
Mechanisms
Phenotypically, MR is determined according to MIC breakpoints
with susceptible being ≤4 mg/L, LLMR 8 –256 mg/L and HLMR
.512 mg/L.21,26 Mupirocin MICs of 8–64 mg/L are usually due
to non-synonymous changes in the native isoleucyl-tRNA synthe-
tase gene. S. aureus isolates with an MIC of 128 or 256 mg/L are
uncommon but are considered to demonstrate LLMR; these
isolates have acquired base changes in the native isoleucyl
RNA synthetase gene, ileS.14,21,27 MICs of ≥512 mg/L reflect
HLMR and this is mediated by the acquisition of a conjugative plas-
mid containing mupA (ileS2), which encodes an alternative
isoleucyl-tRNA synthetase.26,28 Plasmid-mediated HLMR can
spread clonally and horizontally, even between different staphylo-
coccal species.29 In addition to the mupA gene, another mechan-
ism of HLMR, mediated by a novel locus (mupB), has been
reported.30 The mupB gene (3102 bp) shares 65.5% sequence
identity with mupA, but only 45.5% with ileS. The resultant MupB
protein shares 72.3% and 41.8% similarity with MupA and IleS,
respectively. These findings support the presence of non-mupA-
mediated HLMR as reported by others.21,30,31 Molecular studies of
MR in S. aureus populations indicate that nearly all S. aureus isolates
with HLMR have the mupA gene.27 However, low or non-expression
of the ileS2 gene has been described amongst LLMR isolates.32
Although ileS2 does not encode resistance to other antibiotics,
the presence of ileS2-carrying plasmids has been associated with
resistance to antibiotics such as clindamycin, tetracycline, erythro-
mycin and levofloxacin.33 A recent review of the presence of ileS2 in
CoNS bloodstream infection (BSI) isolates found that the increase in
the percentage of CoNS isolates carrying ileS2 (8% in 2006 to 22%
in 2011; P¼0.01) was correlated with increased mupirocin use in
each of the corresponding years (3.6 kg/year in 2006 to 13.3 kg/
year in 2010).34 Widespread acquisition of MR following nasal
decolonization with mupirocin among CoNS is reported from the
Netherlands and higher MR among CoNS is reported from a preva-
lence survey in France.35
Prevalence
Increased mupirocin use predisposes to both LLMR and
HLMR.14,17,18,35 – 43 Some of the larger studies are outlined in
Table 1. In a Canadian study, the proportion of MRSA strains
with HLMR increased from 1.6% in the first 5 years of surveillance
(1995–99) to 7.0% (2000–04). The pattern of mupirocin use dur-
ing the study periods is not described, but the investigators
acknowledge the widespread use of mupirocin in their institu-
tion.14 Another study in a tertiary care facility in the USA over
18 months reported MR amongst positive MRSA patients on hos-
pital admission in 20/591 (3.4%); HLMR occurred in 0.62% and
LLMR in 2.9%.36
A surveillance programme carried out over 2 years in a 24 bed
surgical ICU between December 2002 and December 2004 in
Missouri, USA, with a low level of mupirocin use, detected MRSA
in 13.6% (n¼338/2840); 13.2% of 302 isolates were MR, 8.6%
being HLMR and 4.6% LLMR.37 A nationwide prospective study
of MR amongst staphylococcal isolates in France between
October 2011 and February 2012 reported a resistance rate of
10.3% amongst 708 isolates of CoNS, mainly HLMR (5.6%).
Among the MRSA isolates, 2.2% (n¼8) were MR, of which 0.8%
were HLMR and carried the mupA gene.35 Another study com-
pared MR during two time periods in a 500 bed tertiary hospital
in Brazil. In the first period (1990–95), when mupirocin was
used extensively including application to any skin wound compris-
ing ,20% of body surface, 28/43 (65%) MRSA infections were
caused by MR isolates, which decreased to 15% when mupirocin
use was restricted to only patients colonized in the nose (1996–
2000).38 The effect of mupirocin ointment for nasal decoloniza-
tion along with other infection prevention and control measures
was evaluated in a study during an MRSA epidemic in a
Canadian hospital. There was a significant increase in MR, from
2.7% to 65%, between the beginning of the first year at the
onset of the epidemic (1990) and the end of the third year.39
Similar findings have been reported from another study in Brazil
in two tertiary care university hospitals, in one of which there
was extensive use of mupirocin and where 72/114 (63%) of iso-
lates were MR, compared with the second hospital in which mupir-
ocin use was controlled and where only 3/49 (6.1%) were MR.18
The emergence of HLMR MRSA following the use of mupirocin
for prophylaxis at intravenous exit sites to prevent local infection
and BSI was reported in 3% of patients on a peritoneal dialysis
unit after a 4 year period of continuous use.40 In a screening pro-
gramme in Shanghai and Wenzhou (China), 53/803 (6.6%) iso-
lates that were MR MRSA over a 3 year period were HLMR with
the mupA gene detected by PCR.41 In a prevalence study in a ter-
tiary care hospital in Singapore, HLMR was reported from 34/307
(11%) isolates; 14% from screening isolates and 10% from clinical
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Table 1. Larger studies on the prevalence of MR
Author Year Country
Study
description Patient population No. of patients/no. of isolates Molecular methods used
Prevalence (%)
LLMR HLMR overall
Miller et al.39 1990–93 Canada LS hospital 231/310 NA NA NA 2.7–65
Vivoni et al.38 1990–95 Brazil LS hospital 43/43 PCR, PFGE NA NA 65
Vivoni et al.38 1996–2000 Brazil LS hospital 89/108 PCR, PFGE 9 6 15
dos Santos et al.18 1995–2004 Brazil PS hospital 62/114 NA NA NA 6.1–63
Simor et al.14 1995–99a Canada LS hospital NA/4980 PCR 6.4 1.6 NAa
2000–04b 10 7 NAb
Jones et al.37 2002–04 USA PS hospital, SICU 338/302 PCR 4.6 8.6 13.2
Liu et al.41 2005–07 China LS hospital NA/803 PCR 0 6.6 6.6
Babu et al.36 2008 USA PS hospital 948/591 NA 2.9 0.6 3.4
Choudhury et al.17 2010 Singapore PS hospital NA/307 PCR 0 11 11
Park et al.42 2011 Korea PS hospital, NICU 101/101 PFGE 0 47 CA/79 HA 73
Walker et al.19 2004 USA LS, 5 eras hospital, mixed
population
50–100 isolates per era,
random
PCR 28 31 67
Caffrey et al.16 2010 USA retrospective
case–control
hospital 310/40 cases MR and 270
controls mupirocin
susceptible
NA NA NA NA
Cadilla et al.15 2011 USA LS hospital 837 isolates (191 MDR and 646
non-MDR)
PCR 0 6.8 MDR NA
Lee et al.20 2011 Switzerland nested case–
control
hospital, acute 150/75 cases and 75 controls;
HLMR was excluded from
the study
Etest, PCR NA NA 9–81
Desroches et al.35 2013 France PS hospital, national
surveillance
NA/367 PCR, PFGE, microarray 1.4 0.8 2.2
LS, laboratory surveillance; NA, not available; PS, prospective surveillance; SICU, surgical ICU; NICU, neonatal ICU; CA, community acquired; HA, hospital acquired.
aPeriod 1.
bPeriod 2.
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isolates during 2009–2010.17 HLMR was also reported from a
neonatal ICU in Korea where 101/223 (45%) of admissions were
MRSA positive; of these, 79% of heathcare-associated MRSA iso-
lates and 47% of community-acquired MRSA were HLMR.42
A multicentre study in care homes involving 3806 residents in
the USA over 30 months detected MR in 101 (12%) isolates; HLMR
in 78 (9%) isolates and LLMR in 23 (3%) isolates.43 In a review of
240 MRSA isolates recovered over 20 years from patients who had
failed decolonization, MR was identified in 63% of the isolates.44
In a matched case–control study of 40 cases with MR MRSA
and 270 controls without MR MRSA during 2004–08, prior expos-
ure to mupirocin in the preceding year was the most significant
independent predictor for both LLMR and HLMR.16
In the Netherlands, widespread acquisition among CoNS of
MR following nasal decolonization with mupirocin has been
reported.34,45 In the first study (2012), among the 238 CoNS BSI
isolates, Staphylococcus epidermidis was most prevalent [150 iso-
lates (63%)] and it was also the most common species amongst
HLMR isolates, i.e. 25 isolates. In the latter report, a nasal decol-
onization study (2015), among the 607 CoNS isolates collected
from 469 patients post-decolonization with mupirocin, 588
(97%) were HLMR. S. epidermidis was most prevalent with 568 iso-
lates (94%).45 A review of the clinical implications of MR among
S. aureus suggests that unrestricted over-the-counter use and
treatment of wounds and pressure sores with mupirocin are
strongly associated with resistance.22
Associated chlorhexidine resistance
In most MRSA infection prevention programmes, chlorhexidine is
a major component and is often used in various forms as part of
oral care, skin antisepsis prior to intravascular device placement,
before surgical procedures, during patient bathing and as a
component of some antimicrobial-impregnated catheters and
dressings. As with any antimicrobial or antiseptic agent, increased
use raises concerns about emerging chlorhexidine resistance and
its implications for MRSA decolonization strategies. Chlorhexidine
is a biguanide cationic bactericidal agent that is rapidly taken up
by S. aureus.46,47 Chlorhexidine gluconate (CHG) is a topical anti-
microbial agent with broad-spectrum activity, including against
S. aureus. At low concentrations it disrupts the integrity of the
cell wall and membranes, resulting in leakage of the intracellular
contents; at high concentrations, chlorhexidine causes coagula-
tion of the intracellular contents. Significant reductions in central
line-associated BSI were observed when CHG was used for pro-
cedural skin preparation.48 Bacterial resistance to chlorhexidine
was initially reported in 1995.47 Resistance to chlorhexidine is con-
ferred by two gene families, qacA/B and smr.49 These plasmid-
mediated qacA/B genes encode proton-dependent multidrug
efflux pumps, expression of which results in high-level resistance
to antiseptics, whereas the smr gene confers low-level resist-
ance.20,47,50 MRSA isolates carrying the qacA/B gene initially
belonged to a single clone, but the qacA/B gene has been detected
in MRSA isolates belonging to seven different clones from different
countries.20,43,44,51 – 53
Concomitant resistance to other antiseptics and systemic anti-
bacterial agents presents additional challenges in terms of decol-
onization strategies. For example, a strong association has been
reported between HLMR and resistance to at least four non-b-
lactam antimicrobial classes.15 In that study, the investigators
also identified that mupA was significantly more likely to be car-
ried by isolates resistant to gentamicin, rifampicin or trimethoprim/
sulfamethoxazole (P,0.0001) in comparison with erythromycin-,
clindamycin- or ciprofloxacin-resistant isolates (P¼1.00, P¼0.30
and P¼0.07), respectively.
Very high prevalence of qacA and/or qacB MRSA isolates has
been reported from Taiwan where chlorhexidine has been used
for .20 years for hand hygiene; of 240 isolates obtained during
1990–2005, the proportion of MRSA isolates with a chlorhexidine
MIC of≥4 mg/L was 1.7% in 1990, 50% in 1995, 40% in 2000 and
46.7% in 2005. Among these isolates, 46/83 (55.4%) carried the
qacA/B gene. In addition, qacA and/or qacB were identified in 91%
of MRSA isolates from patients who had failed decolonization.44
Similar findings were reported from a secondary and tertiary hos-
pital in Korea over 4 years among the MR MRSA isolates; the qacA/
B and smr genes were detected in 65% of isolates.51 A nested
case–control study of MRSA decolonization found that combined
LLMR and the presence of chlorhexidine resistance significantly
increased the risk of persistent MRSA carriage.20 However, the
investigators reported that chlorhexidine resistance alone did
not predict persistent carriage, suggesting that the combination
of LLMR and chlorhexidine resistance may be necessary for clinical
failure, i.e. persistent colonization. In practice, both these agents
(mupirocin and CHG) are often administered concurrently as part
of MRSA decolonization regimens. Studies evaluating chlorhexi-
dine resistance and MRSA and the clinical significance are outlined
in Table 2.
Controlling MR
In controlling MR, Patel et al.21 proposed three approaches. First,
additional studies are needed to quantify the efficacy and unin-
tended consequences of mupirocin use as a prevention strategy.
Second, a strategy for monitoring the prevalence of resistance
should be developed and implemented whenever mupirocin is
routinely used. Third, monitoring should not only focus on MR
itself, but also should help determine whether mupirocin use
might amplify the spread of other MDR via its linkage to other
resistance determinants.21 There may be a benefit in incorporat-
ing MR surveillance as part of ongoing surveillance programmes
such as EARSS-Net, which monitors antibiotic resistance amongst
invasive isolates of MRSA, i.e. in BSI. While these do not represent
isolates from the nose or other carriage sites, they are representa-
tive of isolates responsible for serious infection throughout Europe
and from a population in which many have had or will be under-
going MRSA decolonization.
The assessment of mupirocin susceptibility amongst isolates
of MRSA varies. While most centres determine and report mupir-
ocin susceptibility when MRSA is initially isolated from an individ-
ual patient, the ongoing testing of repeat isolates from the same
patient varies. For persistent MRSA carriers, mupirocin MIC testing
should be repeated to assist in informed decision making and pro-
vide the potential opportunity to impact on the control of resist-
ance. Point prevalence surveillance in centres where mupirocin is
widely used and/or resistance is reported is also indicated.
Control of mupirocin use, i.e. targeted decolonization in
selected patients based on risk assessment rather than the decol-
onization of all MRSA-positive patients, has proved an effective
strategy to combat MR. For example, in the ICU there may be little
point in attempting to eradicate upper respiratory tract
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Table 2. Studies evaluating MR and chlorhexidine resistance and their clinical significance
Author Year Country Study design
Patient
population
MRSA/
MSSA
No. of patients/
isolates
Molecular
method Follow-up
Prevalence
of MR
Prevalence of
qacA/B, smr Comments
Wang et al.44 2008 Taiwan longitudinal
analysis
hospital MRSA 240 BSI and
clinical
isolates
MLST NAP NA 1.7% (1990),
46.7% (2005)
83/240 had high CHX
MIC .4 mg/L, 55.4%
carried qacA/B
Vali et al.53 2008 UK (Scotland) longitudinal
analysis
hospital MRSA 120 clinical
isolates
PCR NAP NA 8.3% (n¼10)
qacA/B, 44.2%
(n¼53) smr
high resistance to AMX,
GEN, OXA, CTX, CXM
and CIP; low
resistance to TET;
none resistant to VAN
Lee et al.20 2011 Switzerland nested case–
control
hospital MRSA 150: 75 cases
and 75
controls
PCR 2 years LLMR present in
all qacA/
B-positive
isolates
91% cases
(n¼68), 68%
controls
(n¼51)
qacA/B
HLMR excluded
Longtin et al.46 2011 Canada longitudinal
analysis
hospital ICU MRSA 234 isolates PCR NAP NA 2% (n¼7) qacA/
B, 7%
(n¼23) smr
McDanel
et al.43
2013 USA longitudinal
analysis
nursing
homes
(n¼26)
MRSA 3806 patients,
829 MRSA
isolates
PCR NAP 3% (n¼23)
LLMR, 9%
(n¼78)
HLMR
0.6% (n¼5)
qacA/B
all five were resistant to
CLI, ERY, LVX, TET, SXT
and GEN
Lee et al.51 2013 Korea longitudinal
analysis
hospital
(n¼2)
MRSA 456 isolates MLST, PCR NAP 12% (n¼53)
LLMR, 2%
(n¼9) HLMR
65% (n¼40)
qacA/B, 71%
(n¼44) smr
all MR isolates resistant
to ERY, CLI, GEN and
CIP; none resistant
to VAN
Fritz et al.52 2013 USA longitudinal
analysis
hospital MSSA
and
MRSA
1089 patients/
696 isolates
PCR NAP 2.1% (n¼23) at
baseline to
4.5% (n¼31)
0.9% (n¼10) at
baseline to
1.6% (n¼11)
qacA/B
isolates resistant to CLI
were more likely to be
MR compared with
CLI-susceptible
isolates; CHX
resistance was not
associated with
resistance to other
systemic antibiotics
NAP, not applicable; NA, not available; CHX, chlorhexidine; AMX, amoxicillin; GEN, gentamicin; OXA, oxacillin; CTX, cefotaxime; CXM, cefuroxime; CIP, ciprofloxacin; TET, tetracycline;
VAN, vancomycin; CLI, clindamycin; ERY, erythromycin; LVX, levofloxacin; SXT, trimethoprim/sulfamethoxazole.
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colonization, including nasal carriage, in a patient who is intu-
bated and ventilated given the presence of an endotracheal
tube or a tracheostomy to which the bacteria will adhere and
form a biofilm. Targeted decolonization therefore involves an anti-
microbial stewardship programme, healthcare worker education
and refresher training, surveillance, feedback and electronic
alerts.19 There was a precipitous decline in the number of isolates
with HLMR (from 31% to 4%) and also LLMR (from 26% to 10%)
after measures were introduced to control or limit the use of
mupirocin over 2 years in a mixed healthcare setting that included
acute, domiciliary and nursing homecare.
Similar reductions in MR following the control of mupirocin use
were reported from a neonatal unit in the Netherlands by
Zakrzewska-Bode et al.54 where the routine application of mupir-
ocin to central vascular catheter insertion sites was discontinued.
Finally, in Western Australia, susceptibility testing of S. aureus iso-
lates was mandated from 1993 and restricted mupirocin use led
to similar reductions, where MR decreased from 6.4% (n¼16) in
1994 to 0.3% (n¼3) in 1997.55
Recent years have seen an emphasis on horizontal infection
prevention and control approaches, i.e. applying measures to a
whole population rather than to those at risk. An example of
this is the use of mupirocin and chlorhexidine applied to all
patients in an ICU compared with their use in those patients
screened and found to be positive for MRSA. The case for the uni-
versal decolonization approach in ICU settings may inevitably
contribute to higher MR as well as resistance to chlorhexidine.56
The independent effect of mupirocin could not be distinguished
from the combined mupirocin/chlorhexidine effect in the same
study. The downside of universal decontamination is the unneces-
sary use of mupirocin in 70%–80% of the patients not carrying
S. aureus, potentially enhancing resistance in CoNS and creating
a reservoir of MR for S. aureus.22 A systematic review on chlorhexi-
dine body washing reports that evidence is lacking that it reduces
carriage or infections with antimicrobial-resistant bacteria.57
Consequently, if this practice becomes more widespread, it will
be essential to monitor for the emergence and spread of both
MR and chlorhexidine resistance.
In a multicentre, cluster-randomized, non-blinded crossover
trial, the effect of daily bathing with chlorhexidine-impregnated
washcloths on the acquisition of MDR organisms and the inci-
dence of hospital-acquired BSI was evaluated.58 The overall rate
of hospital-acquired BSI was 4.78 cases per 1000 patient-days
with chlorhexidine bathing versus 6.60 cases per 1000 patient-
days with non-antimicrobial washcloths (P¼0.007), a 28%
lower rate with chlorhexidine-impregnated washcloths. However,
when analysed by individual organism, there were no significant
reductions in MRSA acquisition or S. aureus BSI. In a similar trial,
paediatric ICU patients demonstrated a 36% reduction in BSI
with 2% CHG bathing, which failed to achieve significance in the
ITTanalysis. In that study, the incidence of BSI was lower in patients
receiving CHG bathing compared with standard practices.59
Other antimicrobial agents
Bacitracin ointment, usually in combination with polymyxin B
and neosporin (e.g. polysporin), has been studied as a potential
decolonization strategy for MRSA and the results have not been
as encouraging as those for mupirocin. In a double-blind,
randomized controlled trial (RCT), bacitracin was compared with
mupirocin and all the patients received daily CHG body washes.
Only 15/49 (30.6%) patients in the polysporin arm were MRSA
negative at all sites at 48 h, compared with 35/54 (64.8%) of
those given mupirocin.60
Retapamulin is a pleuromutilin (a new class of antibiotic) that
exhibits activity against various skin bacteria including MSSA and
MRSA and is used for the treatment of impetigo. An in vitro study
assessed susceptibilities amongst various MSSA and MRSA strains
from acute and chronic wounds to commonly used topical
antimicrobial agents. The investigators found that mupirocin
treatment was the most effective antimicrobial, with areas of
inhibition ranging from 30.34 to 61.70 cm2 (P,0.05), as com-
pared with the next most effective, retapamulin, with areas of
inhibition ranging from 11.97 to 23.54 cm2.61 Another study
reported that retapamulin had good activity against 15/16 (94%)
of MR isolates.62 A recent double-blind RCT concluded that the
clinical success rate in the treatment of secondarily infected trau-
matic lesions amongst patients with MRSA was significantly lower
with retapamulin compared with linezolid.63
Alternative approaches to decolonization
The increasing prevalence of MR and associated chlorhexidine
resistance means that alternative agents to decolonize patients
with MRSA need to be considered. In 2009, Coates et al.12 dis-
cussed alternatives that were in various stages of development
with a diversity of mechanisms, but had yet to be proved effica-
cious in clinical trials. While considering the alternatives, the inves-
tigators were of the opinion that a more bactericidal antibiotic
than mupirocin is needed, on the grounds that it might reduce
the relapse rate and so clear the patient of MRSA for a longer per-
iod of time than mupirocin.12 Oral antimicrobials for decoloniza-
tion of MRSA carriage may be considered in certain populations
(e.g. multiple sites of colonization) or under specific circumstances
(e.g. prior to surgery); however, the risk of resistance to oral ther-
apy or systemic side effects must be carefully considered. This is
beyond the scope of this review and below we focus on emerging
promising topical agents.
Octenidine dihydrochloride
Decolonization of the nose and other body sites has been investi-
gated using octenidine dihydrochloride body wash along with the
intranasal application of 2% mupirocin. The efficacy was highest
in the nose, where decolonization was successful in 28/32
(87.5%), and in the decolonization of extranasal sites it was suc-
cessful in 18/32 (56.3%) of patients.64
Polyhexanide
The efficacy of polyhexanide (Prontodermw) Gel Light nasal oint-
ment, body foam and mouthwash was retrospectively compared
with the success rate achieved with a chlorhexidine and mupirocin
regimen. Persistent MRSA was identified among 51/72 (71%) of
those who underwent the Prontodermw regimen compared with
20/44 (45%) of those who underwent the chlorhexidine and
mupirocin regimen.65
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Ethanol
The bactericidal activity of 70% ethanol combined with emollients
and a preservative (Nozin Nasal Sanitizer), when applied to the
nasal vestibules of S. aureus-colonized volunteers, was compared
with a placebo. The nasal application was performed at 0, 4 and
8 h during the course of a normal workday. The researchers
reported a significant reduction in nasal vestibular carriage of
both S. aureus and other cultivable bacteria in the antiseptic
group. The reductions were very consistent, with a median
decrease in the antiseptic-treated group of 98.8% at the end of
the normal (10 h) workday. The investigators claim that the
ethanol-based antiseptic provides a unique opportunity for regu-
lar daily use over prolonged periods by patients and staff in long-
term care environments as it is unlikely to contribute to bacterial
resistance.66
Sodium hypochlorite
Sodium hypochlorite (bleach) was originally described in 1915 by
Dakin and has since been used extensively as a topical antimicro-
bial for the treatment of wounds and burns. IDSA guidelines rec-
ommend nasal mupirocin and dilute bleach baths for 15 min
twice weekly for 3 months as treatment for patients with refrac-
tory MRSA skin and soft tissue infections.67 An RCTcomparing vari-
ous decolonization regimens using mupirocin, chlorhexidine and
bleach on patients with community-based skin and soft tissue
infections and multisite S. aureus colonization revealed that the
highest rate of successful S. aureus eradication (71%) in patients
occurred with a combination of nasal mupirocin and daily bleach
baths.68
Lysostaphin
Lysostaphin is a glycylglycine endopeptidase that cleaves the
cross-linking pentaglycine bridges in the cell walls of staphylo-
cocci. In an animal model, a single application of 0.5% lysostaphin
cream eradicated MSSA and MRSA from the nares of animals more
effectively than mupirocin.69 In 24 h time–kill studies, lysostaphin
has also been found to be superior to mupirocin and tea tree oil.70
However, to date, there have been no studies in humans and its
potential remains to be confirmed.
Omiganan pentahydrochloride
Omiganan pentahydrochloride is a novel topical cationic peptide
active against a broad spectrum of bacteria and yeast. An
in vitro study has demonstrated potent activity against S. aureus
regardless of the underlying resistance mechanism. The observa-
tion that omiganan remains equally active against all isolates of
S. aureus at a level significantly below the clinical formulation con-
centration (1% gel) is promising and warrants further studies.71
Natural honey
Honey is of interest to healthcare practitioners involved with
wound management and reduces the numbers of MRSA in open
wounds.72 –76 An in vitro study of four types of honey, three sourced
from Northern Ireland and one from Suisse Normande, France,
found that they reduced the bacterial count of community-
acquired MRSA isolates.77 Similar findings are reported elsewhere
when medical-grade honey was applied to chronic wounds.76,78
The antibacterial properties of honey vary between different geo-
graphic regions and floral species.79
Tea tree oil
Tea tree (Melaleuca alternifolia) oil has also been investigated as
an antimicrobial and anti-inflammatory agent. Edmondson
et al.80 investigated the efficacy of tea tree oil for the decoloniza-
tion of wounds positive for MRSA in 12 patients and concluded
that although wounds in most cases showed signs of healing,
they remained persistently colonized with MRSA. In another
study, a tea tree oil-based regimen was compared with standard
treatment consisting of mupirocin, chlorhexidine or silver sulfadia-
zine.81 Of the patients who received standard treatment, 56/114
(49%) were cleared of MRSA carriage. Of the patients who
received the tea tree oil regimen, 46/110 (42%) were cleared.
Mupirocin was significantly more effective at clearing nasal car-
riage than tea tree cream (78% versus 47%; P¼0.0001).
However, tea tree oil treatment was more effective than chlor-
hexidine or silver sulfadiazine in clearing superficial skin sites
and skin lesions of MRSA. A Phase 2/3 RCT in two ICUs evaluated
the effect of daily washing with tea tree oil (Novabac 5% skin
wash) compared with standard care with a baby soft wash
(Johnson’s Baby Softwash) on the incidence of MRSA colonization.
There was no statistical difference between the two approaches.
The investigators therefore did not recommend tea tree oil as an
effective means of MRSA decolonization.82 Tea tree oil has been
reported to cause allergic dermatitis in addition to gynaecomas-
tia, probably owing to its oestrogenic and antiandrogenic proper-
ties, and should therefore be used with caution.71
Probiotics
The potential of probiotics as agents for MRSA decolonization was
investigated by Sikorska et al.,83 who reported that many strains of
lactobacilli and bifidobacteria isolated from a variety of sources
inhibited in vitro the growth of S. aureus including clinical isolates
of MRSA, suggesting that further research is warranted including
clinical trials.
Silver
The successful topical application of silver agents (Acticoat 7w,
Smith & Nephew) in treating MRSA surgical site infection (n¼2)
without systemic antibiotics as well as with gentian violet
(0.5%) for skin lesions (n¼28) and for the eradication of nasal car-
riage (n¼9) has been described.84
Bacteriophages
Bacteriophage therapy could also be an alternative to antibiotics
for the treatment of chronic MRSA infections, as success has been
reported both in treating infections (n¼6) as well as eradication of
MRSA carrier status in a healthcare worker.85 The potential for an
engineered Staphylococcus-specific phage lysin (ClyS) to be used
for topical decolonization was investigated in a mouse model.86
ClyS eradicated a significantly greater number of MSSA and
MRSA with a 3 log reduction compared with a 2 log reduction
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with mupirocin. The use of ClyS also demonstrated a decreased
potential for the development of resistance amongst MRSA and
MSSA compared with mupirocin in vitro. Another agent, P128, a
chimeric protein that combines the lethal activity of two enzymes,
consists of a phage tail-associated muralytic enzyme of phage K
and the staphylococcal cell wall-targeting domain (SH3b) of
lysostaphin. Using the broth microdilution method, the investiga-
tors found that P128 was active against S. aureus clinical strains
including MRSA, MSSA and MR MRSA. MBCs and MICs of P128 (1–
64 mg/L) were similar across the 32 S. aureus strains tested, dem-
onstrating its bactericidal nature. In time –kill assays, P128
reduced cfu by 99.99% within 1 h and inhibited growth up to
24 h.87 Evidence that phages can effectively combat experimen-
tally induced S. aureus infections in animals warrants further
study in clinical trials.88
Overall, there is a paucity of studies on alternative agents for
eradication of MRSA, such as alcohol-based agents, omiganan
pentahydrochloride, lysostaphin, honey, bacteriophages and
other agents. Clinical trials are warranted to confirm their
potential before such agents can be routinely used for MRSA
decolonization.
Conclusions
Nasal carriage of MRSA is a recognized risk factor and a precursor
for invasive infection. Clinical trials report that of all the various
topical treatments used for the eradication of MRSA from the
nose, mupirocin is the most effective. Increasing MR, either
alone or combined with chlorhexidine resistance, means that
ongoing monitoring of resistance is necessary, especially where
there is widespread and even indiscriminate use of decolonization
regimens. Before application, LLMR is significantly associated with
persistent MRSA carriage and in addition there is a strong associ-
ation between previous mupirocin exposure and both LLMR and
HLMR. An association exists between HLMR (mupA carriage) and
MDR. The presence of qacA and/or qacB and MR is another factor
associated with failed decolonization.
The emergence of HLMR in CoNS isolates indicates an expand-
ing reservoir of plasmids encoding MR, which can be transferred to
other CoNS strains as well as to S. aureus including MRSA. HLMR
and resistance to other antibiotics amongst CoNS may result in
a reduction in oral antibiotic options for prolonged treatment of
prosthetic infections with CoNS. Mupirocin should be used with
caution if at all in patients with chronic extranasal colonization
and should be limited to one or two 5 day courses of nasal appli-
cation to reduce the emergence of resistance. However, the out-
come following repeated courses of mupirocin application in the
same patient is not explicit in the studies evaluated. We may
eventually reach a point, or have done so already in some centres,
where the benefits from mupirocin use are restricted to a minor-
ity of patients. Persistent colonization in the setting of MR may
still be associated with reduced numbers of colonizing bacteria
after attempts at decolonization, thus helping to reduce the risk
of infection compared with patients colonized with MRSA who
have not undergone decolonization of any kind. New antimicro-
bial therapies either on their own or in combination with alterna-
tive therapies are needed. There are very few antibacterial agents
with new mechanisms of action under development to meet the
challenge of MDR. The EU identifies a widening gap between the
burden of infections due to multidrug antibacterial resistant
organisms and the development of new systemic agents as a
key priority.89 This also applies to topical agents used in decolon-
ization. Tea tree oil, medical-grade honey, bacteriophages and
other natural agents with antiseptic and antibacterial properties
show promise but need to be further evaluated. Many of these
have been initially developed in the academic sector or by small
commercial enterprises, neither of which usually has the
resources to develop the agents further and to carry out the
necessary clinical trials to confirm or not their usefulness in
the clinical arena. Consequently, there is a need for national
and international agencies to sponsor further studies and
evaluations.
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Understanding an illness (MRSA) can lead to more favourable health behaviours and disease outcomes. The Brief Illness Perception Questionnaire (BIPQ) is a simple and rapid assessment of illness
perceptions. It includes eight dimensions; perceived consequences, timeline, personal control, treatment control, identity and concern, coherence, emotional representation and an open ended question
about cause, rated on an 11 point scale to assess the perceived importance.
Background
• To assess patients beliefs and perceptions on MRSA carriage.
• To assess patients beliefs on the source of acquisition of MRSA.
Aims Methods
Questionnaire. A modified BIPQ was administered to patients participating in a RCT of two 
approaches to nasal MRSA decolonisation. Ethical approval for the study was granted by a 
Recognised Ethics (Medical Research) Committee.
The beliefs and emotional response of patients colonised with MRSA
Toney T Poovelikunnel1, Georgina Gethin2, Mary Codd3, Hilary Humphreys1,4
1RCSI Hospitals Group, Dublin, 2NUI Galway, 3 UCD, Dublin, 4Royal College of Surgeons In Ireland
toneythomas@beaumont.ie
Results
Results - 2
• MRSA colonisation had little or no consequence for 74% (26) patients.
• 83% (29) believed that colonisation would continue forever.
• Most (94%) believed that they did not have any control of their MRSA.
• All respondents assigned the maximum score for treatment/control.
• Only 23% (8) patients experienced symptoms they related to MRSA.
• MRSA was a matter of concern for 80% (28).
• More than one half, 57% (20) had a good understanding of MRSA.
• Most patients 77% (27) were not emotionally affected by MRSA carriage.
Table 1: Ranked order of importance
Most patients (94%) believed that they did not have any control of their MRSA, and all respondents assigned the
maximum score denoting the importance of treatment/control.
Figure 1: Beliefs and perceptions on MRSA carriage
BIPQ elements Rank of importanceLess important (0-4) Mid score (5) Most important (6-10)
Consequences 66% 8.00% 26.00%
Timeline 8.50% 8.50% 83.00%
Personal control 94.00% 0 6.00%
Treatment control 0 0 100%
Identity 77.00% 6.00% 17.00%
Concern 20% 9.00% 71.00%
Coherence 43.00% 23.00% 34.00%
Emotional representation 77.00% 11.50% 11.50%
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Results -1
• The survey response rate was 87.5% (n=35).
• Mean age 73.3 y & 35% were females.
• The ranked order of importance the participants assigned to the 11 point
scale is displayed in table 1 and figure 1.
• The mean, median and inter-quartile range (IQR) of each item scores are
displayed in table 2.
• Hospitalisation, surgery and poor hospital hygiene were mostly
associated as the cause of MRSA acquisition, as shown in figure 2.
Figure 2: Ranked order of MRSA Acquisition
In decreasing order, hospitalisation, surgery, poor hospital hygiene, chronic illness, antibiotic use and contact with HCW,
were felt to be responsible for MRSA acquisition.
Table 2: BIPQ mean, median and inter quarter range scores
• Patients consider MRSA carriage as chronic condition and that decolonisation is beneficial.
• Most patients believed they had no control over MRSA, but it had no serious consequence on their lives.
• Only few patients had any MRSA related symptoms. 
• Patients were generally emotionally detached from their colonisation of MRSA.
• Almost 50% of patients did not have a reasonable understanding of MRSA, which highlights necessity for 
continued patient education.
This project was funded by Health Research Board (HRB) Ireland Fellowship Grant: HPF 495/2013.
Conclusions Acknowledgements
BIPQ elements Mean Median IQR
Consequences 2.94 1 0-5.5
Timeline 8.69 10 8.5-10
Personal control 0.77 0 0
Treatment control 9.69 10 10
Identity 2.09 0 0-4
Concern 6.83 7 5-10
Coherence 4.77 5 3-6
Emotional representation 2.74 2 1-4
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Mupirocin and medical grade honey to eradicate nasal 
MRSA.  Efficacy and molecular epidemiology of isolates 
Toney Thomas1, Deirdre Fitzgerald-Hughes3, Georgina Gethin2, Hilary Humphreys1,3
1Beaumont Hospital, Dublin, 2NUI Galway, Ireland 3Royal College of Surgeons In Ireland
MRSA
•Staphylococcus aureus (S.aureus) most frequently colonise in the anterior nares, 
although other body sites such as throat and perineum are also colonised.
•Nasal carriers of S.aureus also have an increased risk of acquiring an infection with this 
pathogen1. The widespread use of antibiotics has led to the emergence of resistance and 
meticillin-resistant Staphylococcus aureus (MRSA) is the term used to describe these 
resistant isolates.
•Up to 70% of invasive S.aureus infections are drug-resistant in the European Union 
(EU)2. 
•Eradicating MRSA from the nose is important in preventing MRSA infection. An 
association between previous mupirocin exposure and subsequent mupirocin resistance in 
MRSA is reported, which restricts the use of repeated courses of intra-nasal mupirocin. 
•Higher rates of mupirocin resistance have been reported with widespread use or abuse of 
mupirocin3. 
•There is also a strong association between  high level mupirocin resistance (HLMR) and 
resistance to ≥4 non-β-lactam antimicrobial classes4.
•Lack of evidence based alternate options for nasal MRSA decolonisation lead the 
researchers to investigate for viable alternatives.
Nasal  MRSA decolonisation
Interim review of  20 patients enrolled shows that:
•67% (6) patients were successfully decolonised with mupirocin.
•40% (4) patients were successfully decolonised with MGH.
•11% (1) patient acquired high level mupirocin resistance (MIC >512µg/ml) .
•Mupirocin susceptibility among persistent MRSA carriers in study group were 
unchanged.
Spa types
•The predominant spa-types were t022, t032, t515, t557 and t4559. 
•The predominant sequence type was ST22. 
•75% of the historical isolates were identical to the pre-decolonisation isolate. 
To determine if medical grade honey (MGH) is an alternative to mupirocin  for nasal 
decolonisation of MRSA by conducting a randomised control trial (RCT). 
The purpose of the interim review was; 
BACKGROUND
PURPOSE
RESULTS
Group Results
Nasal decolonisation Persistent colonisation Mupirocin susceptibility 
Control = 9 6 3 1HLMR*
Intervention = 10 4 6 No change
Table 1. Results
* HLMR – High level mupirocin resistance
Sequence Type Historic Isolates Baseline Isolates
Table 2. Sequence Type
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Recruitment and decolonisation
•MRSA colonised patients were identified from prospective laboratory reports.
•Nasal MRSA colonised patients were evaluated for suitability based on predetermined 
criteria.
•Consenting patients were recruited and randomised to control and study groups.
•Control group received upto two courses of mupirocin2% nasal ointment, three times a day 
for five days.
•Study group received upto two courses of nasal MGH, three times a day for five days.
•Triclosan1% was used for non nasal decolonisation i.e. body wash and shampoo for both 
groups. 
•MRSA screening was done at least 48 hours after the last dose of the nasal application.
•Screening results guided the necessity for a second course of either product and follow up.
Characterisation of isolates and susceptibility testing
•First time MRSA isolates (historical) and baseline isolates (recruitment) were investigated 
for mupircoin susceptibility and compared.
•MRSA isolates; historical and baseline isolates were genetically characterised using spa
typing. The sequence type (ST) was inferred from the spa type.
1. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, et al. The role of 
nasal carriage in Staphylococcus aureus infections. The Lancet infectious diseases. 2005;5(12):751-62.
2. European Antimicrobial Resistance Surveillance System. EARSS Annual report 2005. Bilthoven, The 
Netherlands .
3. Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin resistance. Clinical Infectious Diseases: An Official 
Publication Of The Infectious Diseases Society Of America. 2009;49(6):935-41.
4. Cadilla A, David MZ, Daum RS, Boyle-Vavra S. Association of high-level mupirocin resistance and 
multidrug-resistant methicillin-resistant Staphylococcus aureus at an academic center in the midwestern 
United States. Journal Of Clinical Microbiology. 2011;49(1):95-100.
•Successful nasal decolonisation may be possible with MGH. The final result of the RCT  
should inform and guide further investigation.
•The laboratory evidence confirms that MRSA colonising strains do not vary over time 
among persistent carriers. The findings supports evidence of persistent colonisation 
rather than re-colonisation with a different MRSA isolate among such carriers.
•To characterise study isolates using spa typing. 
•To determine and evaluate mupirocin susceptibility of MRSA isolates from individual 
patients at specific time periods.
MATERIALS AND METHODS
CONCLUSIONS
BIBLIOGRAPHY
ST22 14 14
ST8 1 1
ST1 1 0
Unknown Sequence 1 4
Missing / failed 3 1
Total 20 20
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Appendix - Ⅰ  
Natural honey to eradicate nasal methicillin-resistant 
Staphylococcus aureus (MRSA)  
Results of the pilot study. 
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Background 
Staphylococcus aureus is a frequent coloniser of normal skin and is a common cause of 
bloodstream infection. The widespread use of antibiotics has led to the emergence of 
resistance and methicillin-resistant Staphylococcus aureus (MRSA) is the term used to 
describe these resistant isolates. A study reported by European Disease Surveillance Centre 
(ECDC) confirms that MRSA was the most common, multidrug-resistant bacterium in the 
EU.1 Around 3% of the public, rising to 6–7% of those admitted to hospital, are carriers of 
MRSA.2 In 2009, 1,309 cases of S. aureus bloodstream infection (BSI) were reported in 
Ireland; MRSA accounted for 355 (27.1%) of 1,309 S. aureus isolates.3  
 
Nasal colonisation of MRSA is often a precursor of invasive infections such as BSI , surgical 
site or wound, device and implant infections. Nasal decolonisation with mupirocin is reported 
to be sub-optimal but potential abuse has resulted in increasing levels of resistance to 
mupirocin. Rossney et al report increasing high-level mupirocin resistance (MpR) among 
MRSA BSI isolates between 1999 (1.4% to 2.9%) and 2007.4 Surveillance of new MRSA 
isolates of MRSA in Beaumont Hospital found that 7.3% of isolates were resistant to 
mupirocin in 2009. Therefore, there is a need for developing alternative approaches that are 
safe and cost-effective.  
 
The ability of natural honey as a potential beneficial therapeutic agent is widely reported in 
the published literature.5,6,7,8 Honey-based dressings are now used in the treatment of ulcers. 
The specific antimicrobial action of honey includes the ability to bind to proteins9 the inherent 
non-peroxide antibacterial activity generated by methylglyoxal (MGO)10, 11, 12 and the high 
osmotic pressure which render an adverse environment for bacterial survival, all of which 
represent factors that inhibit bacterial survival when exposed to honey preparations. In 
addition it is reported that resistance to honey cannot be induced under conditions that 
rapidly induce resistance to antibiotics.13  A bactericidal mode of action using manuka honey 
against S.aureus is also reported in the scientific literature.14 We propose that the properties 
of natural honey, in particular the bactericidal action, could be beneficial in the 
decolonisation of nasal MRSA and undertook a preliminary study to later inform a larger 
clinical trial.  
 
Methods 
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Pilot study design 
An open label pilot study was conducted in Beaumont Hospital, an acute tertiary referral,  
between March and September 2012 to assess the effectiveness of natural honey 
(Dermacream®) in eradicating nasal carriage of MRSA. Ethical approval for the study was 
obtained from Beaumont Hospital and the trial was conducted in accordance with good 
clinical practice (GCP) guidelines. 
 
The investigative product chosen for the study, Dermacream®50gm tube Medihoney 
(Europe) Ltd, was purchased and stocked in the hospital pharmacy in accordance with 
protocols on storage of trial medicinal products. Labelling of the honey product was done 
according to GCP guidelines in the Beaumont Hospital’s pharmacy (Appendix 1 - sample 
label). This was to ensure traceability of the study products supplied to study participants 
and to comply with clinical trial requirements. A log of product dispensing was maintained 
during the pilot study. No monetary or other rewards were offered to patients to participate in 
the study, which was entirely voluntary.  
 
Inclusion and exclusion criteria 
Patients over 18 years, who were capable of providing consent, were invited to participate. 
(Appendix 2- consent form).  Laboratory confirmation of nasal MRSA colonisation was a 
prerequisite for inclusion in the study.  Patients were excluded if they were participating in 
another study, had uncontrolled diabetes mellitus, or were unable to provide written consent.  
 
Protocol 
Study subjects agreed to the nasal application of Dermacream®50gm tube (Appendix 3), 
three times a day for five consecutive days. If the study participants were colonised at non-
nasal body sites i.e. groin/perineum, then the standard decolonisation regimen using a body 
wash and shampoo with 1% triclosan (Skinsan) was commenced according to Beaumont 
Hospital policy (Appendix 4). The screening of nasal and other body site/s was done as per 
the hospital’s MRSA screening protocol. A second course, three times a day, for five days 
with Dermacream® was commenced if screening identified persistent MRSA colonisation. 
Invasive sterile collection swabs (EUROTUBO) were used for specimen collection.  
 
Up to two five day courses of nasal Dermacream® were administered to study participants. 
Successful MRSA decolonisation was confirmed if three follow-up MRSA screens taken 48 
hours apart, i.e. nasal, groin and other relevant body sites, were negative for MRSA. The 
screening swabs were processed in the CPA accredited Beaumont hospital laboratory using 
chromogenic medium plate (BIORAD®) followed by coagulase testing to confirm the 
identification of the organism, i.e. MRSA with antibiotic susceptibilities undertake according 
to routine methods (PHOENIX®).  
 
The study participants’ perception of using a non-antibiotic product for nasal MRSA 
decolonisation, as well as their experience of the application of the investigative product 
were collected during the study. This information was collected using structured statements 
(Appendix 5).  
 
 
Results 
Seven patients consented for inclusion, all of whom were persistent carriers  of MRSA, i.e. 
had nasal and other body site decolonisation, despite the standard decolonisation regimen, 
i.e. nasal mupirocin and Triclosan 1% body wash, on two or more occasions.  Therefore all 
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had failed MRSA decolonisation attempts before recruitment to this pilot study. One of the 
patients enrolled was colonised with mupirocin-resistant MRSA who had had one course of 
Naseptin® for ten days but MRSA colonisation persisted. Nasal and other body site/s 
screening were done as per the hospital MRSA screening protocol. 
 
Two of the seven patients discontinued the study agent up to two days after 
commencement. Therefore five patients completed one or two full course of the nasal honey 
application.  Successful nasal MSA decolonisation was confirmed in three cases, including 
the successful decolonisation of the patient with mupirocin resistant MRSA. Two patients 
had persistent nasal MRSA colonisation after two courses of nasal honey application.  
 
Table 1 Details of the patients recruited and the outcome. 
No MRSA first 
detected 
Previous 
decolonisation 
attempts 
Number of 
Dermacream® 
course/s 
Outcome 
1 September 
2009 
Two or more <1 Discontinued on day 2 due 
overall clinical deterioration 
with end-stage renal disease 
and gastrointestinal 
haemorrhage 
2 June 2011  Two or more <1 Discontinued day 2 due to 
unpleasant and intolerable taste 
3 Jan 2011  Two or more 02 Successful decolonisation 
4 Nov 2009 Two or more 02 Successful decolonisation 
5 Nov 2010 Two or more 02 Failed nasal decolonisation 
6 Dec 2006 Two or more 02 Failed nasal decolonisation but 
could not comply with protocol 
due to chronic obstructive 
disease 
7 Dec 2008 Two or more 02 Successful decolonisation 
 
The study also sought to document patients’ perception and experience of using the trial 
product. Six of the seven patients recruited responded using the structured statement 
questionnaire and their experiences were:. 
• All six found that the trial product was not sticky, did not cause any unpleasant 
sensation in the nose and was easy to apply to the nasal passage.   
• Two of the six felt that their nose was moist and runny after nasal application of the 
product. 
•  Given a choice, five of the six participants preferred the use of a natural product to 
an antibiotic to eradicate MRSA from the nose. 
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Discussion and recommendations 
The potential beneficial therapeutic agent of honey is described in the published literature 
with most of the data originating in the last 20 years. Honey-based dressings are used in the 
treatment of ulcers. The high osmotic pressure of honey and the bactericidal mode of action, 
in addition to other beneficial factors, renders honey a potential therapeutic agent. This 
approach could also be utilised in the decolonisation of nasal MRSA as identified in this pilot 
study. If successful, this approach may provide an alternative approach to the current MRSA 
decolonisation strategies with a key advantage of not inducing antimicrobial resistance.  
However, controlled trials are essential before the clinical efficacy of natural honey can be 
fully confirmed and established in comparison to other products that are currently 
recommended for nasal MRSA decolonisation.  
 
A systematic review of the literature on the use of honey for nasal MRSA should be 
undertaken. Following this a randomised controlled trial comparing honey versus mupirocin 
for nasal decolonisation of MRSA with sufficient power should be carried out.  Both would 
expand our knowledge of the clinical effectiveness of natural honey for nasal decolonisation 
of MRSA. 
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Appendix -Ⅱ 
Figure 1.Literature review search process  
499 records identified through database searching, screened 
for title and abstract 
304 excluded including duplicates and 
those not meeting the inclusion and 
exclusion criteria 
194 articles reviewed  
107 excluded; not relevant to the review 
 
89 articles included in the review  
13 Randomised controlled trials  
2 Case control studies 
10 Non-controlled cohort studies 
3 Observational studies 
19 Diagnostic / laboratory studies 
12 Surveillance reports 
8 Reviews 
5 Guideline, expert opinion, consensus reports 
9 Qualitative reports 
7 Investigation / In vitro studies 
1 Mixed methods 
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Appendix -Ⅲ 
Mupirocin resistance: Clinical implications and potential alternatives, JAC July 
2015 (a full copy of the article in publications) 
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Appendix -Ⅳ 
Approval – Recognised Ethics Committee_24th January 2014 
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Appendix - Ⅴ 
EUDRACT Registration and EUDRACT number 
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Appendix - Ⅵ 
Response from Irish Medicines Board for conduct of the study 
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Appendix - Ⅶ 
Laboratory protocol: LP-MIC-Screens Revision 4-2013 
 
 
 
7. PROCEDURE  
7.1  Specimen receipt 
Specimens are received on the BHIS (see LP-MIC-COMPUTER) 
7.2 Culture  
• Containment Level 2 
• All work which is likely to generate aerosols should be performed in a microbiological safety 
cabinet. 
(See fig. 1) 
Refer to LP-MIC-SPEC.PUT-UP for instructions on specimen put up. 
7.2.1  Reading primary MRSA Plates DAY 1 
Read primary plates after exactly 24 hours (i.e., at 9am unless otherwise indicated). Plates 
read before or after this time may give erroneous screening results and lead to unnecessary 
work and delays in reporting results. 
 
• Check control plate and ensure that growth is as expected 
 Positive (S. aureus ATCC 43300) control: Deep pink colonies 
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 Negative (S. aureus ATCC 25923 ) control: Scanty and faint pale pink hazy 
growth 
 
• Examine test plates for the presence of pink colonies 
• Follow the algorithm outlined in the Appendix1   
• Report all previously known and MRSAs once confirmed by primary identification tests 
(see Table 3). 
• Prepare purity plates on blood agar of all query new MRSAs and those too scanty for full 
controlled Pastorex Staph-Plus  
• Incubate for referral to the Phoenix next day 
• Record query new MRSA on the BHIS only after full controlled Pastorex Staph-Plus has 
been performed.  
• Check on PIPE that the patient is a query new MRSA by checking their risk group (RG) 
status (see Appendix 2) 
• Record and report results as outlined in the Computer Reporting table 
Note: Any growth, even one or two colonies, is significant and should be followed up. For 
very scanty cultures, it may be necessary to plate out for purity and perform primary 
screening tests the following day. This should be recorded in the notes field of the workcard. 
  
 
7.2.2 MRSA DAY 2 
 
Follow-on of subbed purity plates 
• Perform confirmatory tests (eg. Pastorex Staph-Plus) on scanty growths from the previous 
day 
• Check all purity plates are acceptable for the Phoenix 
• Order Gram Positive Phoenix panels on the BHIS for all cultures sent to Phoenix  
Table 2: MRSA Reading and Storage Guidelines 
Organism Primary 
Identification 
Tests 
Susceptibility 
Testing 
Storage of 
Isolates 
Recording of 
Isolates 
Organism Referral 
MRSA Pastorex, 
Catalase, 
Gram Stain 
All new isolates: 
Order 
PM67sensitivity 
panel and submit 
organism on 
Blood Agar purity 
plate for testing 
All new 
isolates on 
Nutrient Agar 
slopes held at 
room temp. 
 
All new 
isolates in the  
MRSA book  
Outbreaks or where 
epidemiologically 
indicated. 
On direction of 
CMT 
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• Record the isolate number, QMRSA and all tests carried out on the purity plate 
• Transfer plates to the Phoenix as soon as possible to avoid delay in set-up 
7.2.3 MRSA DAY 3 
Phoenix Follow on 
• Slope and record all confirmed isolates returned from the Phoenix 
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Appendix - Ⅷ 
Patient Information Leaflet - VERSION 3 
Protocol Title: Honey to Eradicate Nasal MRSA, A Randomised 
Control Trial 
 
Principal Investigator:  Toney Thomas, HRB Research Fellow, Beaumont Hospital. 
Telephone No: 01 8093133. 
Co-investigator: Prof. Hilary Humphrey’s, Consultant Microbiologist, Beaumont 
Hospital. Telephone No: 01 8093312. 
 
You are being invited to take part in a pilot clinical research study carried out at 
Beaumont Hospital.  Before you decide whether or not you wish to take part, you 
should carefully read the information provided below and, if you wish, discuss it with 
your family, friends or GP (family doctor).  Take time to ask questions – don’t feel 
rushed and don’t feel under pressure to make a quick decision. 
 
You should clearly understand the risks and benefits of taking part in this study so 
that you can make a decision that is right for you. This process is known as 
‘Informed Consent’.  
 
You don't have to take part in this study if you prefer not to. If you decide not to take 
part it won’t affect your future medical care. 
 
You can change your mind about taking part in the study any time you like.  Even if 
the study has started, you can still opt out.  You don't have to give us a reason.  If 
you do opt out, you can be assured that this decision won't affect the quality of 
treatment you get in the future.  
 
  
WHY IS THIS STUDY BEING DONE?  
The presence of meticillin resistant Staphylococcus aureus (MRSA) in the nose 
without symptoms or evidence of infection is called, “MRSA carriage”.  Such carriage 
may predispose to infection and therefore in hospital, efforts are made to eradicate 
MRSA from the nose, i.e. MRSA decolonisation. However, most patients carrying 
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MRSA are well and are merely carrying the MRSA, i.e. carriage.  The medication 
normally used to decolonise or remove MRSA from the nose is an antibiotic, 
mupirocin, but its use is restricted to a maximum of two courses, to prevent the 
emergence of resistance.  
 
There is some evidence to suggest that  honey may have a beneficial effect on 
MRSA decolonisation. Studies done on wounds and ulcers have reported effective 
MRSA decolonisation or eradication in addition to the healing of the wound or ulcer. 
A pilot study was done in Beaumont Hospital recently. The results of the study show 
evidence of successful nasal MRSA decolonisation in patients after nasal honey 
application, similar to or higher than what would be normally expected from using 
nasal mupirocin. However, a larger study is required to confirm that before the 
widespread use of nasal honey. It is not fully understood how  honey eradicates 
MRSA from the nose.  If we could understand this process more clearly, it might help 
us develop new medications to eradicate MRSA.   
 
In order to investigate the effects of  honey, we plan to use  honey to eradicate 
MRSA in those patients who would normally be tested for the presence of MRSA in 
the nose and who would normally receive mupirocin.  The  honey product we will be 
using is called Medihoney “Derma cream”.  
 
In order to scientifically demonstrate that nasal decolonisation of MRSA using nasal 
honey is of the same or better than using mupirocin, a clinical study that involves 
investigating the outcome among patients who receive the honey product and 
mupirocin in two separate groups using a random controlled trial is required. Your 
participation in the study means that you may be allocated to either group that is 
nasal honey or nasal mupirocin. If you are in the study group and received nasal 
honey and nasal decolonisation of MRSA is not achieved with Medihoney ® “Derma 
cream” even after two courses, you will subsequently be offered mupirocin for nasal 
application. 
 
WHO IS ORGANISING AND FUNDING THIS STUDY? 
The study is being carried out by the Infection Prevention and Control Department 
and the Microbiology Department in Beaumont Hospital. 
 
Mr Toney Thomas, Health Research Board (HRB) Research Fellow, Beaumont 
Hospital is the Principal Investigator in the study and the Co-Investigator is Prof. 
Hilary Humphreys, Consultant Microbiologist, Beaumont Hospital.  Both are full-time 
employees of Beaumont Hospital/RCSI.  
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This academic study is funded by the HRB by means of a research grant. The 
investigator will also pursue a doctoral degree conducting the research. No other 
funding from any other sources will be utilised for the study. The investigators are not 
paid to enrol patients to this study.  
 
WHAT AM I BEING ASKED TO PARTICIPATE IN? 
You are being asked to take part in the study because the laboratory has confirmed 
that you have MRSA in the nose. Normally in such a situation a patient admitted to 
the hospital (and in some cases seen in the outpatients) would be offered 
decolonisation or attempted removal of MRSA followed by screening of the nose at 
intervals to confirm the presence or absence of MRSA afterwards. The presence of 
MRSA in the nose is not unusual i.e. carriage, and most patients are not ill as a 
result.  However, in many patients it is best to try and remove the MRSA from the 
nose, i.e. decolonisation. 
 
HOW WILL THE STUDY BE CARRIED OUT? 
This study will be carried out by the Infection Prevention and Control Department 
and the Microbiology Department in Beaumont Hospital over a period of 24 months. 
Approximately 200 patients will be recruited to this study. Patients in the study will be 
provided with nasal honey or nasal mupirocin followed by MRSA swabs tested in 
Beaumont Hospital, that includes nasal, groin and other relevant body sites such as 
wounds/ulcer, during the period of study all free of charge.  
 
WHAT WILL HAPPEN TO ME IF I AGREE TO TAKE PART? 
If you agree to participate in this study, you will receive a 50gm tube of Medihoney 
Derma cream or a 3 gm tube of mupirocin depending on the group you are allocated 
to. You will be shown how to apply either of the products to the nose.  A course of 
nasal application will involve its use three times a day for five consecutive days. You 
will also receive one unit of Skinsan® which is the routine hospital- approved 
antiseptic body wash and shampoo for application to the rest of the body for five 
consecutive days irrespective of which group you are allocated to.  
The study involves the taking of swabs from the nose and groin and from other 
relevant body sites on three separate occasions at least two days apart after 
finishing a five day course. This approach is the same as when using mupirocin to 
eradicate MRSA from the nose.  These repeat swabs are required to confirm 
effective MRSA decolonisation. The first set of samples will be taken two days after 
finishing the five day course of one of the products and Skinsan. A second course of 
nasal Derma cream or mupirocin and Skinsan application may be required if MRSA 
persists in the nose and the groin. In this case the follow up screening will be similar 
i.e. three separate screens at least two days apart on completion of the second five 
day course. Three sets of negative results are required to confirm effective MRSA 
decolonisation.  
 
If you continue to be an inpatient your swabs will be collected while in the hospital. If 
you are discharged during the course of the study, the collection of swabs and or the 
provision of Derma cream or mupirocin will be arranged either through your GP or 
through a home visit, which will be pre arranged by the Primary Investigator. 
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The study is expected to take from two to four weeks.  
 
You will be asked to complete a short anonymous questionnaire on your experience 
using the product and your perception on MRSA.  
 
Only the study team and the regulatory authorities will have direct access to your 
personal medical records. This will ensure that the study is performed according to 
the approved protocol and that the coded data is correctly recorded. All study team 
representatives and other healthcare staff are ethically and professionally obliged to 
maintain patient confidentiality at all times. 
 
WHAT OTHER TREATMENTS ARE AVAILABLE TO ME? 
For nasal MRSA decolonisation the current recommended product is mupirocin. 
Patients in the control group will be given mupirocin. You will be offered mupirocin if 
you decide not to take part in the study. Your decision to take part or not to take part 
in the study will not result in any change to your medical care in Beaumont Hospital.  
You will continue to be followed up by your doctors in Beaumont Hospital as usual.   
 
WHAT ARE THE BENEFITS? 
The main reason for carrying out this study is to improve our knowledge about the 
effectiveness and ease of the use of honey to eradicate MRSA from the nose and to 
compare it with nasal mupirocin. You are likely to benefit from participating in the 
study by the eradication of MRSA from your nose. Your participation may also 
benefit others as our ultimate study aim is to scientifically demonstrate that nasal 
decolonisation of MRSA using nasal honey is as good as or better than mupirocin. If 
it is as good or better, this would mean that we have an alternative choice to 
eradicate MRSA from the nose. Your participation may also help reduce 
antimicrobial resistance by the use of a product rather than an antibiotic. 
 
WHAT ARE THE RISKS?  
No adverse consequences after the use of honey for medicinal purposes have been 
reported in the healthcare literature. There may be a possibility that the honey 
product is inferior to the antibiotic that is used to decolonise nasal MRSA. There 
were no adverse reactions when we conducted our pilot study using honey. 
However, to date honey has not been extensively used and it is possible that there 
may be other risks which are not known at this time. A “runny nose” may occur 
based on experience from the pilot study. However, the research team will carefully 
monitor any unintended effects of honey used during the course of the study.  Honey 
is generally well-tolerated when swallowed, when applied to the skin, to ulcers and to 
chronic wounds such as when it is included in wound dressings.  
 
WHAT IF SOMETHING GOES WRONG? 
The researchers in this study are covered by state healthcare insurance (indemnity), 
which includes Beaumont Hospital as well in the very unlikely event that you are 
harmed in any way as a direct result of this study. 
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WILL IT COST ME ANYTHING TO TAKE PART? 
No. You will be provided with the products free of charge in addition to the follow up 
tests that will be done during the study. If you are discharged from the hospital 
during the study follow up period, swabs will be organised either through your GP or 
through a home visit which will be arranged by the Primary Investigator.  
 
IS THE STUDY CONFIDENTIAL? 
Your hospital consultant will be notified of your participation in the study which is 
essential, and your GP if you are agreeable to this. 
 
Your medical record will be accessed by the Primary Investigator who is a registered 
nurse, and fully trained in Infection Prevention and Control. Your MRSA screening 
results will be electronically filed in your health record. The results from your 
screening will be discussed with you. Unless you specifically request, the screening 
results will not be provided to your GP. The MRSA bacteria from the screening tests 
may be stored in the Microbiology Department in Beaumont Hospital for the purpose 
of scientific research. The coded results of this study may be used in the future to 
identify better methods to eradicate MRSA from the nose and from other body sites. 
However, such data will not include your name or any other identifiable details. 
 
Data will be kept in “coded” form – this means that a number, rather than your name, 
will appear beside any information about you, thereby maintaining your anonymity. 
The coded results from the research may be published in scientific journals and 
conferences at a later date.   
 
WHERE CAN I GET FURTHER INFORMATION? 
If you have any further questions about the study or if you want to opt out of the 
study, you can be rest assured that it won't affect the quality of any treatment you 
receive in the future. If you need any further information now or at any time in the 
future, please contact:  
Mr. Toney Thomas to discuss the nature of the study in more detail. You are, of 
course, also entitled to seek an opinion from a separate source if you so wish. 
 
Name:   Mr. Toney Thomas  
Address:   Infection Prevention and Control Department,  
Beaumont Hospital, Beaumont Road, Dublin 9         
Phone No: 01-8093133. Please note that this number is only answered during 
normal office hours. 
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Appendix - Ⅸ 
Natural honey for nasal MRSA 
eradication Study 
 
 
 
Standard Operating Procedures for Pharmacy 
 
 
 
 
Version 1 dated 17th February 2014 
 
 
 
 
 
 
 
Beaumont Hospital 
Department of Infection Prevention and Control,  
Post Box 1297, Dublin 9. 
Dublin, Republic of Ireland  
Telephone 353 1 8093133 www.beaumont.ie  
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Purpose  
The purpose of this document is to describe the pharmacy procedures for the conduct of the 
Natural honey for nasal MRSA eradication research project at Beaumont Hospital pharmacy.  
 
Overview of the Protocol  
 
Overview  
 
Natural honey for nasal MRSA is an open label, randomised controlled trial of 188 patients 
comparing the effect of Natural honey Medihoney® Derma Cream to mupirocin on patients 
with nasal MRSA colonisation. Patients will be recruited based on prospective laboratory 
MRSA screening results confirming nasal MRSA colonisation. Consent for participation will 
be obtained from individual patients prior to randomisation. Eligible patients will be 
randomized to receive either Medihoney® Derma Cream or mupirocin nasal application, 
daily three times for five consecutive days, for up to maximum of two courses.  
 
The primary outcome is: proportion of patients with sustained nasal MRSA decolonisation 
after one or two courses of Medihoney® Derma Cream or mupirocin, followed by three 
consecutive negative nasal MRSA screens at least 48 hours apart.   
 
Serious adverse events will be monitored from commencement to completion of the study, 
approximately one month after randomisation.  
 
MRSA screening 
 
Routine MRSA screening involves collection of swabs from both nasal passages and groin 
or perineum in addition to other body sites that are clinically relevant such as wounds, ulcers, 
catheter specimen of urine, sputum and device insertion sites. Patients with history of MRSA 
colonisation or infection as well as who fit criteria for MRSA screening as per hospital MRSA 
guidelines are screened on admission to the hospital or during clinic visits. 
 
Patients enrolled for the study will receive either nasal application of Derma cream or 
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mupirocin three times a day for five consecutive days, followed by two intervention free days. 
Thereafter patients will undergo MRSA screening; nasal and groin in addition to relevant 
body sites. Up to two courses of Derma cream or mupirocin may be administered to each 
patient depending up on the outcome of MRSA screening.  
 
 
Diagram of Study Procedure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmacy Procedures  
 
Study Product  
 
The study product for the experimental decolonisation arm is natural honey 30% 50gm in 
pre-filled tube, Medihoney® Derma Cream manufactured by Derma Sciences Europe 
Limited.  
The standard product for the control decolonisation arm is mupirocin 2% (20 mg/g) 3gm in 
pre-filled tube.  
Approximately 2 cm of Derma cream OR 0.5cm (match head size) of mupirocin will be 
administered by nasal application into both nostrils three times a day for five days, and if 
required followed by a second course; three times of nasal application for five days. This will 
Laboratory identification 
Consent  
Randomise 
DC  MUH  DC  MUH 
 
4 week follow up 
 
Course 1 Course 1  Course 2  Course2 
Screening 1 Screening 1 Screening 2  Screening 2  Follow up  
                                                                                                                    screen 2, 3 
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be based on the nasal screening tests.  
 
 
 
Study Product Supply and Storage  
 
Upon receipt of the Medihoney® Derma Cream, the product will be stored at controlled room 
temperature according to product information in the Pharmacy Department.  
Mupirocin will be supplied by the site Pharmacy Department and stored at controlled room 
temperature according to product information. The ointment is recommended to be kept at 
room temperature, 15-30 C (59-86 F).   
Temperature logs with daily minimum and maximum temperature readings will be kept by 
the pharmacy personnel to monitor the storage temperature of the study drugs.  
The temperature monitoring device for recording the storage temperatures should have 
routine calibration records, which will be managed by the pharmacy department.  
 
Temperature logs will be kept on pharmacy file and made available for inspection upon 
request.  
Products will be labelled by Pharmacy and stored in the clinical trials area of the pharmacy. 
 
Study products and study documentation will be kept in an area with restricted access to 
authorised site personnel only.  
 
The PI will dispense the study product in the original packing and will have the following 
labelling:  
Clinical Trial Protocol: NATURAL HONEY FOR NASAL MRSA 
Patient Name and Hospital Identification 
Number / Case number 
Date of dispensing 
 
Dispensing procedure  
 
The Primary investigator (PI) will (a) randomize the eligible patient after (b) consent. A pre-
printed sticker indicating the correct product will be affixed on the (c) Kardex which will be (d) signed by 
a registered medical practitioner. 
 
For patients in experiment group will receive:  
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One unit of Medihoney® Derma Cream 50gm tube labelled with patient details  
For patients in control group will receive:  
One unit of mupirocin 2% w/v 3gm tube labelled with patient details. 
Picture: mupirocin 3gm tube 
 
Pharmacy label for tube: mupirocin 2%w/v 
 
Mupirocin 2%w/v nasal ointment 3g 
NHNMRSA study  
Apply three times a day for 5 days  
Patient initials:   Date of Birth: 
Study No: 
Investigator T Thomas   
Disp date .../.../....... 
Clinical Trial use only  
Pharmacy Dept Beaumont Hospital 
Beaumont Road Dublin 9 
 
 
Picture: Derma cream 50gm tube 
 
 
 
 
Pharmacy label for Derma cream tube 
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Derma cream 50gm 
NHNMRSA study  
Apply three times a day for 5 days  
Patient initials:   Date of Birth: 
Study No: 
Investigator T Thomas   
Disp date .../.../....... 
Clinical Trial use only  
Pharmacy Dept Beaumont Hospital 
Beaumont Road Dublin 9 
The dispensed study product should be documented on the Product Inventory Log. 
If the product is not given for any reason, the product should be returned to the PI and the 
returned product should be documented on the Inventory Log.  
 
 
Administration by investigator  
 
Randomization must be performed and patient allocated to experiment or control group after 
consent. Thereafter the experimental or control product must be prescribed by a medical 
practitioner for each patient. The experimental or control product will be then issued by the 
primary Investigator, who will then offer the product to the named patient.  
On administration of the first dose of the prescribed product, the PI will sign off the product 
administration, and or Medication order chart (Kardex - in patients) as appropriate. Subsequent 
doses on self administration will be marked off on the product administration sheet by the 
patient, or if nurse assisted will be signed (Kardex - in patients) by the nurse administering the 
dose.  
The product is to be stored in its packaging after applying the cap and held with the patient.  
 
 
 
 
Destruction of products 
 
Any expired Medihoney® Derma Cream or mupirocin can be destroyed on site after 
documentation on the product Inventory Log.  
Expired product will be destroyed according to Beaumont hospital standard operating 
procedures.  
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Purchasing Program  
 
Both Medihoney® Derma Cream and mupirocin will be purchased by the Beaumont Hospital 
Pharmacy department  
Written request will be provided via a letter to purchase the products specifying quantities signed 
by the primary investigator to the Chief or Chief 11 Pharmacist.  
 
The PI will monitor stock for a minimum of 5 units of Medihoney® Derma Cream and mupirocin 
for the study, during the period specified.  
 
 
Site Signature Log  
A  Signature and Responsibility Log will be kept and the Primary Investigator. PI will be trained 
by the lead clinical trials pharmacist who will sign off certifying that the Primary Investigator is 
suitably qualified and trained.  
The lead Pharmacist will sign the Signature and Responsibility Log located in the Investigator 
Site File.  
 
 
Protocol Deviations  
Please enter a note stating deviation if any on the comment box on the Dispensing Form in the 
event of a protocol deviation.  
 
Additional units of mupirocin 3gm or Medihoney® Derma cream 50gm tubes if required for a 
patient enrolled in the study will be issued on prescription of the product on Kardex using pre-
printed sticker and signed by a registered medical practitioner. 
 
 
Regulatory Requirements for the Study  
 
1. Ethics (Medical Research) Committee Approval letter.  
 
 
References  
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Appendix 1:  Pharmacy Request to Purchase Form 1 
 
NATURAL HONEY FOR NASAL MRSA 
 
Protocol NHNMRSA /BH2014 
 
Pharmacy Request to Purchase Medihoney® Derma cream  50gm tube  
 
Instructions:  
• Complete this Form. 
• Send the completed Form and the Medihoney® Inventory Log to Beaumont hospital 
pharmacy. 
• File all purchase approval forms in Pharmacy Manual  
• Allow 2 working days for approval to purchase 
 
Site Name: Beaumont Hospital 
Site Number:  
Investigators Name: Toney Thomas 
Date of Request:  
Requested By: 
 
Telephone: 
Fax: 
Email: 
 
(Print name) 
Quantity to be purchased: number of 
Medihoney® Derma cream 50gm tubes 
 
Date Stock required on site:  
 
 
 
Approved by:     ___________________(print name) 
Signature     ____________________ 
Date:      ____________________ 
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Appendix 2:  Pharmacy Request to Purchase Form 2 
 
NATURAL HONEY FOR NASAL MRSA 
 
Protocol NHNMRSA /BH2014 
 
Pharmacy Request to Purchase Bactroban® (mupirocin2%w/v) 3gm tube  
 
Instructions:  
• Complete this Form. 
• Send the completed Form and the Bactroban® (mupirocin) Inventory Log to 
Beaumont hospital pharmacy. 
• File all purchase approval forms in Pharmacy Manual  
• Allow 2 working days for approval to purchase 
 
Site Name: Beaumont Hospital 
Site Number:  
Investigators Name: Toney Thomas 
Date of Request:  
Requested By: 
 
Telephone: 
Fax: 
Email: 
 
(Print name) 
Quantity to be purchased: number of 
Bactroban® (mupirocin) 3gm tubes 
 
Date Stock required on site:  
 
 
 
Approved by:     ___________________(print name) 
Signature     ____________________ 
Date:      ____________________ 
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Appendix 3: Inventory Log 1. Medihoney® Derma cream 50gm tubes 
 
 
NATURAL HONEY FOR NASAL MRSA 
 
Protocol NHNMRSA /BH2014 
 
Site: Beaumont Hospital 
Inventory Log 
 
Medihoney® Derma cream 50gm tubes 
Lot Number: _____________________ Expiry Date: ________________________ 
 
Date Patient 
Study 
Number 
Patient 
initial 
Quantity 
Received 
Quantity 
Dispensed 
Balance 
No 
Signature Comments 
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Appendix 4: Inventory Log 2. Bactroban® (mupirocin) 3gm tube 
 
 
NATURAL HONEY FOR NASAL MRSA 
 
Protocol NHNMRSA /BH2014 
 
Site: Beaumont Hospital 
Inventory Log 
 
Bactroban® (mupirocin 2%w/v) 3gm tube 
Lot Number: _____________________ Expiry Date: ________________________ 
 
Date Patient 
Study 
Number 
Patient 
initial 
Quantity 
Received 
Quantity 
Dispensed 
Balance 
No 
Signature Comments 
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Appendix 5:  Temperature Log  
 
NATURAL HONEY FOR NASAL MRSA 
 
Protocol NHNMRSA /BH2014 
 
Site: Beaumont Hospital 
Temperature Log 
 
Medihoney® Derma cream 50gm tubes and 
Bactroban® (mupirocin 2%w/v) 3gm tubes 
Store at room temperature 15-30 degree Celsius 
Instructions:  
• For the purposes of the study the pharmacy’s current temperature monitoring chart that   
complies with the requirements of the study will be used. 
 
Date Minimum 
temperature 
Maximum temperature Signature 
    
 
    
 
    
 
    
 
    
 
    
 
 
 
   
 
 
   
 
 
Note: For the purpose of this study, Beaumont Hospital Pharmacy Department 
temperature monitoring log held on file is agreed to be used and available on 
request.  
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Appendix 6: Product Dispensing Log 
 
 
NATURAL HONEY FOR NASAL MRSA 
 
Protocol NHNMRSA /BH2014 
 
Site: Beaumont Hospital 
Principal Investigator: Toney Thomas 
Product Dispensing Log 
 
Patient Name Patient ID 
(case 
number) 
Date of 
supply 
Dispensing 
initials 
Date of 
return 
Comments 
  
MDC____ 
 
__/__/____ 
  
__/__/____ 
 
  
MDC____ 
 
__/__/____ 
  
__/__/____ 
 
  
MDC____ 
 
__/__/____ 
  
__/__/____ 
 
  
MDC____ 
 
__/__/____ 
  
__/__/____ 
 
  
MDC____ 
 
__/__/____ 
  
__/__/____ 
 
  
MDC____ 
 
__/__/____ 
  
__/__/____ 
 
  
MDC____ 
 
__/__/____ 
  
__/__/____ 
 
  
MDC____ 
 
__/__/____ 
  
__/__/____ 
 
  
MDC____ 
 
__/__/____ 
  
__/__/____ 
 
  
MDC____ 
 
__/__/____ 
  
__/__/____ 
 
  
MDC____ 
 
__/__/____ 
  
__/__/____ 
 
  
MDC____ 
 
__/__/____ 
  
__/__/____ 
 
  
MDC____ 
 
__/__/____ 
  
__/__/____ 
 
  
MDC____ 
 
__/__/____ 
  
__/__/____ 
 
  
MDC____ 
 
__/__/____ 
  
__/__/____ 
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Appendix 7: Site Signature Log 
 
 
NATURAL HONEY FOR NASAL MRSA 
 
Protocol NHNMRSA /BH2014 
 
Site: Beaumont Hospital 
Site Signature Log 
Instructions:  
• The Primary Investigator is responsible for the study will sign the Site 
Signature & Responsibilities Log.  
• The lead pharmacist will be responsible for training of the Primary 
Investigator. 
• The lead pharmacist’s signature certifies that the Primary Investigator is 
qualified and has received training to perform the study tasks.  
 
Name Initials Signature Date from Date to Primary 
Investigators 
signature 
      
      
      
      
      
 
 
Original to Natural honey for nasal MRSA Eradication study Site File. Copy filed in Pharmacy 
Manual.  
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Appendix - Ⅹ: NHNMRSA RCT sequence of actions flow chart 
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Appendix - ⅩⅠ a: Product experience questionnaire_Version 2_Medihoney™ Derma Cream 
Honey to Eradicate Nasal MRSA 
Patient Questionnaire – Experience with Medihoney Derma cream. 
Please circle below the option in the grid that best fits your opinion about the statements below 
  Strongly 
agree 
Agree Neither agree 
or disagree 
Disagree Strongly 
disagree 
1 I found it easy to apply Derma cream to my nose.      
2 My nose was sticky after applying Derma cream.      
3 My nose was “runny” after applying the Derma cream.      
4 I experienced an unpleasant sensation in my nose 
immediately after or during application of the Derma Cream 
     
   
5 If given a choice between an antibiotic or a natural product 
to eradicate MRSA from the nose, which would you prefer. 
 
Antibiotic 
 
Natural product 
Comment__________________________________________________________________________________________________________
______________________________________________________________________________________________ 
Thank you for taking time for completing the questionnaire. Please return the questionnaire in the envelope addressed to the investigator. 
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Appendix - ⅩⅠ b: Product experience questionnaire_Version 2_mupirocin 2% (Bactroban® 2%) 
Honey to Eradicate Nasal MRSA 
Patient Questionnaire – Experience with Mupirocin nasal ointment. 
Please circle below the option in the grid that best fits your opinion about the statements below 
  Strongly 
agree 
Agree Neither agree 
or disagree 
Disagree Strongly 
disagree 
1 I found it easy to apply mupirocin to my nose.      
2 My nose was sticky after applying mupirocin.      
3 My nose was “runny” after applying mupirocin.      
4 I experienced an unpleasant sensation in my nose 
immediately after or during application of mupirocin 
     
   
5 If given a choice between an antibiotic or a natural product 
to eradicate MRSA from the nose, which would you prefer. 
 
Antibiotic 
 
Natural product 
Comment__________________________________________________________________________________________________________
______________________________________________________________________________________________  
Thank you for taking time for completing the questionnaire. Please return the questionnaire in the envelope addressed to the investigator. 
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Appendix - ⅩⅡ: NHNMRSA RCT: Case Report Form_Version_2 
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Appendix - ⅩⅢ: NHNMRSA RCT Data dictionary_Version_1_2014 
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Appendix - ⅩⅣ: NHNMRSA RCT documents not listed else where 
ⅩⅣ a. Patient Consent Form 
STUDY TITLE: HONEY TO ERADICATE NASAL MRSA STUDY 
 
I have read and understood the Information Leaflet about this research 
project.  The information has been fully explained to me and I have been 
able to ask questions, all of which have been answered to my satisfaction. 
Yes   No  
I understand that I don’t have to take part in this study and that I can opt 
out at any time.  I understand that I don’t have to give a reason for opting 
out and I understand that opting out won’t affect my future medical care. 
Yes  No  
I am aware of the potential risks of this research study. Yes  No  
I give permission for researchers to look at my medical records to get 
information.  I have been assured that information about me will be kept 
private and confidential. 
Yes  No  
I have been given a copy of the Information Leaflet and this completed 
consent form for my records. 
Yes  No  
I consent to take swabs from nose and groin for the purpose of 
microbiological testing during my participation in the study. 
Yes  No  
Storage and future use of information: 
I give my permission for information collected about me to be stored or 
electronically processed for the purpose of scientific research and to be 
used in related studies or other studies in the future but only if the 
research is approved by a Research Ethics Committee. 
Yes  No  
 
 |   |  
-------------------------------------------------------------------------------------------------------------------------- 
Patient Name (Block Capitals) | Patient Signature | Date 
 
To be completed by the Principal Investigator or nominee. 
 
I, the undersigned, have taken the time to fully explain to the above patient the nature and 
purpose of this study in a way that they could understand. I have explained the risks 
involved as well as the possible benefits. I have invited them to ask questions on any aspect 
of the study that concerned them. 
 
 
 |   |  | 
--------------------------------------------------------------------------------------------------------------------------
Name  (Block Capitals) |  Qualifications | Signature | Date 
 
3 copies to be made: 1 for patient, 1 for PI and 1 for hospital records. 
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ⅩⅣ b: Proforma NHNMRSA trial Sticker for placement on Clinical Notes 
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ⅩⅣ c: MRSA illness perception questionnaire 
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ⅩⅣ d: Directions for application of Medihoney® Derma Cream_ VERSION 1  
Study name: Natural Honey for Nasal MRSA Eradication Randomised Control Trial 
(NHNMRSA trial) 
Three times a day application for five consecutive days. 
 
1. Wash hands. Verify the product with the label with details of the study 
and your name written on the label. 
2. Remove the product from packing and check the label. 
3. Open the cap of the tube and squeeze approximately 2 centimetre of the 
cream into the applicator. This is about the size of last digit of your little 
finger. 
4. Apply the cream into one of the nostril at a time. 
5. Repeat step 3, i.e. squeeze 2 centimetre of the cream into the applicator 
and apply it into the other nostril. 
6. Pinch the nose with two or more fingers and rub for 10-15 seconds. 
Wash your hands with soap and water. 
7. Close the cap and place the cream in its packing. 
8. Lay on your back with head up preferably raised on a pillow for at least 
five minutes. 
9. If you experience wet nose, wipe nose with a disposable paper towel or 
cloth. Avoid force blowing off the nose if possible immediately after the 
application of the cream. 
 
WHAT SHOULD I DO IN CASE OF OVERDOSE? 
If an overdose or too much honey is applied to the nose, use a disposable tissue 
paper and blow the nose to remove excessive Derma cream. Seek medical advice if 
you wish.  
 
WHAT DO I DO IF I MISS A DOSE? 
If you miss a dose of Derma cream, apply it as soon as you remember. Do not apply 
Derma cream to the nose more than three times a day. If it has been more than 6 
hours since you missed the last dose wait and apply the next dose at the regular 
time.  
 
Principal Investigator:  Toney Thomas, Research Fellow, Infection Prevention & 
Control, Beaumont Hospital. Telephone No: 01 8093133. 
Co-investigator: Prof. Hilary Humphrey’s, Consultant Microbiologist, Beaumont 
Hospital. Telephone No: 01 8093133. 
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Directions for application of Medihoney® Derma Cream 
 
Patient record 
 
Study name: Natural Honey for Nasal MRSA Eradication Randomised Control Trial 
(NHNMRSA trial) 
 
Three times a day application for five consecutive days.  
 
√ Tick the time box after you have applied the cream into your nose. 
 
First course commencing date---------------- 
 
Day & date Time Time Time Comments if any 
1     
2     
3     
4     
5     
No treatment - - -  
No treatment - - -  
Nasal screening     
 
Second course commencing date---------------- 
 
1     
2     
3     
4     
5     
No treatment - - -  
No treatment - - -  
Nasal screening     
 
 
Principal Investigator:  Toney Thomas, Research Fellow, Infection Prevention & 
Control, Beaumont Hospital. Telephone No: 01 8093133. 
Co-investigator: Prof. Hilary Humphrey’s, Consultant Microbiologist, Beaumont 
Hospital. Telephone No: 01 8093312. 
 
 
267 
 
ⅩⅣ e: Directions for application of Bactroban® 2% mupirocin _VERSION 1 
Study name: Natural Honey for Nasal MRSA Eradication Randomised Control Trial 
(NHNMRSA trial) 
Three times a day application for five consecutive days. 
 
1. Wash hands. Verify the product with the label with details of the study 
and your name written on the label. 
2. Remove the product from packing and check the label. 
3. Open the cap of the tube and squeeze approximately 0.5cm of the 
ointment into the applicator. This is about the size of a “match stick 
head”. 
4. Apply the ointment into one of the nostril at a time. 
5. Repeat step 3, i.e. squeeze 2 centimetre of the ointment into the 
applicator and apply it into the other nostril. 
6. Pinch the nose with two or more fingers and rub for 10-15 seconds. 
Wash your hands with soap and water. 
7. Close the cap and place the ointment in its packing. 
8. Lay on your back with head up preferably raised on a pillow for at least 
five minutes. 
9. If you experience wet nose, wipe nose with a disposable paper towel or 
cloth. Avoid force blowing off the nose if possible immediately after the 
nasal application. 
 
WHAT SHOULD I DO IN CASE OF OVERDOSE? 
If an overdose or too much mupirocin is applied to the nose, use a disposable tissue 
paper and blow the nose to remove excessive ointment. Seek medical advice if you 
wish.  
 
WHAT DO I DO IF I MISS A DOSE? 
If you miss a dose of mupirocin, apply it as soon as you remember. Do not apply 
mupirocin to the nose more than three times a day. If it has been more than 6 hours 
since you missed the last dose wait and apply the next dose at the regular time.  
 
Principal Investigator:  Toney Thomas, Research Fellow, Infection Prevention & 
Control, Beaumont Hospital. Telephone No: 01 8093133. 
Co-investigator: Prof. Hilary Humphrey’s, Consultant Microbiologist, Beaumont 
Hospital. Telephone No: 01 8093133. 
 
 
268 
 
 
Directions for application of Bactroban® 2% mupirocin 
 
Patient record 
 
Study name: Natural Honey for Nasal MRSA Eradication Randomised Control Trial 
(NHNMRSA trial) 
 
Three times a day application for five consecutive days.  
 
√ Tick the time box after you have applied the cream into your nose. 
 
First course commencing date---------------- 
 
Day & date Time Time Time Comments if any 
1     
2     
3     
4     
5     
No treatment - - -  
No treatment - - -  
Nasal screening     
 
Second course commencing date---------------- 
 
1     
2     
3     
4     
5     
No treatment - - -  
No treatment - - -  
Nasal screening     
 
 
Principal Investigator:  Toney Thomas, Research Fellow, Infection Prevention & 
Control, Beaumont Hospital. Telephone No: 01 8093133. 
Co-investigator: Prof. Hilary Humphrey’s, Consultant Microbiologist, Beaumont 
Hospital. Telephone No: 01 8093312. 
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ⅩⅣ f: Letter to consultant doctor 
Consultant’s Name and Address   Patient’s Name and Address 
       Date 
Dear Dr. 
I am writing to inform you that your patient, XXXXX ,has agreed to take part in a research 
study in Beaumont Hospital to assess the effectiveness of a honey preparation to eradicate 
MRSA from the nose compared to mupirocin, the standard treatment.  This is a randomised 
control study to evaluate eradication of MRSA from this site, following a pilot study recently 
carried out in Beaumont Hospital. The study is being funded by the Health Research Board. 
As you may be aware, meticillin-resistant Staphylococcus aureus (MRSA) colonisation of the 
nose predisposes to infection. Current guidelines recommend nasal decolonisation of MRSA 
using mupirocin for a maximum of two courses. Decolonization is especially recommended 
in patients, who are due to undergo an elective operative procedure, who have a prosthesis 
in situ, or who are in a clinical area where there is a high risk of colonisation leading to 
invasive infection. There is some evidence to suggest that natural honey may have a 
beneficial effect on MRSA decolonisation and this is increasingly important as many MRSA 
strains are resistant to mupirocin..  
As part of a randomised controlled study being conducted with Professor Hilary 
Humphreys, we plan to recruit patients with recently confirmed nasal colonisation of 
MRSA or who have completed two courses of mupirocin to eradicate MRSA from the 
nose but without success. Patients will receive either a nasal application of 
Medihoney Derma Cream© or Bactroban© (mupirocin) nasal ointment depending on 
the group the patient is randomly allocated to.  Both treatments will be applied three 
times a day for five days and nasal screening two days after completion of a five day 
treatment will be undertaken to assess if the MRSA has been eradicated or persists. 
The course of Medihoney or mupirocin may be repeated for a second time if the 
follow-up samples after the first course remain positive for MRSA. MRSA eradication 
will be confirmed when three sets of nasal swabs at least two days apart are 
negative for MRSA.    
 
Patients will be recruited from Beaumont Hospital and follow up screening will be 
done to confirm decolonisation or failure to eradicate MRSA.  The conduct of this 
study will not affect any other aspects of this patient’s management. 
 
I am happy to forward a copy of the protocol as required.  Feel free to contact me if you have 
any queries on extension 01-8093133 or on my mobile 087-1957264. A similar letter has 
been forwarded to the patient’s general practitioner. 
Yours sincerely, 
_________________ 
Toney Thomas,  
Health Research Board Research Fellow  
Beaumont Hospital. 
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ⅩⅣ g: Letter to family doctor 
GP’s name and Address     Patient’s Name and Address 
       Date 
Dear Dr. 
I am writing to inform you that your patient, XXXXX ,has agreed to take part in a research 
study in Beaumont Hospital to assess the effectiveness of a honey preparation to eradicate 
MRSA from the nose compared to mupirocin, the standard treatment.  This is a randomised 
control study to evaluate eradication of MRSA from this site, following a pilot study recently 
carried out in Beaumont Hospital. The study is being funded by the Health Research Board. 
As you may be aware, meticillin-resistant Staphylococcus aureus (MRSA) colonisation of the 
nose predisposes to infection. Current guidelines recommend nasal decolonisation of MRSA 
using mupirocin for a maximum of two courses. Decolonization is especially recommended 
in patients, who are due to undergo an elective operative procedure, who have a prosthesis 
in situ, or who are in a clinical area where there is a high risk of colonisation leading to 
invasive infection. There is some evidence to suggest that natural honey may have a 
beneficial effect on MRSA decolonisation and this is increasingly important as many MRSA 
strains are resistant to mupirocin..  
As part of a randomised controlled study being conducted with Professor Hilary 
Humphreys, we plan to recruit patients with recently confirmed nasal colonisation of 
MRSA or who have completed two courses of mupirocin to eradicate MRSA from the 
nose but without success. Patients will receive either a nasal application of 
Medihoney Derma Cream© or Bactroban© (mupirocin) nasal ointment depending on 
the group the patient is randomly allocated to.  Both treatments will be applied three 
times a day for five days and nasal screening two days after completion of a five day 
treatment will be undertaken to assess if the MRSA has been eradicated or persists. 
The course of Medihoney or mupirocin may be repeated for a second time if the 
follow-up samples after the first course remain positive for MRSA. MRSA eradication 
will be confirmed when three sets of nasal swabs at least two days apart are 
negative for MRSA.    
 
Patients will be recruited from Beaumont Hospital and follow up screening will be 
done to confirm decolonisation or failure to eradicate MRSA.  The conduct of this 
study will not affect any other aspects of this patient’s management. 
 
I am happy to forward a copy of the protocol as required.  Feel free to contact me if you have 
any queries on extension 01-809133 or on my mobile 087-1957264. A similar letter has been 
forwarded to the patient’s Beaumont Hospital consultant. 
Yours sincerely, 
_________________ 
Toney Thomas,  
Health Research Board Research Fellow  
Beaumont Hospital 
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Appendix - ⅩⅤ: List and source of MRSA isolates with the comparison of spa types  
Natural Honey for Nasal MRSA Eradication A RCT - spa type comparison and 
analysis of historic clinical, baseline and end of study nasal MRSA isolates 
No 
Source of 
Historic 
(First) isolate 
Study 
No 
spa type 
- 
Historic 
spa type 
- 
Baseline 
spa type 
-      
Final 
spa type 
comparison of 
historic and 
baseline isolates 
spa type 
comparison of 
baseline and final 
isolates 
1 NOSE 1111 t515 t6764 9999 D NA 
2 NOSE 1112 t032 t032 t032 ID ID 
3 SP CATH 1113 t032 t4559 9999 D NA 
4 NOSE 1114 t032 t7636 t7636 D ID 
5 GROIN 1115 t032 t020 t020 D ID 
6 NOSE 1116 t032 t032 9999 ID NA 
7 NOSE 1117 t032 t032 9999 ID NA 
8 GROIN 1118 t032 t4559 9999 D NA 
9 SupPdev site 1119 9999 Failed 9999 Napp NA 
10 NOSE 1120 t032 t4559 9999 D NA 
11 Line tip Jr 1121 9999 t4559 t032 Napp D 
12 BAL 1122 t127 t4559 t127 D D 
13 CELLULITISLL 1123 t022 t4559 9999 D NA 
14 MSU 1124 t515 t4559 9999 D NA 
15 ULCER  1125 t557 t4559 9999 D NA 
16 ULCER L 1126 t032 t4559 t4559 D ID 
17 NOSE 1127 t15373 t15373 t15373 ID ID 
18 Abd Cellulitis 1128 t190 t190 9999 ID NA 
19 NOSE 1129 t515 t515 t515 ID ID 
20 Wound 1130 9999 t515 9999 Napp NA 
21 NOSE 1131 9999 t515 t515 Napp ID 
22 GROIN 1132 9999 t020 t020 Napp ID 
23 NOSE 1133 t032 t032 9999 ID NA 
24 RESP 1134 t032 t032 9999 ID NA 
25 SKIN 1135 t032 t040 9999 D NA 
26 NOSE 1136 9999 t032 t032 Napp ID 
27 Wound 1137 t2436 t2436 t2436 ID ID 
28 CELLULITISLL 1138 t032 t032 t032 ID ID 
29 GROIN 1139 t020 t020 9999 ID NA 
30 
DISCHARGE 
ns 1140 9999 t515 9999 Napp NA 
31 NOSE 1141 t032 t032 t032 ID ID 
32 NOSE 1142 t379 t379 9999 ID NA 
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33 Wound TOE 1143 t2436 t2436 9999 ID NA 
34 NOSE 1144 t032 t032 9999 ID NA 
35 NOSE 1145 t032 t032 9999 ID NA 
36 NOSE 1146 t032 t032 9999 ID NA 
37 NOSE 1147 t1214 t032 t032 D ID 
38 BLOOD 1148 t032 
not 
typeable 9999 D NA 
39 SPUTUM 1149 t032 t032 9999 ID NA 
40 NOSE 1150 t032 t032 9999 ID NA 
41 Ulcer L 1151 9999 t032 9999 Napp NA 
42 NOSE 1152 t032 t032 t032 ID ID 
43 SPUTUM 1153 9999 t515 t515 Napp ID 
44 Ulcer L 1154 unknown  t127 t127 D ID 
45 Pus Penis 1155 t515 t515 t515 ID ID 
46 CSU 1156 9999 t032 9999 Napp NA 
47 Nose 1157 t127 t127 9999 ID NA 
48 Nose 1158 t515 t515 
Unknown 
type ID D 
49 NOSE 1159 9999 t515 t515 Napp ID 
50 NOSE 1160 t8046 t8046 9999 ID NA 
51 NOSE 1161 t127 t127 t127 ID ID 
52 Wound 1162 t127 t127 t127 ID ID 
53 CELLULITISLL 1163 9999 t032 t032 Napp ID 
54 GROIN 1164 t032 t032 9999 ID NA 
55 
DISCHARGE 
LL 1165 t032 t032 t032 ID ID 
56 NOSE 1166 t008 t127 t127 D ID 
57 GROIN 1167 t020 t020 9999 ID NA 
58 Blood CS PVC 1168 9999 t045 9999 Napp NA 
59 NOSE 1169 t515 t515 9999 ID NA 
60 NOSE 1170 9999 t032 t032 Napp ID 
61 
WOUND 
FOOT 1171 9999 t032 9999 Napp NA 
62 
WOUND 
FOOT 1172 t032 t032 9999 ID NA 
63 
ULCER FOOT 
R 1173 9999 t032 9999 Napp NA 
64 ULCER LEG 1174 9999 t032 t032 Napp ID 
65 
WOUND 
FOOT L 1175 9999 t515 9999 Napp NA 
66 NOSE 1176 9999 t022 9999 Napp NA 
67 NOSE 1177 9999 t032 9999 Napp NA 
68 WOUND TOE 1178 t032 t032 9999 ID NA 
69 ULCER LEG L 1179 t223 t127 9999 D NA 
70 
CANNULA TIP 
FEM LINE 1180 9999 t032 t032 Napp ID 
71 Blood CS PVC 1181 9999 t022 t032 Napp D 
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72 NOSE 1182 t032 t032 t032 ID ID 
73 NOSE 1183 9999 t127 9999 Napp NA 
74 NOSE 1184 t1612 t1612 t1612 ID ID 
75 ILEAL STOMA 1185 9999 t578 9999 Napp NA 
76 SPUTUM 1186 t1370 t1370 9999 ID NA 
77 NOSE 1187 t1612 t1612 t1612 ID ID 
78 MSU 1188 9999 t9570 9999 Napp NA 
79 NOSE 1189 t022 t022 9999 ID NA 
80 GROIN 1190 t022 t022 t032 ID ID 
81 NOSE 1191 t032 t032 t032 ID ID 
82 
THROAT 
DISCHARGE 1192 9999 t032 9999 Napp NA 
83 
WOUND 
SURGICAL RT 
UP LEG 1193 9999 t032 t032 Napp ID 
84 SPUTUM 1194 9999 t15959 9999 Napp NA 
85 BLOOD -PVC 1195 t127 t127 t127 ID ID 
86 NOSE 1196 9999 t032 t032 Napp ID 
87 NOSE 1197 t032 t515 t515 D ID 
88 ULCER LL 1198 9999 t032 9999 Napp NA 
89 GROIN 1199 t032 t127 9999 D NA 
90 URINE 1200 9999 t020 9999 Napp NA 
91 GROIN 1201 9999 t1499 9999 Napp NA 
92 NOSE 1202 t127 t032 9999 D NA 
93 NOSE 1203 9999 t515 t515 Napp ID 
94 
WOUND 
ABDM 1204 9999 t032 9999 Napp NA 
95 ULCER LL 1205 t032 t032 9999 ID NA 
96 NOSE 1206 t032 t032 9999 ID NA 
97 PENIS DISCH 1207 t032 t032 9999 ID NA 
98 WOUND LL 1208 t1612 t1612 t1612 ID ID 
99 NOSE 1209 t084 t127 t127 D ID 
100 MSU 1210 t032 t032 t032 ID ID 
ID - spa type indistinguishable, D - spa type distinguishable, Napp - Not applicable (Historic  isolate not 
available), NA - Not available (participant decolonised or final outcome not available), 9999 – isolate not 
available 
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Appendix - ⅩⅥ: The Brief Illness perception questionnaire (BIPQ) 
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Appendix - ⅩⅦ:  NHNMRSA RCT: Abbreviations  
 No Abbreviation Full form 
1 ADL Activities of daily living  
2 AE Adverse Event  
3 AIIR Airborne infection isolation room 
4 atl Autolysin 
5 B. cereus  Bacillus cereus  
6 B. subtilis  Bacillus subtilis  
7 BH Beaumont Hospital  
8 BIPQ Brief illness perception questionnaire 
9 BSI Bloodstream infection 
10 C. diff Clostridium difficile 
11 χ2 Chi-square 
12 CA-MRSA Community-acquired MRSA  
13 ccr Cassette chromosome recombinase  
14 CE Conformité Européene  
15 cfu Colony forming units 
16 CHD Chronic Heart disease 
17 CHG Chlorhexidine gluconate 
18 CI Confidence interval 
19 ClyS Staphylococcal-specific phage lysin  
20 CoNS Coagulase negative Staphylococci 
21 CONSORT Consolidated Standards for Reporting of Clinical Trials  
22 COPD Chronic obstructive pulmonary disease 
23 CP Contact precautions  
24 CRE Carbapenem resistant enterobacteriacae 
25 CRF Case report form 
26 CSTAR 
Centre for Support and Training in Analysis and 
Research 
27 CT Clinical Trial 
28 CVC Central vascular catheter 
29 DFU Diabetic foot ulcers  
30 DM Diabetes mellitus  
31 E. coli Escherichia coli 
32 EARS-Net 
European Antimicrobial Resistance Surveillance 
Network  
33 ESBL Extended spectrum beta lactamase organisms 
34 ESRD End stage renal disease  
35 EU European Union  
36 FDA US Food and Drug Administration  
37 GAS group A Streptococcus  
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38 GCP Good clinical practice  
39 GDP Gross domestic product  
40 HA-MRSA Healthcare-associated MRSA 
41 HCF Health care facility 
42 HCW Health care worker 
43 HIV Human immuno-deficiency virus 
44 HLMR High level mupirocin resistance 
45 HPRA Health Products Regulatory Authority  
46 HPSC Health Protection Surveillance Centre  
47 HSE Health Services Executive 
48 IL Interlukin 
49 IMB Irish Medicines Board  
50 IMP Investigational medicinal product  
51 IPC Infection prevention and control  
52 IPQ Illness perception questionnaire 
53 IQR Inter-quartile range 
54 ITT Intention to treat 
55 ITU Intensive care unit  
56 LG Logistic regression  
57 LLMR Low level mupirocin resistance 
58 LOS Length of stay 
59 LP-MIC Laboratory protocol - MIC 
60 MBC Minimum bactericidal concentration  
61 MDRO Multi drug resistant organisms  
62 mecA methicillin resistance gene  
63 MGH Medical grade honey  
64 MGO Methylglyoxal 
65 MIC Minimum inhibition concentration  
66 MM6 Mono Mac 6  
67 MMP-9 Matrix metalloproteinase -9 
68 MR Mupirocin resistance  
69 MRMRSA Mupirocin resistant MRSA 
70 MRSA Methicillin resistant Staphylococcus aureus  
71 MS Mupirocin susceptibility  
72 MSSA Methicillin susceptible Staphylococcus aureus  
73 mupA MR isoleucyl-tRNA synthetase gene 
74 NDFU Neuropathic diabetic foot ulcers  
75 NHNMRSA Natural honey for nasal MRSA 
76 NIS Nursing dependency information system 
77 NR2 Nagelkarke R2  
78 PAG Project Advisory Group  
79 PBP Penicillin binding protein  
80 PCR Polymerase chain reaction  
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81 PEQ Product experience questionnaire 
82 PICC Peripherally inserted central vascular catheter 
83 PIPE Patient Information Profile Explorer  
84 PP Per protocol 
85 PVC Peripheral vascular catheter 
86 qacA/B Chlorhexidine resistance genes 
87 RCT Randomised control trial 
88 RJ Royal jelly  
89 RNA Ribo nucleic acid 
90 ROS Reactive oxygen species  
91 S. aureus Staphylococcus aureus 
92 S. epidermidis  Staphylococcus epidermidis  
93 S. pyogenes Streptococcus pyogenes  
94 SAE Serious adverse Event  
95 SCC Staphylococcal cassette chromosome  
96 SCCmec Staphylococcal cassette chromosome mec  
97 SD Standard deviation  
98 SD Standard deviation 
99 SEM Scanning electron microscopy  
100 smr Low level chlorhexidine resistance gene 
101 SP Standard precautions  
102 SSTI Skin and soft tissue infections 
103 ST Sequence Type 
104 TBP Transmission-based precautions  
105 TEM Transmission electron microscopy  
106 TNF-α tumour necrosis factor-α  
107 UC Urinary catheter  
108 UCD University College Dublin  
109 UspA Universal stress protein A  
110 VRE Vancomycin resistant enterococci 
 
 
  
 
